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Research context 
Bacterial antibiotic resistance constitutes a worldwide threat to public health. The propagation of multiple-
drug resistant bacteria, especially Gram-negative bacteria, risks causing hospital and community infections 
for which there are no effective antibiotics. The human and economic costs of the antibiotic resistance 
burden are enormous. In Europe at least 25 000 patients die per year because of resistant infections which 
are not treatable with available antibiotics, and the estimated costs rise to more than 1.5 billion EUR 
annually. 
These facts emphasize the urgent need of new antibiotics able to target resistant bacteria. However, the 
antibiotic research and development pipeline from pharmaceutical companies is in decline. Several factors 
have led to the absence of antibiotic discovery, between them, the lack of return on investments, the 
scientific challenges to obtain approval and the restrictions on antibiotic use because of the risk of 
developing resistance. New models encouraging the investment on antibiotic research with intelligent 
measures to avoid their misuse have to be established. 
In the search for new antibiotics, nature represents a vast reservoir of bioactive compounds that merit to be 
exploited. Plant secondary metabolites are provided of an inherent antimicrobial activity as a result of long 
evolutionary process aiming at the protection and survival of plants in their environment. Essential oils (EOs) 
for example, are complex mixtures of compounds where all, major and minor components, seem to 
cooperate in the antibacterial activity. Indeed, synergistic interactions between EO components might thus 
occur, potentiating their antibacterial action. Furthermore, as EO affects multiple bacterial targets, the risk 
of resistance development is lower than single-targeted antibiotics. With the purpose of antibiotic discovery 
based on natural products, a pharmaceutical company has developed CIN-102, a synthetic and synergistic 
blend that resembles the composition of cinnamon EOs. The fact that CIN-102 is a defined blend with known 
concentrations for each active component, avoids the problem of unknown concentration and composition 
variability typically found in botanic drugs. Preliminary studies showed that CIN-102 is an interesting new 
antibacterial candidate with potential to treat infections caused by resistant bacteria. Among all the possible 
therapeutic applications for this new agent, we were interested in targeting Inflammatory Bowel Diseases 
(IBD). 
IBD comprises Crohn’s disease and ulcerative colitis, which are chronic diseases whose etiology has not yet 
been completely understood. Nevertheless, there is abundant evidence about the role of enteric bacteria in 
the origin and the course of these diseases. Even though the main treatment is basically focused on an 
immunomodulatory approach, the use of drugs capable of modulating the intestinal microbiota has an 
increasing interest. Among them, antibiotics could be useful to reduce increased bacterial loads commonly 
found in the ileum and colon of IBD patients; as well as to target specific bacteria with potential pathogenic 
 xiv 
 
activity like enterobacteria. This way, regulation of intestinal microbiota disorders might decrease the 
aggressive immune response to bacterial antigens, alleviating the outcomes of intestinal inflammation.  
Drugs that intend to have a local action in the lower part of the gastrointestinal tract, like in the case of IBD, 
present the challenge of an appropriate design of the pharmaceutical dosage form. Given that an oral 
dosage form has to pass through the stomach and the small intestine before arriving to the colon, release or 
absorption of the drug in the upper part of the gastrointestinal tract might occur. This could limit the 
amount of drug available at the site of action, requiring administration of high drug concentrations to ensure 
a therapeutic effect, increasing the risk of adverse effects. In this context, colonic targeted drug delivery 
technologies permit oral forms to resist degradation and release of the drug in the stomach and small 
intestine, while enhancing drug delivery at the colon overcoming the aforementioned shortcomings. For this, 
colonic targeted systems should be able to sense their arrival into the colon in order to trigger drug release. 
Specific physiological characteristics found in the colon, in comparison to those of the upper gastrointestinal 
tract can thus be used in the fabrication of colonic oral dosage forms.  
Objectives 
The present work has 3 main objectives:  
- To characterize the in vitro bacteriological activity of CIN-102. 
o  A long evaluation of CIN-102 activity to confirm its spectrum of activity using a wide panel of 
clinical bacterial isolates.  
o Determination of the logarithmic reduction time of CIN-102 against a panel of bacterial 
isolates. 
o  Determine if CIN-102 possess a post-antibiotic effect and if sub-inhibitory concentrations 
have an effect on bacterial growth. 
o A study of the interactions between CIN-102 and currently commercialized antibiotics 
against a wide panel of clinical bacterial isolates, searching for future therapeutic 
applications in combined therapies. 
 
- To fabricate colon targeted multi-particulate formulations of CIN-102 aiming a future therapeutic 
application against IBD. 
o Fabrication and optimization of sustained release reservoir formulations of CIN-102: in vitro 
evaluation of drug release from coated pellets. 
o Fabrication and optimization of sustained release matrix formulation of CIN-102: in vitro 
evaluation of drug release from mini-tablets. 
 xv 
 
o In vivo evaluation of the efficacy of multi-particulate sustained release formulations of CIN-
102, as well as CIN-102 antibacterial activity using a model of colitis. 
 
- To analyze the in vitro antibacterial activity of peroxisome proliferator-activated receptor gamma 
(PPARγ) agonists and antibiotics commonly used in the treatment of IBD. 
o Determination of the antibacterial activity of 5-aminosalicylic acid and GED-0507-34-Levo 
against anaerobic clinical isolates. 
o Determination of the antibacterial activity of narrow and broad spectrum antibiotics against 
anaerobic clinical isolates. 
 
Presentation of the work 
The present work is composed of four chapters: the first one is an introduction describing the problem of 
antibiotic resistance, the actual role of pharmaceutical companies in antibiotic discovery, the potential of 
natural products as new antibacterial agents, the relevance of bacteria in the etiology and treatment of IBD; 
and the different approaches to deliver drugs into the colon.  The second, third and fourth chapters 
correspond to the research work done to achieve the 3 aforementioned objectives, respectively. Each of 
these three chapters presents a brief introduction about the subject, the materials and methods used, the 
results obtained and discussions; and a concise conclusion. Finally a general conclusion will regroup the goals 
achieved in this work, and the perspectives will throw new light on the continuation of this research project. 
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1. The threat of resistant bacteria  
Antibiotic resistance has emerged as one of the greatest global health challenges to be addressed in the 21st 
century.  In its first technical report, the European Center for Disease prevention and Control (ECDC) rated 
resistant bacterial infections as one of the most important health threats in Europe because of the increase 
in infections due multidrug-resistant bacteria in Europe[1]. The risk of widespread antibiotic resistance 
threatens to mitigate the positive changes made in modernizing healthcare systems; therefore, new 
approaches as well as new and effective antibacterial drugs are essential. Presently, at least 25 000 patients in 
Europe die per year because their bacterial infections are not treatable with available antibiotics at the 
estimated cost of more than 1.5 billion EUR annually[1,2]. 
1.1. Principles of antimicrobial resistance 
Bacteria can be intrinsically resistant to certain antibiotics but can also acquire resistance via mutations 
in chromosomal genes and by horizontal gene transfer (HGT)[3,4]. 
 The intrinsic resistance is given by the ability to resist the action of an antibiotic as a result of 
inherent structural or functional characteristics determined by naturally occurring genes in 
bacteria’s chromosome[3,4]. 
 The acquired resistance involves mutations in genes targeted by the antibiotic and the transfer of 
resistance determinants borne on mobile genetic material[3]. 
Three mechanisms of bacteria gene transfer have been identified[5]:  
o Transformation, which involves the uptake and incorporation of naked DNA. It depends on 
bacterial competence which is variable between species;  
o Conjugation, a cell contact-dependent DNA transfer mechanism found to occur in most 
bacterial genera. The vast majority of reports of HGT in the environment concern 
conjugation; and  
o Transduction, whereby host DNA is encapsulated into a bacteriophage that acts as the 
vector for its injection into a recipient cell. 
 
 
 
 
 
 
 
 
Fig. 1: Acquisition of antibiotic resistance (Abr)[3] 
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HGT shows that drug resistance is mobile. Indeed, genes for resistance traits can be transferred among 
bacteria of different taxonomic and ecological groups by means of mobile genetic elements 
(bacteriophage, plasmids, transposons, integrons or naked DNA)[6]. Resistant plasmids are not only 
maintained stable, but also usually transferred between bacterial cells at a very high efficiency[7]. Plasmids 
may carry resistance to several antibiotics, selection by one antibiotic may result in selection for 
resistance to other antibiotics carried by the same plasmid. Transposons and integrons have evolved as a 
mean for microorganisms to change more rapidly than possible by only mutations. They are frequently 
carried on plasmids, but can also have a chromosomal location[8]. Bacteriophages are very common in the 
environment and are relatively stable, being protected by the protein coat. Phages are also more compact 
and thus more diffusible than naked DNA[5]. 
Bacterial resistance can be mediated by several mechanisms, which fall into the following main groups[4,8]: 
 Those that minimize the intracellular concentrations of the antibiotic as a result of poor 
penetration (such as lack of porins) into the bacteria or antibiotic efflux;  
 Those that modify or inactivate the antibiotic target by genetic mutation or post-translational 
modification of the target;  
 Those that introduce a new resistant target, overproduction of target or other by-pass mechanisms; 
and 
 Those that inactivate the antibiotic by hydrolysis or modification.  
 
 
 
 
 
 
 
 
 
 
 
 
    Fig. 2: Mechanisms of antibiotic resistance[9] 
 
In addition, the same kind of drug resistance mechanism can be specified by many different genes, and 
more than one type of mechanism may provide resistance to the same antibiotic[6]. 
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Antibiotics target important bacterial functions, so it is not surprising that resistant mutants usually suffer 
a decrease in biological fitness. The acquisition of resistance genes by HGT also carries a fitness cost. The 
decreased fitness caused by resistance may be rapidly and efficiently counterbalanced by compensatory 
mutations without a loss of resistance. Compensatory evolution can stabilize resistant bacterial 
populations in the absence of antibiotics by making them as fit as susceptible clones[10]. And this explains 
why many types of resistance may never disappear in bacterial populations[5]. Thus, reversibility in clinical 
settings is expected to be slow or non-existent, compensatory evolution and cost-free resistances can 
reduce the cost and thereby reduce the driving force for reversibility[10].  
However, antibiotics do more than select for resistance. In fact, subpopulations of bacteria can survive 
lethal doses of antibiotics becoming resistant by a transient and non-hereditary mechanism, called 
persistence[11]. This persister population is genetically identical with the susceptible cells. The presence of 
persisters is now thought to be an example of the strategy whereby bacteria naturally generate mixtures 
of phenotypically different populations, so that one of them can be advantageous to a changing 
environmental demand[7]. Antibiotic pressure also selects for bacteria with an elevated mutation rate, this 
hypermutable clones can indirectly select for increased probability of resistance to non-related 
antibiotics[11].  
1.2. Sources of resistant bacteria 
The antibiotic resistome is the collection of all genes that directly contribute to antibiotic resistance, 
both in the environment and in the clinic[12]. The source of resistance genes is composed of producing 
organisms (antibiotic-producing microbes, which must defend themselves from the antibiotics produced) 
and microorganisms in the environment, especially those found in soil (which have been exposed to 
various antibiotics throughout their evolutionary history). Soil bacteria typically undergo higher rates of 
gene transfer[7].  
 
Even though the number and diversity of resistance genes in clinical pathogens are relatively small 
compared to their diversity in the environment, numerous studies have confirmed the fact that antibiotic 
resistance genes have an environmental reservoir[12]. Changes in this environmental resistome might be 
relevant for the emergence of previously unknown resistance determinants in bacterial pathogens[13].  
 
The predominant role of human activities in the generation of environmental reservoir of antibiotic 
resistance cannot be disputed. Since the 1930s, ever-increasing amounts of antibiotics have been 
manufactured, used, released into the environment, and widely disseminated. This way, anthropogenic 
changes provide constant selection and maintenance pressure for populations of resistant strains in all 
environments[14]. This might enrich the population of resistant bacteria and facilitate the transfer of 
resistance genes to human pathogens[13]. It should be noted that therapeutic use in humans accounts for 
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less than half of all applications of antibiotics produced commercially. Alternative uses of antimicrobial 
agents are: growth, promotion and prophylactic use in animals; therapeutic and prophylactic use in 
aquaculture and in household pets; pest control and cloning for plants and agriculture; use as biocides in 
toiletries and in hand care; household cleaning products; culture sterility, cloning, and selection in 
research and industry[14]. Large amounts of antibiotics used for human therapy and for anthropogenic 
activities including agriculture, veterinary medicine, animal husbandry, aquaculture, waste disposal and 
other nonhuman applications create major environmental reserves of resistance[7,14].  Another important 
issue is the potential effect of contamination by antibiotics themselves[13]. Taking into consideration the 
large-scale disposal of toxic wastes and residues of manufacturing processes, the amounts of noxious 
xenobiotics released into the biosphere are inestimable. The fact that many of the chemicals disposed 
are recalcitrant to biodegradation makes the issue worse[14]. Additionally, the increase in human 
population and the widespread lack of efficient wastewater treatment bring with them a risk of transfer 
of antibiotic resistance[13].Antibiotics and bacteria resistant to them in waste water, surface water, 
ground water, sediments and soils are being reported with increasing frequency and are potentially 
important contributors to the environmental selection of antibiotic-resistance organism[7,15].  
 
Besides these sources, the human gut, containing a densely populated microbial system, offers ample 
opportunities for HGT of resistance genes. Antibiotic resistance genes harboured by the gut microbiota 
constitutes the gut resistome[16]. Furthermore, animal contributions to the resistance problem in human 
infections are small but not insignificant; they have a major role if enteric organisms are involved[6]. All 
these factors resulted in the selection of pathogenic bacteria resistant to multiple drugs[7,14].  
1.3. Multiple-drug resistant (MDR) bacteria 
Bacteria resistant to multiple families of antibiotics constitute a worrisome threat to public health. In this 
regard, Chang et al[17]explained the mechanisms that have led to an excess of MDR. Unexpectedly high 
rates of origin and high rates of spread of MDR strains or determinants, or both, cause this excess. 
Certainly, a major complicating factor is the possibility of HGT, which can disseminate resistance to 
multiple antibiotics in a single step.  
Which is the origin of MDR strains?[7,17] 
 Single biochemical mechanisms conferring resistance to multiple drugs; 
 Genetic linkage: MDR strains may arise because determinants of resistance to multiple drug classes 
are genetically linked; 
 Highly mutable or recombinogenic bacterial lineages; and 
 Multidrug therapy with accelerated treatment failure in resistant infections.  
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Once MDR have emerged in one or more hosts, their proliferation depends on their ability to survive and 
to be transmitted to other hosts. How can MDR strains proliferate?[5,17] 
 Associated linkage selection: multi-resistance proliferation does not need to be consequence of 
direct selection but may result from selection of other genes that are inherited along with it.  
 Bystander selection: when a drug is used to treat infection with a particular species, other species 
carried by the same host might be affected by the treatment.  
 Positive epistasis between drug resistance determinants: if the fitness cost of MDR in the absence 
of antimicrobial use is smaller than the total cost of each resistant determinant on its own, MDR 
strains may outcompete strains with a limited number of resistance elements and spread more 
quickly. 
 Niche differentiation: aggregation of multiple drug selection pressures within specific populations.  
 Importation of MDR strains and geographic source-sink dynamics: MDR strains in source 
populations may be introduced into other sink populations, where they continue to spread. In 
clinical practice, widespread use of antimicrobials in the intensive care units and for 
immunocompromised patients has resulted in the section of MDR organisms. 
1.4. There is no ESKAPE? 
As reported by Rice[18] and further described by Boucher et al.[19], a group of bacteria has emerged that 
escape the lethal action of antibiotics: vancomycin-resistant Enterococcus faecium, methicillin-resistant 
Staphylococcus aureus (MRSA), extended-spectrum β-lactamase (ESBL) producing Escherichia coli and 
Klebsiella pneumoniae, carbapenemase-hydrolyzing β-lactamases K. pneumoniae, MDR Acinetobacter 
baumannii, Pseudomonas aeruginosa and Enterobacter species (ESKAPE). These bacteria are a threat to 
immunocompromised patients and are primarily, although no longer exclusively, associated with the 
nosocomial environment[18]. 
 
Even though infections caused by resistant Gram-positive bacteria like MRSA and vancomycin-resistant 
enterococci (VRE) have been partially controlled, it is worth mentioning that rates of community-
acquired methicillin-resistant S. aureus (CA-MRSA) capable of causing hospital outbreaks and developing 
multiple resistance, are increasing. Furthermore, glycopeptide-resistant enterococci are of concern 
because of their ability to transfer resistance to other species. The rare appearance of vancomycin-
resistance in MRSA is worrying, but the transfer of resistance to vancomycin to virulent and highly 
transmissible strains of CA-MRSA would be calamitous[20]. And also the fact that animals are a reservoir 
of MRSA clonal complex 398, able to colonize and infect humans could undermine existing MRSA control 
programs[21,22].  
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Now, the increased burden of multidrug-resistant Gram-negative bacteria is a real phenomenon[23]. 
These bacteria remain an important threat as few antimicrobial agents targeting Gram-negative are 
reliably active and very little is expected to be available in the near future[24]. The increased 
dissemination of Gram-negative resistance outside hospitals is attributed to several factors: mobile 
genes that can readily spread through bacterial populations, human travel and migration[20,25], contact 
with animals and food products[26,27]. Of particular interest is that much of this dissemination is 
undetected, with resistant clones carried in the normal human flora and only becoming evident when 
they are the source of endogenous infections[25]. 
 
Asymptomatic fecal carriage of β-lactamase and ESBL-producing enterobacteria in healthy people has 
been reported[28,29,30,31]. These facts show that the community is a reservoir of ESBL-producing 
enterobacteria, which has dramatically increased worldwide, and that might constitute a sustaining 
source for nosocomial infections and compromise the efficacy of hospital infection-control measures[29].  
The growing prevalence of ESBL producers is sufficient to drive a greater reliance on carbapenems. 
Consequently, there is selection pressure for carbapenem resistance in Enterobacteriaceae, and its 
emergence is a global public health concern since there are few antibiotics in reserve beyond 
carbapenems[25,32]. Indeed, it is alarming to confirm the spread of New Delhi metallo-B-lactamase (NDM)-
producing enterobacteria in community infections[25,33]. The findings of Arpin et al.[34] require special 
attention since resistance to colistin, one of the last-resort drugs against carbapenemase-producing 
enterobacteria, was found in a strain of NDM- K. pneumoniae in a community patient. Other cases of 
resistance to colistin have also been reported in the community[35]. The possibility that polymyxin 
resistant, community-acquired strains exist increases the dilemma of treating patients with infections 
caused by such organisms[35]. These findings only emphasize the crisis of multi-resistant bacteria not 
only in hospitals, but also in the community, and highlight the urgent need for new antimicrobials able 
deal with these microorganisms. 
1.5. Costs of Bacterial Resistance 
Antimicrobial resistance results in increased morbidity, mortality, length of hospitalization, evolution of 
new pathogens, frequency of surgical interventions required to control infection, isolation procedures 
resulting in escalating healthcare costs[36,37,38]. 
 
Patients with infections due to antimicrobial resistant organisms have higher costs than do patients with 
infections due to antimicrobial susceptible organisms[36,38]. Even though hospital studies have shown an 
association in the order of a 1.3 to 2-fold increase in mortality, morbidity, and cost of patients for 
resistant versus susceptible infections, its perspective offers only a limited view of the health care impact 
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of resistance. Indeed, significant portions of clinical care are now provided in rehabilitation facilities in 
nursing homes, and at home[36]. 
 
Furthermore, increasing antimicrobial resistance and MDR have resulted in bigger difficulties in their 
treatment. Resistance leads to inappropriate empirical therapy, delay in starting effective treatment, 
and the use of less effective, more toxic and more expensive drugs[36,37]. In fact, the factor with the 
greatest effect on attributable mortality is the efficacy of initial empirical antibiotic therapy[38].  
Considering the patient perspective, infections caused by resistant bacteria lead to loss of work and 
family time associated with increased hospitalization time and subsequent recovery, and even an 
emotional impact[36,37]. 
1.6. Pharmaceutical industry and antibiotic discovery 
Infectious diseases are the second leading cause of death worldwide[39].  In 2004, a report from the 
World Health Organization (WHO) on “priority medicines for Europe and the World” identified infections 
caused by resistant bacteria as the number one therapeutic area requiring priority medicines based on 
the potential public health impact[39].  Therefore, the main rationale for the development of novel 
antibacterial agents is the emergence and dissemination of resistant strains[40].  
1.6.1. The need of new antimicrobials 
Since their discovery, antibiotics have served society by saving tens of millions of lives[41]. The use of 
antibiotics has brought huge changes to the world that we live in, especially our expectations of 
survival of children into adulthood, the numbers of people that are able to be productive in the 
workforce, and ability to live to an old age[42]. These drugs are the cornerstone of infectious disease 
therapy and are the hidden backbone of advanced medical care[43]. Despite all of this, antibiotics are 
not perceived as essential to health or to the practice of medicine[42] and there is a substantial gap 
in the discovery of new antibacterials, which is responsible for the current lack of newly approved 
systemic antibacterial agents[43].This might carry terrible consequences in a world where bacteria 
have developed resistance to all current types of antibiotics.  
 
The number of new antibacterials that make it through the complete development process and 
ultimately receive the Food and Drug Administration (FDA) approval has precipitously decreased 
over the past 25 years. Recent reports about the decrease in discovery research efforts in large 
pharmaceutical companies and the decrease in antibacterial clinical trials, further highlight the 
diminishing industry focus on antibacterial drug research and development[19].  
 
To better illustrate this, Freire-Moran et al.[44] published an interesting review compiling available 
information about antibacterial agents in clinical development, evaluating their novelty and 
potential use against MDR. In this study, 66 new active agents were found, of which 15 could be 
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systemically administered. Of these agents, 12 were active against Gram-positive, and only 4 had 
documented activity against Gram-negative resistant bacteria. Furthermore, only 2 acted on new 
or possibly new targets and crucially, none acted via new mechanisms of action. These results 
clearly show the current paucity of development of active antibacterial agents, especially against 
the multi-resistant Gram-negative bacteria that are of particular concern. 
 
This reflects the difficulties encountered in identifying new bacterial targets and the possibility that 
the majority of targets amenable to antibacterial activity have already been identified[44]. Indeed, 
examination of the current status of potential novel antibacterial drugs indicates that there are only 
a few compounds in development by the large pharmaceutical companies, with the majority of 
candidates coming from the smaller biotechnology pharmaceutical companies. The observed trend 
is a combination of the acquisition of niche products that have not been developed by larger 
pharmaceutical companies, the exploitation of scientific discoveries not successfully applied to drug 
discovery by larger pharmaceutical companies and an incremental improvement in an existing class 
of agents[45]. 
 
Novel intravenous and oral drugs to treat both hospitalized and community-based patients are 
needed, as opposed to “me too” drugs that provide minimal improvement over existing therapies. 
Priority should be given to antimicrobials with the potential to treat serious infections that are 
resistant to current antibacterial agents.  There is an urgent, immediate need for new agents with 
activity against pan-resistant organisms[19]. A wide range of measures is needed to ensure both: that 
currently available antibiotics remain effective as long as possible and to promote research in novel 
drugs and alternatives to traditional antibiotics to combat MDR.   
1.6.2. Why have the pharmaceutical companies abandoned antibiotic R&D? 
There are several reasons why development of new antimicrobial drugs has stalled in the world. 
Among them is the difficulty to develop antibiotics targeting pathogens endowed with antimicrobial 
resistance[2]. Additionally, antibiotic discovery and development has evolved into an expensive, time 
consuming, cumbersome and bureaucratic process involving multiple interest groups such as 
pharmaceutical manufacturers, governmental regulatory authorities, patent officers, academic and 
clinical researchers and trial lawyers[40]. 
 
First, a vast underestimation of the implications of antibiotic resistance has in part, contributed to 
this situation. Since antibiotics were discovered, they have been used excessively and with little 
attention to the inevitable consequence of resistance, without full appreciation that they are a 
limited resource that can be renewed only with great difficulty and expense[41]. 
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Another reason is that it is scientifically challenging to discover new antibiotics that are active 
against resistant bacteria of current clinical concern[43]. Unlike most drugs, an antibacterial usually 
has to be active against many targets (i.e. bacteria), have activity for many infections, with low toxic 
effects on humans and be effective at different body sites. This is exacerbated with the difficulty of 
obtaining approval for use when candidate antibacterial wants to be translated into drugs that can 
be administered to patients. In addition, the FDA has stated that novel antibacterials should 
demonstrate frank superiority for approval. These challenges on the part of regulators is self-
defeating in an age of antibacterial drug resistance[40]. To show non-inferiority to the comparator 
drug, large numbers of patients are needed in clinical trials[42]. 
 
However, the main hurdle is diminished economic incentives[43], the perceived lack of return on 
investments by pharmaceutical companies with several factors contributing to this problem. Among 
them, the shift of investment towards the target of chronic diseases, a more cost-effective area 
than antimicrobials used for short course therapies in most cases[40,42]. Pharmaceutical companies 
need to recognize that many expensive medicines in their portfolio and in development might be 
useless if patients succumb to fatal infections. Therefore, their return on investment for products to 
treat cancer or chronic diseases depends, in part, on effective treatment of infections[42]. 
Furthermore, the expense of clinical trials have increased dramatically, especially for antibacterials. 
These trials become very expensive as larger numbers of patients are needed to show non-
inferiority to the comparator drug[40,42]. Therefore, to achieve reasonable levels of income, it is 
necessary to demand prices that appear to be excessive[40]. Besides that, the availability of generic 
forms is a clear market pressure likely to result in lower revenues[40].  
 
Moreover, use of antibiotics is associated with fear of selecting resistance, calling for restrictions 
on their use. These factors have led to reduced use and hence low return on investment[42]. It is 
undeniable that the level of antibiotic use is directly related to the emergence and dissemination of 
resistant strains, but the goal of preventing resistance cannot be elevated above the primary 
responsibility of treating infected patients[40].  
 
These factors have coalesced to make development of new antimicrobials a largely unattractive 
prospect for drug companies[2]. 
1.6.3. What can be done to encourage antibiotic R&D? 
Several approaches to overcome these barriers to antibiotic development have been proposed. All 
stakeholders have a part in this general industry term, including those that discover and develop 
drugs, those that approve drugs for licensing, prescribe drugs for infections, the patients, and the 
administrator and/or payers of the cost expenditures for antimicrobial therapy[45].  
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Most certainly, the regulatory issues relating to the licensing of new antimicrobials are extremely 
important[42]. Lack of clear regulatory guidance is a major disincentive to anti-infective drug 
development, therefore clarity about  both trial design and overall program requirements for the 
development of new antimicrobial agents is needed[19]. Allowing for smaller sized clinical trials 
coupled with faster and easier regulatory approvals[40].  
 
Wise et al.[46] stated that changes in the economic field related to antibiotic development are most 
likely to yield results. Antimicrobial development must allow pharmaceutical companies realistic 
returns on their investment. This is crucial if the society is to obtain new agents. There should be a 
rebalancing of risks and, more importantly, benefits. The price of antibiotics should be related to 
their value. Antibiotics are substantially cheaper than many other life-saving drugs such as cancer 
drugs, which sometimes only extend life for weeks or months, whereas antibiotics can extend life 
for years[42]. Wise et al.[46] suggested that antimicrobials should be at a higher premium.   
 
In the same way, better reimbursement rates are necessary as well as to support pharmaceutical 
companies’ intellectual property. Extending market exclusivity could be an incentive through 
prolonged patents[40]. Furthermore, research and development tax credits to developers of new 
infectious diseases products need to be fostered[19]. To make developing antibacterial a viable 
option for companies, the creation of new incentives for antibiotic discovery and the elimination of 
disincentives are needed[19].  
 
Thus, efforts to stimulate new antibiotic development must be paired with programs and policies to 
limit inappropriate use of antibiotics[41]. A shared understanding of antibiotics as precious drugs but 
with a diminishing activity due to resistance, as well as the creation of favorable environments for 
discovery of new agents must be fostered. New economic models capable of reconciling these goals 
are imperative[43].  
 
All the initiatives come to the same conclusion: antibiotic resistance and a need for new antibiotics 
is a global problem and need multistakeholder and multifaceted action[42]. The solutions call for 
changes in public/social policy and a culture of cooperation between stakeholders: one that 
recognizes that there must be a balance between public health/clinical needs and the commercial 
realities of drug discovery and development[40].  
 
2. Natural products (NPs) as source of new antibiotics 
There is a renewed interest in NPs as a source of chemical diversity and lead generation in drug discovery. The 
availability of new analytical chemistry and molecular biology methods and the gradual transition away from 
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the mono-substance therapy towards multi-targeted therapy have resumed research in NPs[47]. The Plant 
Kingdom for example, represents an enormous reservoir of the most structurally diverse compounds, offering 
rich mines of biologically valuable molecules. In this respect, plant secondary metabolites (PSMs) are proven 
to be active against a vast number of microbial species, making these molecules an interesting starting point 
in drug development[48].  
2.1. Why NPs as new antibacterials? 
There are several reasons why NPs are of main interest in the discovery of drugs as new antibacterials: 
 The abundant scaffold diversity of NPs is coupled with a “purposeful design”. Most microbes and 
plants make by-products with a purpose, usually to afford advantages for survival in environments 
threatening their growth. It is reasoned that these defense systems produced would have an 
inherent antimicrobial activity, giving an evolutionary advantage to the producer organism. In the 
search for novel antibiotics, it would be difficult to imagine a more specific source of naturally 
occurring antimicrobials than nature itself[49].   
 NPs structures have a high chemical diversity, biochemical specificity and other molecular 
properties that make them favorable as lead structures for drug discovery. This serves to 
differentiate them from libraries of synthetic and combinatorial compounds[50]. 
 Suitability of NPs for modulating chemical reactions and protein interactions: NPs can be viewed 
as a population of privileged structures selected by evolutionary pressures to interact with a wide 
variety of proteins and other biological targets for specific purposes[50]. 
 NPs identified as antibacterial leads typically possess bacterial permeability, i.e. access to the 
target. Hence, avoiding the need for engineering in bacterial membrane and cell wall 
permeability, a situation often encountered with synthetic leads[49]. 
Therefore, it seems that the main task in NPs research is to identify and isolate appropriate PSMs from a 
rich pool provided by the Plant Kingdom. The fact that one of the reasons plants biosynthesize these 
compounds is the defense against microorganisms justifies the efforts aimed towards finding PSMs with 
antimicrobial activity[48]. 
2.2. Which are the shortcomings of NPs? 
Despite the above-mentioned advantages, NPs have some limitations that could explain the fact that 
these mixtures are currently not commercialized as antibacterials:  
 NPs library and high-throughput screening (HTS): The heterogeneity of NPs library samples adds 
two additional levels of complexity to the screening process[50]: 
o Once a response for the sample is detected by HTS, one or more rounds of chemical 
purification and biological assays might be necessary for identifying and isolating the active 
components in the mixture.  
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o The complexity of crude or semi-pure NPs libraries challenges the robustness of HTS 
technology. 
 Usefulness of in vitro data: Active concentrations in in vitro conditions frequently cannot be 
reached in vivo and so in vitro results cannot correlate with in vivo activities of the tested 
compounds[48].   
 Therapeutic window: most of the time therapeutic windows of active PSMs are not specified as 
they are for other drugs, leaving a risk of appearance of side effects. Toxicity studies, for example 
towards host cells, have to be carried out. Side effects of NP drugs with synthetic drugs in co-
medication must also been studied[48].  
 Variable composition of NP drugs: relative concentrations of individual components in a sample 
are not know precisely, and are highly susceptible to external geographical, climatic and 
ecological factors that influence plant metabolism[48,50]. 
In such way, biological activity is just one of the necessary prerequisites for NP substances to be applied 
as pharmaceuticals. Despite of the shortcomings, PSMs are still considered a good starting point in the 
search for/design/development of new antimicrobial agents[48]. Biological activities of NPs aiming a 
therapeutic application must also be verified in controlled clinical trials, before they can be submitted as 
conventional drugs[47]. 
2.3. Intelligent mixtures 
Plant species often respond to stress by increasing the biosynthesis of different classes of molecules, 
rather than just an individual PSM[48]. In light of the cost-benefit aspect, it is beneficial for a plant to 
produce mixtures of small molecules made of simple and ubiquitous building blocks that easily diffuse to 
reach a maximal number of potential targets. Networks of synergic molecules could greatly enhance the 
chance for fitness, closer to a trial and error-type of selection[51]. 
 
Mixtures of bioactive compounds are widely claimed to be superior over monosubstances, and a 
synergistic therapeutic effect might be mainly responsible for this[48]. Thus, a PSM does not need to 
completely inhibit a target but partially inhibit different targets within a network. Other authors state that 
multi-target effects predominate over synergistic mechanisms[51]. Of importance is the fact that 
production of diverse compounds is an evolutionary advantage developed by plants to overcome 
emerging resistance. It is much harder for microorganisms to shield themselves simultaneously against all 
these different PSMs. In this way, it is highly likely that the mixture of these compounds is in fact 
responsible of the onset of their activity[48].  
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Therefore, in the search for new potent antimicrobials, research should move towards the investigation of 
combination of substances to achieve efficacy[48]. However, we need to scientifically address the 
therapeutic potential of NPs. The reengineering of botanical drugs would make the area of medicinal 
plant research more reproducible, and may even lead to the de novo engineering of more intelligent 
mixtures than the ones provided by plants. By doing so, our understanding of pharmacological efficacy 
would be based on measurable parameters, and also avoid the problem of variable concentrations[51].  
 
Probably the best way of corroborating the pharmacological efficacy of NP drugs would be to reengineer 
the mixtures. By taking apart and reassembling all bioactive constituents, one would be able to find out 
which ones contribute to the final pharmacological effect either directly (interacting with particular 
targets) or indirectly (modulating solubility bioavailability)[51]. 
 
Mechanisms of synergy in NPs: Based on studies, the following mechanisms can be observed[47]:  
 Synergistic multi-target effects: The single constituents of a natural blend affect not only one 
single, but also several targets; cooperating therefore in an agonistic, synergistic way. 
 Pharmacokinetic or physicochemical effects: Certain components that do not possess specific 
pharmacological effects themselves may increase the solubility and/or the resorption rate of 
other constituents; enhancing thereby its bioavailability and resulting in higher effectiveness of 
the mixture rather than an isolated constituent. 
 Interactions with resistance mechanisms of bacteria: some PSMs are able to partly or completely 
suppress bacterial resistance mechanisms working synergistically with antibiotics. 
 The elimination or neutralization of adverse effects by compounds in the mixture: even if this is 
not a real synergistic effect, it generates better effectiveness in therapy. It occurs when a 
constituent of the mixture neutralizes or destroys another possessing toxicity. 
2.4. Essential oils (EOs) as antibacterial agents 
EOs are PSMs composed of complex mixtures of several components at quite different concentrations. 
They are characterized by 2 or 3 major components at fairly high concentrations compared to the others. 
Generally, these major components determine the biological properties of the EOs. The EOs components 
include 2 groups of distinct biological origin: terpenes and terpenoids; and phenylpropane derivatives[52].  
EOs can be present in all plant organs, but are generally stored by the plant in secretory cells, cavities, 
canals, glandular trichomes or epidermic cells[53]. They do not appear to participate directly in plant 
growth and development. Instead, EOs play an important role in the protection of plants against 
microbial infection[48].  
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EOs possess antibacterial properties and have been screened worldwide as potential sources of novel 
antimicrobial compounds as alternatives to treat infectious diseases and promote food preservation, and 
for the fight against resistant bacteria[54]. 
Mechanisms of action of EOs: The activity of an EO can affect both the external envelope of the cell and 
the cytoplasm. The antimicrobial activity of EOs, similar to all natural extracts, is dependent on their 
chemical composition and on the concentration of the components. Generally, the antimicrobial activity is 
not attributable to an unique mechanism, but is instead a cascade of reactions involving the entire 
bacterial cell[53]. 
 Targeting the membranes: 
The lipophilicity typical of EOs is responsible for their interaction with bacterial membranes[55]. 
The hydrophobicity of EOs enable them to partition with lipids of bacterial cell membrane, 
disturbing the phospholipid bilayers, leading to an increased permeability[53,54,56,57].  
 
This might cause degradation of the cell wall, damage of the cytoplasmic membrane, damage of 
membrane proteins involved in active transport, inactivation of enzymatic mechanisms like 
reduction of the intracellular adenosine triphosphate (ATP) pool via decreased ATP synthesis, 
leakage of cell contents, reduction of the proton motive force and membrane potential, 
disruption of the electron transport system and coagulation of cell contents[53,55,58]. 
Furthermore, some EOs can cause a change on the fatty acids profile of the bacterial cell 
membrane. This is induced by an increase in the percentage of unsaturated fatty acids (UFAs) 
responsible for the fluidity of the membrane, causing membrane structural alterations[59]. Indeed, 
Kwon et al.[60] showed that EO components caused elongation and filamentation in B. cereus 
because septa formation was incomplete. Other effects on bacterial cell morphology, like swelling 
of bacterial surfaces, have also been reported[61]. 
 
 Other targets 
o Components of EOs can also act on cell proteins embedded in the cytoplasmic membrane. 
ATPases are located in the cytoplasmic membrane and bordered by lipid molecules. Hence two 
mechanisms have been suggested whereby EOs components could act:  lipophilic 
hydrocarbons could accumulate in the lipid bilayer distorting the lipid-protein interaction; or a 
direct interaction of the lipophilic compounds with hydrophobic parts of the protein[55,62].  
Components of EOs can directly bind to proteins affecting cell division[63] and to enzymes[64].  
EOs may also affect the enzymes that are involved in fatty acid synthesis[65].  
o EOs can also inhibit bacterial toxin production[66]. 
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o Intracellular processes such as DNA/RNA synthesis can also be affected[67] as well as protein 
expression[68]. 
o Effect on ATP: EOs disrupt the cell membrane alter the intracellular and external ATP balance 
such that ATP is lost through the disturbed membrane[69,70]. Other events may contribute to 
the intracellular ATP decrease like disrupted balance of K+ and H+ by EOs[71]and decrease ATP 
synthesis as mentioned before[53]. 
o Effects on the metabolome: Picone et al.[72] found that glucose tends to accumulate when 
microbial cells are treated with EOs components and that cells are unable to metabolize the 
glucose, leading to a loss of viability. An important change in the production of bacterial 
metabolites has also been shown[73]. 
o Communication between bacterial cells involves the production and detection of diffusible 
signal molecules and it is known as Quorum Sensing (QS). The discovery that many pathogenic 
bacteria employ QS to regulate their virulence makes this system interesting as target for 
antimicrobial therapy[74]. EOs components can affect QS in bacteria[75,76]. 
Considering the large number of different groups of chemical compounds present in EOs, it is most likely 
that their antibacterial activity is not attributable to one specific mechanism but that there are several 
targets in the cell. Not all of the mechanisms are separate targets; some are affected as a consequence of 
another mechanism being targeted. Hence, studies have concluded that whole EOs have a greater 
antibacterial activity than the major components alone, suggesting that the minor components are critical 
to the activity and many have a synergistic effect or potentiating influence[58]. 
Furthermore, EOs in combination with other antimicrobial can improve antimicrobial effectiveness. EOs 
could have important implications for the development and implementation of therapeutic antimicrobial 
strategies[54].  
Moreover, the presence of multiple compounds and a possible multiplicity of action in EOs is favorable 
since drugs that interact with multiple targets are highly desirable because they have a low likelyhood for 
or can delay development of bacterial resistance[77,78]. It is likely more difficult for bacteria to develop 
resistance to the multi-component EOs than to common antibiotics that are often composed of only a 
single molecular entity[54]. 
2.5. EOs vs. MDR bacteria 
In the fight against MDR strains, multidrug therapy has become of paramount importance[48] and EOs are 
good sources for combination therapy[79]. In this context, EOs can overcome several mechanisms of 
bacterial resistance: 
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 Receptor or active site modification: Nicolson et al.[80], have shown that the phenolic diterpene 
totarol potentiated the activity of methicillin against MRSA by significantly reducing the 
expression of penicillin-binding protein 2a (PBP 2a). This protein, encoded by MecA has reduced 
affinity for β-lactam antibiotics (BLA).  
 Enzymatic degradation and modification of the drug: ESBL are enzymes that confer resistance to 
BLA like third generation cephalosporins. Cinnamaldehyde and eugenol hydrogen bonded with 
catalytic and other crucial amino acid residues of ESBL enzymes of pathogenic bacteria[81], which 
may restore BLA activity. 
 Decreased outer membrane (OM) permeability: The OM of Gram-negative bacteria functions as 
a permeability barrier for many agents. EOs like thymol and carvacrol are membrane 
permeabilizers[57] that could enhance penetration of antibiotics. 
 Active efflux: Efflux pumps are one of the defense mechanisms employed by bacteria to reduce 
the accumulation of antibiotics inside the cell. EOs were able to block efflux pumps in Gram-
negative bacteria[82]. 
 
 
 
 
 
 
    Fig. 3: EOs as modifiers of multidrug resistance mechanisms[79] 
 
3. Inflammatory Bowel Diseases (IBD) and its link to bacteria 
Ulcerative colitis (UC) and Crohn’s disease (CD) are collectively called the IBDs because of such similarities as 
a chronic remitting and relapsing course, their inflammatory nature, and their unknown causes[83]. CD 
manifests itself as a chronic granulomatous inflammation of the gastrointestinal (GI) tract able of affecting its 
entire length with the presence of “skip” lesions. It preferentially affects the terminal ileum. UC, on the 
contrary, presents as a continuous inflammatory lesion affecting the rectum and colon, lacking 
granulomatous characteristics[84]. 
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3.1. Etiology of IBD 
The most widely held hypothesis on the pathogenesis of IBD is that they result from an overly of 
aggressive immune response to a subset of commensal enteric bacteria in genetically susceptible hosts, 
and environmental factors precipitate the onset or reactivation of disease[85]. 
 
 
 
 
 
 
 
 
 
     Fig. 4: Multi-factorial etiology of IBD[85] 
3.1.1. Genetic factors 
More than 100 genes have now been involved in conferring genetic susceptibility to CD. The most 
important ones are described here: 
3.1.1.1. NOD2/CARD15 (Nucleotide-binding oligomerization domain / Caspase recruitment 
domain ) 
NOD2/CARD15 is an intracellular receptor responsible for the direct recognition of bacterial 
peptidoglycan through the binding of muramyl dipeptide (MDP). It is expressed in various cells 
including monocytes, dendritic cells (DCs), Paneth cells and intestinal epithelial cells 
(IECs)[86,87]. This was the first gene to be associated with CD. There are three mutations found 
within the region of NOD2/CARD15 that encodes a leucine-rich repeat, which is responsible 
for bacterial recognition through binding of MDP present in almost all bacteria. The binding of 
MDP by dimerized NOD2/CARD15 activates nuclear factor kappa B (NFκB), eliciting pro-
inflammatory reactions[86]. 
 
Mutation in this region may explain the findings of higher NFkB tissue levels in IBD patients[88]. 
Mutant NOD2/CARD15 affects the clearance of invasive bacteria that is dependent on NFκB 
activation[89]. CD patients with NOD2/CARD15 mutations present a decrease in α-defensin 
production, as this gene is expressed in Paneth cells, the source of secreted antimicrobial 
peptides[90]. 
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3.1.1.2. ATG16L1 and IRGM (Autophagy-related 16-like 1 and Immunity-related GTPase family 
M) 
Recent genome-wide association studies identified polymorphisms in autophagy genes: 
ATG16L1 and IRGM as important risk factors for the onset of CD. These genes are critically 
involved in the innate immune response to invading pathogens. Dysfunction of these 
molecules results in the increased survival of intracellular bacteria, defective antigen 
presentation and pro-inflammatory cytokine secretion. Furthermore, levels of these two 
proteins are significantly decreased in CD patients[91,92]. 
3.1.1.3. SLC22A4/OCTN1 and SLC22A5/OCTN2 (Soluble carrier family / Organic cation-carnitine 
transporter) 
One of the most important findings in the genetics of IBD is the identification of 
OCTN1/SLC122A4 and OCTN2/SLC22A5 genes coding for integral membrane proteins. The 
function of these proteins is multispecific in bidirectional transmembrane transport of 
carnitine and organic cations[93]. 
 
Two functional variants of these transporters have been associated with CD in association with 
NOD2 mutations[94]. Mutations in SLC22A4 and SLC22A5 affect the transcription and function 
of these transporters. These variants are most actively expressed in the intestinal epithelium, 
macrophages and T cells, causing decreased carnitine transport[95]. 
 
Carnitine is an essential mediator of fatty acid oxidation. Inhibition of fatty acid oxidation can 
evoke clinical and pathologic signs of colitis[96] which may explain why impairments in carnitine 
transport may confer an increased risk for IBD.  
3.1.1.4. DLG5 (Drosophilia discs large homolog) 
DLG5 is a member of the membrane-associated guanylate kinase (MAGUK) gene family that 
encodes a scaffolding protein involved in the maintenance of epithelial integrity and 
regulation of cell growth[97]. The expression of DLG5 variants associated with CD causes 
increased permeability and disease[93].  A mutation in DLG5 is associated with NOD2 mutation 
in CD patients[85]. 
3.1.1.5. HLA (Human leukocyte antigen) 
These genes are candidates for a role in the pathogenesis of IBD because their products play a 
central role in the immune response[93]. Several studies have addressed the possible 
association between certain HLA polymorphisms and the risk for IBD. The association of UC 
with HLA genes is stronger than CD[98]. 
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3.1.1.6. MDR-1 (multidrug resistance gene) 
This gene encodes a membrane transporter glycoprotein that governs efflux of drugs and 
possibly xenobiotic compounds from cells. Several documented human polymorphisms having 
effects on intestinal absorption and drug pharmacokinetics and MDR1 variants have been 
associated with UC and CD[99].  
3.1.2. Immune factors 
3.1.2.1. Innate immunity 
There is an increase in the number of macrophages and DCs with an activated phenotype in 
the lamina propria (LP) of both forms of IBD. As well, the production of proinflammatory 
cytokines, chemokines, adhesion molecules and co-stimulatory molecules is enhanced[85]. 
 
Toll-like receptors (TLRs) play a major role both in detecting microbes and in initiating innate 
immune responses. A disturbance in its function predisposes to infections with Gram-negative 
pathogens, possibly influencing the advancement of IBD. In IBD, mucosal DCs are activated, 
express increased levels of TLR2, TLR4 and produce more cytokines[100]. Also alterations in the 
expression of TLR3 and TLR4 by IECs have been described in IBD, suggesting that abnormal 
bacterial sensing contributes to disease pathogenesis[101]. Another TLR that binds to and 
recognizes bacterial DNA, TLR9, may also play an important role in the pathogenesis of IBD. A 
synergy between TLR9 and NOD2 is lost in the CD patients carrying NOD2 mutation, indicating 
impairment in the innate immunity[102]. 
 
Furthermore, there is a decreased production of α-defensins by ileal paneth cells of CD 
patients carrying NOD mutations, perhaps leading to an impaired resistance against enteric 
microorganisms[103]. These facts show a generalized major defects of innate immune responses 
mediated via pattern recognition receptors in IBD[104]. 
3.1.2.2. Adaptive immunity 
The production of antibodies in the systemic as well as mucosal compartments is drastically 
increased as a consequence of chronic gut inflammation[105]. Studies suggested that IgG 
antibodies against a structural protein of colonocytes were selectively produced in UC[106]. 
However, the focus of immune investigation in IBD shifted to T helper (TH) cell subsets and 
their soluble mediators.  
 
In contrast to innate immune responses, which are similarly activated in all forms of IBD, T-cell 
profiles are disparate in CD and UC. 
 CD: Traditional TH1 responses are mediated by interferon gamma (IFN-γ), the 
production of which is stimulated by interleukin (IL)-12[85]. On the other hand, IL-17 
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mediates TH17 responses. The production of this cytokine is stimulated by the 
production of IL-6, transforming growth factor beta (TGFB) and IL-23[107]. Bacterial 
colonization stimulates IL-23 expression[108]. The levels of both IL-23[109] and IL-17 are 
increased in CD tissues[110]. 
 UC: This disease was considered to have a TH2 profile, but concentrations of IL-4 and 
IL-5, which are normally elevated in TH2 responses, have been variable in UC 
tissues[111]. 
3.1.2.3. Non-immune cells 
It was shown that IECs expressed high levels of the class II antigens HLA-DR in actively 
inflamed mucosa of UC and CD patients[112]. IECs from IBD mucosa fail to induce suppressor T-
cells, and instead activate CD4+ T-cells, and thus potentially amplify intestinal 
inflammation[113].  
 
Fibroblasts are also involved in gut injury because they represent a major source of matrix 
metalloproteinases (MMPs), a family of proteolytic enzymes directly responsible for tissue 
destruction during inflammation[114]. Activation of fibroblasts induces upregulation of cell 
adhesion molecules and production of chemokines, inducing migration of T-cells through local 
microvascular cells[115].  
 
Human intestinal microvascular endothelial cells (HIMEC) from CD and UC mucosa exhibit 
higher cytokine-mediated leukocyte binding capacity[116], secondary to their chronic exposure 
to the inflammatory milieu of the IBD mucosa[117]. 
 
Platelets trigger an inflammatory response in the microvasculature of IBD patients[118] thus 
linking this cell type to process of IBD pathogenesis.  
3.1.3. Environmental factors 
A variety of environmental factors are considered risk factors for IBD, including smoking, diet, drugs, 
geography, social status, stress and appendectomy[119]. Although the epidemiological evidence 
linking environmental factors to IBD is fairly solid, it is widely believed that no environmental factor 
alone can directly cause CD or UC, and an intrinsic disease predisposition must also be present[104]. 
The mechanisms by which these factors initiate the onset of disease or reactive quiescent IBD are 
not well understood. From a broad perspective, these triggering factors alter mucosal barrier 
integrity, immune responses, or the luminal microenvironment, each of which have an impact on 
susceptibility to inflammation[85]. 
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Because dietary antigens are, next to bacterial antigens, the most common type of luminal antigen, 
it is logical to surmise that diet might play a role in the expression of IBD[120].  Several studies 
showed the association between sugar intake and CD[121] as well as monounsaturated and 
polyunsaturated fats in both CD and UC[122,123].  Dietary additives such as aluminum and iron have a 
well-described adjuvant activity and stimulate bacterial virulence[124]. Smoking is perhaps the most 
thoroughly documented environmental contributor to IBD, but its opposite effect on CD and UC is 
difficult to understand. In contrast to UC, several studies have implicated cigarette smoking as a risk 
factor for CD[125]. Appendectomy might reduce the risk of UC but increase the risk of CD[120,126]. 
Some studies have suggested a dose response, with higher risks for IBD seen among longtime users 
of oral contraceptives or among users of high estrogen preparations[127]. It has been proposed that 
the expression of IBD may be influenced by events in early childhood, such as mode of feeding, 
domestic hygiene, or perinatal infections[120].  A history of frequent childhood infections or exposure 
to antibiotics has also been proposed as a risk factor for IBD[128]. 
3.1.4. Bacterial factors 
The intestinal microbiota play a crucial role in IBD, it participates in the initiation, maintenance, and 
determination of the phenotype of IBD[129]. The complex microbiota of the distal ileum and colon 
provide a source of adjuvants or antigens triggering immunological responses causing chronic 
intestinal injury[85,130]:  
 As adjuvants (lipopolysaccharides, peptidoglycan, flagellin) they activate innate immune 
responses including DCs and other antigen presenting cells (APCs)[129]. 
 As antigens they stimulate the expansion of T cells, which are stimulated by APCs selectively 
recognized by their receptor[129]. 
3.1.4.1. Evidence of the microbial influences in chronic mediated intestinal inflammation 
An important role for microbial agents in the pathogenesis of IBD has been reported both, in 
IBD patients and in animal studies. This evidence is summarized in Table 1.[131]: 
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Table 1: Evidence of microbial influences in intestinal inflammation[131] 
Clinical Evidence Experimental Evidence 
 IBDs are localized in intestinal 
segments with the highest bacterial 
concentrations. 
 Abnormal microbial composition in 
IBD 
 Altered metabolic activity of 
microbiota in IBD 
 Increased mucosal-associated 
bacteria in IBD patients 
 Serologic and T-cell responses to 
enteric microbial antigens in IBD 
patients 
 Enhanced E. coli virulence in CD 
 Enhanced mucosal  invasion and 
translocation in IBD 
 Polymorphisms of genes that encode 
bacterial receptors and processing in 
CD 
 Fecal stream diversion prevents and 
treats CD, inflammation recurs upon 
restoration fecal flow 
 Antibiotics treat CD 
 Probiotics prevent relapse of UC 
 Luminal commensal bacteria are 
required for chronic inflammation in 
most rodent models 
 Systemic immunoregulatory defects 
can have a colonic phenotype 
 Bacterial antigens stimulate 
pathogenic T-cell responses 
 Increased mucosal association and 
translocation of bacteria 
 Broad spectrum antibiotics, 
probiotics, and prebiotics prevent 
and treat disease 
 Defective bacterial signaling in 
epithelial cells induce chronic, 
immune-mediated intestinal 
inflammation 
 Defective immunoregulation, 
mucosal barrier function, or 
bacterial killing induce chronic, 
immune-mediated intestinal 
inflammation or potentiate acute 
mucosa injury 
 
3.1.4.2. Role of microbes in the pathogenesis of IBD 
Four broad mechanisms explain the complex relationship between microbiota and IBD[129]:  
 Dysbiosis of conventional microbiota 
Increased bacterial concentrations in the ileum and colon of IBD patients revealed a 
direct relationship between bacterial numbers and the severity of the disease[132].  
o Changes in composition: There is an altered composition of the mucosally 
associated and fecal microbiota in IBD patients. Most studies have shown a 
decreased microbial diversity in active IBD, increased numbers of 
Enterobacteriaceae, including E. coli, and decreased Firmicutes, including 
Clostridium species[132,133,134]. 
o Metabolic consequences: Altered composition of luminal microbiota can lead to 
important metabolic changes in the intestinal environment. Enteric bacteria 
metabolize dietary constituents to produce both beneficial and detrimental 
products. For example, reduced levels of Clostridium, responsible for the 
production of shorty-chain fatty acids (SCFA), determined reduced levels of 
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butyrate in IBD patients. These SCFA are important source of energy of colonic 
epithelial cells[135,136].  
 Induction of intestinal inflammation by pathogens and functionally altered 
commensal bacteria 
o Mycobacterium avium subspecies paratuberculosis (MAP): CD has been 
associated with Johne’s disease in cattle caused by MAP, an spontaneous 
granulomatous enterocolitis[137]. Proposed mechanisms of transmission include 
infected milk, meat and water[131]. MAP is an intracellular pathogen that evades 
killing within phagolysosomes[138] and can infect hosts with defective innate 
immune killing, such as NOD2 polymorphisms[139]. Indeed, Feller et al. [140] showed 
the specific association between MAP and CD in a systematic analysis.  
o Functional changes in commensal bacteria: High prevalence of adherent/invasive 
E. coli (AIEC) in genetically susceptible CD patients support the hypothesis that 
this disease can result from AIEC abnormally colonizing of the gastrointestinal 
tract and parasitizing IECs and macrophages[141]. Enterotoxins from colonic 
commensal bacteria like Clostridium difficile[142] and Bacteroides fragilis can 
induce intestinal inflammation[143]. Furthermore, C. difficile infection is increased 
in IBD patients[144].  
 Host genetic defects in containing commensal bacteria 
As already mentioned, host disturbances that affect innate immunity to microbial 
agents as NOD2 mutations and TLR altered expression, can contribute to dysbiosis in 
IBD patients. Furthermore, mutations in autophagy results in increased intracellular 
bacterial survival. 
Another susceptibility factor for CD are mutations on the neutrophil cytosolic factor 
(NCF) 4, a gene that encodes an oxidase that is responsible for the generation of 
reactive oxygen species in response to bacterial infections, resulting in altered killing 
of phagocytosed bacteria[145].  
These defects result in altered antigen presentation, reduced luminal and intracellular 
bacterial killing, leading to increased bacterial persistence in gut mucosa and 
dysbiosis[129]. 
 Defective bacterial host immunoregulation 
o Mucosal barrier defects: IBD is characterized by enhanced mucosal permeability. 
Defects in mucosal barrier exclusion causes permeation of pro-inflammatory 
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molecules, such as bacteria, toxins, antigens, from the luminal environment and 
enhancing inflammatory responses[146]. 
o Defective microbial killing: CD patients present defective microbial killing[147], as 
well as defective antimicrobial peptide production[148] resulting in abnormalities in 
killing bacteria. Moreover, NOD2 polymorphisms are associated with decreased 
defensing production by Paneth cells[90] and defective clearance of intracellular 
pathogens by colonic epithelial cells[149].  
o Defective suppressor cell activation:  IBD patients present serologic responses to 
a wide variety of microbial antigens[150,151] and fail to develop oral tolerance[152]. 
Molecular mimicry between microbial and host antigens has been reported, 
determining autoimmune responses by cross-reactive immunity[153]. 
 
All these mechanisms have a common theme: all increase the exposure of bacterial antigens to 
effector T cells and innate immune cells resident in the intestinal mucosa and/or alter the host 
immune response to commensal bacteria[129]. 
 
 
 
 
 
 
 
 
 
 
 
                
 
 
 
Fig. 5: Role of microbes in IBD pathogenesis[131] 
Ag: antigen; LPS: lipopolysaccharide; PG: peptidoglycan; CpG: oligodeoxynucleotides; SCFA: short-
chain fatty acid; sIgA: immunoglobulin A; IP-10: Inducible protein 10 
 
CHAPTER I 
26 
 
3.2. Treatment of IBD 
As curing is never obtained, the main goals of therapy in patients with IBD are to induce a clinical 
remission and then maintain that remission over time. Despite scientific advances, treatment for most 
patients with IBD continues to rely upon a stepwise therapeutic approach: using less potent, but safer 
medications for milder disease and moving to progressively more potent, but potentially toxic, 
medications as the diseases worsens. In this “step-up” approach, treatment for more patients begins 
with 5-aminosalicylates and antibiotics, next moves to corticosteroids and immunomodulators and 
finally progresses to anti-tumor necrosis factor therapy and surgical intervention[154].  
 
3.2.1. Anti-inflammatory and immunomodulatory drugs 
3.2.1.1. 5-Aminosalicylates (5-ASA) 
5-ASA remains a mainstay of treating active UC, it is effective for maintenance[155] and 
induction therapy in UC[156]. Even though existing data show little benefit for 5-ASA, 
sulfasalazine presented a modest efficacy for the treatment of active CD[157] and controlled-
release of mesalamine was effective as single agent in the treatment of active CD of ileum and 
colon[158]. 
3.2.1.2. Corticosteroids 
Corticosteroids are effective in CD and UC for inducing remission[159]. Even if adverse effects 
for corticosteroids are reported and they are associated with presence of infections, they have 
remained a mainstay of therapy in both CD and UC[160]. In this regard, in a phase III trial, 
budesonide in a controlled release formulation induced remission in patients with active UC 
minimizing systemic side effects[161]. 
3.2.1.3. Thiopurines 
Thiopurine analogs azathioprine and 6-mercaptopurine, may prevent relapse in quiescent UC 
and CD. These agents may therefore be useful steroid-sparing agents and as an adjunct to 
biological therapies[162]. The use of thiopurines further increased with the advent of antibody 
tumor necrosis factor therapy, as they have been shown to enhance the efficacy of this 
biological therapy either through complementary immunomodulatory mechanisms or by 
reducing the likelihood of forming neutralizing antibodies to these agents[160].  
3.2.1.4. Methotrexate 
Like thiopurines, this agent had been used in other immune disease before it was routinely 
used or studied in IBD. In a group of patients with chronically active CD, methotrexate was 
effective inducing remission and reducing requirements for prednisone[163]. In patients with CD 
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who enter remission after treatment with methotrexate, a low dose of this agent maintains 
remission[164]. 
3.2.1.5. Calcineurin inhibitors 
Cyclosporine therapy was rapidly effective for patients with severe corticosteroid-resistant 
UC[165]. Moreover, cyclosporine has a beneficial therapeutic effect in patients with active 
chronic CD and resistance to or intolerance of corticosteroids[166]. However, cyclosporine is 
associated with adverse effects, and is mostly used as a bridge to thiopurine therapy 
considering the renal toxicity with long-term use. In this respect, infliximab has become a 
favored option over calcineurin inhibitors in severely active UC[160]. 
3.2.1.6. Anti-tumor necrosis factor alpha (anti-TNFα) 
The pro-inflammatory cytokine TNF plays a key role in chronic intestinal inflammation found in 
IBD. Accordingly, the most efficient biological agents developed so far in IBD aimed at 
neutralizing TNF[167]. Anti-TNF agents have been a major advance in the management of 
acutely ill or corticosteroid-dependent individuals with CD or UC[160]. 
 
Infliximab is a chimeric anti-TNFα monoclonal antibody that binds to TNFα with high affinity, 
thereby neutralizing its biological activity. Patients with CD who respond to an initial dose of 
infliximab are more likely to be in remission, discontinue corticosteroids, and maintain their 
response for a longer period of time[168]. As well, infliximab was effective in moderate to 
severe active UC patients in achieving clinical remission and corticosteroid-sparing effects[169]. 
However, infliximab is immunogenic, and intermittent administration results in the 
development of human antichimeric antibodies, that lead to infusion reactions, loss of 
efficacy, and delayed hypersensitivity reactions[170].  
 
Adalimumab is a recombinant human monoclonal antibody that binds with high affinity and 
specificity to human TNFα and is frequently less immunogenic than chimeric monoclonal 
antibodies. In CD patients, adalimumab was well tolerated and induced remission[171], 
maintenance and steroid sparing effects[172]. This agent is also effective in UC, inducing 
remission with a safety profile[173]. 
 
One of the major problems with anti-TNF therapy is the need for alternate therapy among 
initial responders, secondary to loss of response or intolerance. Individuals who lose response 
to one anti-TNFα agent may respond to a second, although at a lower response rate. Although 
anti-TNFα agents are quite effective and reasonably safe, they are not effective in up to one-
third of individuals receiving this therapy, and they are quite expensive[160]. 
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3.2.1.7. Anti-adhesion molecules 
TNF antagonists, although efficacious, predispose patients to serious infection[174], showing the 
need of safer therapies. The α4β7 integrin is a cell-surface glycoprotein expressed on 
circulating T and B lymphocytes that interacts with a mucosal cell adhesion molecule on 
intestinal vasculature. Vedolizumab, a humanized monoclonal antibody that specifically 
recognizes the α4β7 heterodimer, is proposed as a therapy that selectively blocks gut 
lymphocyte trafficking. Vedolizumab is effective as both induction and maintenance therapies 
for patients with moderately to severely active UC[175].  As well, patients with moderately to 
severely active CD who were treated with vedolizumab were more likely to induce and 
maintained remission[176]. 
3.2.1.8. Agents in the pipeline 
 Anti-adhesion molecules 
Etrolizumab is a humanized monoclonal antibody that selectively binds the β7 subunit 
of the heterodimeric integrins α4β7 and αEβ7. It led to remission in patients with 
moderately to severely active UC who had no responded to conventional therapy[177]. 
Phase III trials of this agent are ongoing[167]. 
 
 Blockade of cytokines and signaling pathways 
o IL-12/IL-23: IL-12 and IL-23 are inflammatory cytokines implicated in CD. 
Ustekinumab is a human monoclonal antibody against both cytokines. This 
agent was effective in maintenance therapy and increasing rates of remission 
in CD patients[178]. Interestingly, patients with moderate to severe CD that 
were resistant to TNF antagonists had an increased rate of response to 
induction with ustekinumab and remission in maintenance therapy[179]. This 
molecule, approved for the treatment of psoriasis by the FDA, is in a phase II 
trial[167].  
o IL-6: IL-6 is a pleiotropic cytokine with central roles in immune regulation and 
inflammation. IL-6 and its receptor are increased in both serum and intestinal 
tissue of CD patients[180]. Humanized anti-IL-6 receptor monoclonal antibody 
was well tolerated and normalized the acute-phase responses in active CD[181]. 
A phase II clinical trial is ongoing[167]. 
o IL-13: IL-13 has been implicated as a key driver of UC. Tralokinumab is an IL-13 
neutralizing antibody. Tralokinumab did not significantly improve clinical 
response in UC patients but induced higher remission rates than placebo. This 
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suggests a possible therapeutic effect of tralokinumab that requires  further 
study[182]. 
o JAK inhibitors: The involvement of Janus kinase (JAK) 1 and JAK3 in the 
transduction processes of the receptors of several cytokines, has made JAK 
inhibition a potential therapeutic target in IBD. Tofacitinib inhibits JAK family 
members by blocking inflammation, interfering with several cytokine 
receptors[160]. Patients with moderately to severely UC treated with tofacitinib 
were more likely to have clinical response and remission[183]. A phase III trial is 
ongoing[167]. 
3.2.2. Microbial modulatory drugs 
As mentioned before, there is evidence that components of the intestinal microbiota contribute to 
the pathogenesis of IBD. These facts provide the rationale for selective therapeutic manipulation of 
the enteric bacterial population. 
3.2.2.1. Antibiotics 
Antibiotics as primary or adjuvant treatment of IBD have been largely studied. There is a 
therapeutic rationale for using antibiotics active against enteric bacteria, and the mechanisms 
of action proposed are[184]: 
 Decrease luminal and adherent mucosal bacterial concentrations 
 Selectively eliminate detrimental luminal bacterial subsets (alter the ratio of 
beneficial to aggressive commensal bacteria) 
 Decrease tissue invasion, treat micro-abscesses  and secondary bacterial proliferation 
adjacent to mucosal ulcers and fistulas 
 Decrease bacterial translocation and systemic dissemination of viable bacteria 
Many antibiotics and their combinations have been evaluated in IBD. Conclusions about their 
effectiveness against CD and UC are difficult to state as current data are conflicting. In this 
regard, Khan et al.[185] conducted the first comprehensive systematic meta-analysis looking at 
all antibacterial therapies in IBD. Only well-defined controlled assays were considered, 
demonstrating that antibiotics are effective for: 
 Active CD, especially rifamycin derivatives either alone or in combination with other 
antibiotics, inducing remission in active CD.  
 Perianal CD fistula, reducing fistula drainage, using either ciprofloxacin or 
metronidazole. 
 Quiescent CD, preventing relapse especially for combinations including 
antimycobacterials 
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 Active UC, different single or combination of antibiotics, inducing remission. 
However, given the variety of antibiotics tested in the trials, it is not possible to recommend a 
specific antibiotic therapy for IBD. The only exception to this is the use of either ciprofloxacin or 
metronidazole for treating CD perianal fistulas[185].  
Post-operatively, metronidazole[186] and ornidazole[187] were effective preventing CD recurrence, 
showing the efficacy of nitroimidazoles after surgical resection. Furthermore, concomitant use 
of azathioprine and metronidazole resulted in lower post-surgical recurrences and favorable 
outcomes. Thus, this combined treatment seems to be recommendable for operated CD 
patients with enhanced risk for recurrence[188]. 
Therefore, it is clear that altering gut microbial flora may have a role in modulating IBD activity. 
Further studies are needed to determine if antibiotics are having an effect acting on one 
bacterial species or changing the composition of gut microbiome in general. For that, analysis of 
changes in intestinal microbiota should be included in trials of antibiotic therapy to explore 
what effects these interventions are having on gut flora[162].  
As suggested by Pineton de Chambrun et al.[189], antibiotic therapy in IBD needs to be 
personalized. Patients need to be stratified according to pathological type, bacteriological and 
genetic markers. At the same time, antibiotics need to be selected based on what effect on 
microbiota is expected (reduction of total loads or specific pathogens), as well as evaluated for 
their use alone or in combination therapies (with immunomodulators). Additionally, well-
established endpoints as markers of the therapy efficacy are needed. Thus, selecting the 
adequate antibiotic for the right type of patient may lead to better results. 
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Fig. 6: New strategies for the use of antibiotics in IBD[189]  
3.2.2.2. Probiotics 
Probiotics are viable microorganisms with beneficial physiologic or therapeutic activities, 
originally derived from cultured foods, especially milk products[184]. Various species and 
bacterial strains that have been used in IBD clinical trials, are believed to have a potential 
beneficial role. The most evaluated probiotics are E. coli Nissle, VSL #3 (mixture of 4 strains of 
Lactobacillus, 3 strains of Bifidobacterium and one strain of Streptococcus salivarius 
thermophilus), BIO-three (mixture of S. faecalis, Clostridum butyricum, Bacillus mesentericus), 
a mixture of L. rhammosus and L. reuteri, strains of Bifidobacterium brevis, Bifidobacterium 
bifidum, L. acidophilus and Saccharomyces boulardii[190].  
 
Probiotic supplementation can reestablish intestinal bacterial homeostasis and downregulate 
gut inflammation characteristic of IBD patients, thus modulating the inflammatory/anti-
inflammatory balance. Indeed, administration of probiotics can normalize altered intestinal 
microbiota in IBD patients, and increase protective species by reducing the pathogen load, 
positively affecting intestinal permeability, balancing local immune response, producing 
beneficial substances and disintegrating pathogenic antigens in the intestinal lumen[191].  
 
In UC patients probiotics showed promising results: In patients not responding to conventional 
therapy, VSL #3 resulted in induction of remission with no adverse events[192]. Administration 
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of BIO-three improved the clinical symptoms and endoscopic findings[193]. Lactobacillus GG 
was effective and safe for maintaining remission and was more effective than standard 
treatment with mesalazine in prolonging the relapse-free time[194]. E. coli Nissle was as 
effective as 5-ASA in preventing relapse[195] and in maintenance therapy[195,196]. 
 
On the other hand, trials with the use of probiotics in CD are less concordant than in UC. There 
is insufficient evidence to make conclusions about the efficacy of probiotics for induction of 
remission in CD[197]. Results of trials are mixed: randomized controlled trials showed that 
Lactobacillus johnsonii did not prevent endoscopic recurrence in operated patients[198,199]. 
Lactobacillus GG neither prevented endoscopic recurrence at one year nor reduced the 
severity of recurrent lesions in operated patients[200].  On the contrary, E. coli Nissle reduced 
the risk of relapse and minimized the need of glucocorticoids[201]. Guandalini[202] reported 
benefit of Lactobacillus GG in pediatric patients, and Saccharomyces boulardii may represent a 
useful tool in maintenance therapy[203].  
 
However, when the intestinal epithelial layer is inflamed like in IBD, it is important for 
probiotics to be rationally tested, to avoid causing harm. In fact, probiotics should only be 
contemplated if the integrity of the gastrointestinal tract is not severely compromised[160]. 
More recently, genetically engineered bacteria that secrete immunosuppressive substances 
such as IL-10 have been studied[204].  
3.2.2.3. Prebiotics 
Prebiotics are dietary supplementations, usually non-digestible selectively fermented 
glucides, which are energy substrates for protective intestinal organisms. They can stimulate 
for example Lactobacillus and bifidobacterium growth, thus inducing increasing bacterial 
fermentation resulting in SCFA production, in particular butyrate. Consequently, prebiotics 
promote inhibition of harmful species by decreasing the luminal pH, improve epithelial barrier 
function, reduce epithelial adhesion and produce bactericidal molecules[190]. The net result of 
prebiotic administration is functionally equivalent to administering probiotic bacteria[184]. 
 
Fructo-oligosaccharide (FOS) therapy was studied against CD. FOS treatment was well 
tolerated, led to a significant improvement in disease activity and increased fecal 
bifidobacteria concentration. The percentage of DCs producing IL-10, an anti-inflammatory 
cytokine was increased[205]. However, a randomized placebo-controlled trial showed no clinical 
benefit of FOS in inducing remission, despite impacting on DC function. This suggests that 
further studies of the effects of FOS perhaps in maintaining disease remission or in preventing 
the onset, are needed[206]. 
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Germinated barley foodstuff (GBF), which is derived from malt, consists mainly of dietary fiber 
and glutamine rich protein. GBF is a prebiotic foodstuff that effectively increases luminal 
butyrate production by stimulating the growth of protective bacteria[207]. Studies of GBF 
administration in UC patients have been carried out. After 4 weeks of GBF treatment, no side 
effects were observed and there was a decrease in clinical activity and increased fecal 
concentrations of Bificobacterium and Eubacterium limosum[208]. GBF was also effective in 
long-term therapy[209].  This suggests that GBF may have the potency to reduce clinical activity 
of UC, supporting its administration as a new adjunct therapy[208].  
3.2.2.4. Enteral nutrition 
Enteral nutritional (EN) therapy using liquid formulas (elemental, semi-elemental or 
polymeric) is often used in the management of pediatric CD. It can be administered in two 
ways: an exclusive enteral nutrition (EEN) as the sole dietary source, being used as primary 
medical therapy to induce remission; and as partial enteral nutrition (PEN) given in addition to 
a normal diet, with the primary goal to improve nutritional status or to maintain remission[210]. 
Clinical guidelines recommend EEN if a patient declines drug therapy or as an adjunctive 
therapy to support nutrition, rather than as a primary therapy[211]. 
 
EN has been shown to exert both a change in gut microflora and an anti-inflammatory effect. 
Hypotheses about the mechanism of action of EN include: elimination of dietary antigen 
uptake, correction of intestinal permeability, diminution of intestinal synthesis of 
inflammatory mediators via reduction in dietary fat and provision of important micronutrients 
to the diseased intestine[210,212]. 
 
EEN is well-established as a first line therapy instead of corticosteroids to treat active CD in 
children[211]. It has been shown that there is no difference in efficacy between EN and 
corticosteroid therapy in children. The absence of steroids side effects could make EN a better 
choice for first-line therapy in children[213].  Children treated with EEN alone had remission and 
modification of the fecal microflora. However, variations in bacterial species required time to 
achieve stability[214]. PEN can instead, be useful in the maintenance of remission and 
prevention of relapse, delaying the requirement for further therapy[210].  
 
There is also evidence to support a possible role of EEN for adult CD patients, with newly 
diagnosed disease and ileal involvement[211]. O’Morain[215] demonstrated the benefit of EN on 
the induction of remission in adult CD patients, as a safer therapy than corticoids. 
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3.2.2.5. Fecal microbiota transplantation (FMT) 
FMT is the transfer of gut microbiota from a healthy donor, via infusion of a liquid stool 
suspension, to restore the gut microbiota of a diseased individual. The objective of FMT is to 
introduce a complete, stable community of gut microorganisms, which are aimed at repairing 
or replacing the disrupted native microbiota of a patient[216,217]. FMT has recently become 
prominent as a treatment for refractory and recurrent C. difficile infection. Whilst the available 
evidence is limited, FMT could be an effective and safe treatment for IBD, at least when 
standard treatments have failed. However, controlled trials are still required to confirm its 
efficacy[217]. 
 
In a large pilot study, FMT was effective in patients with refractory CD.  These results 
demonstrated that FMT through patient’s mid-gut might be a safe, feasible, and efficient 
rescue therapy for refractory CD[218]. Concerning UC, a controlled trial showed that FMT 
through enema administration induced remission in active UC[219]. Nonetheless, long-term 
follow-up is still lacking.  
 
Temporal fecal microbiota analysis represent an effective option for monitoring colonization 
efficacy and assessing FMT therapy success. In this respect microbiota of UC patients after 
FMT was analyzed. Results showed that healthy bacterial communities such as Bacteroidetes, 
Firmicutes, and Verrucomicrobia were decreased and enterobacteria were abundant. In some 
cases, there was a major shift in patient microbiota towards the donor microbiota that was 
transient, in other, this was maintained several weeks. These findings suggested that the 
colonization of donor microbiota is a gradual process of sequential establishment of 
individual organisms, and that UC patients in remission via conventional medical therapy or 
those with mild disease might be more likely candidates for future FMT trials[220]. 
 
Finally, there is no currently cure for IBDs, these diseases can persist sometimes even after surgery.  
Thus IBD patients will typically need treatment throughout their lives. However, understanding the 
causes of these pathologies will help to find a cure.  
 
4. Colonic-targeted delivery of drugs 
There is an increasing interest in developing oral dosage forms that effect primary drug release to the colon. 
Colonic-targeted drug delivery is of crucial importance for drugs that are unstable or unabsorbed in the upper 
GI tract, drugs that require a delay in absorption and those required for the treatment of colonic 
pathologies[221].  Therefore, in the treatment of IBD, oral forms providing a colonic drug delivery are of 
relevance.  
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Furthermore, for local colonic pathologies like IBD, a colon targeted approach not only increases the 
bioavailability of the drug at the site of action, but also reduces the amount of drug needed to be 
administered resulting in decreased side effects[221,222]. 
 
For this purpose, oral dosage forms aiming a colonic drug delivery have to overcome many physiological 
barriers. Absorption or degradation of the drug in the upper part of the GI tract is one of the major obstacles 
that has to be circumvented for successful colonic drug delivery. For this, oral forms that can respond to the 
physiological changes in the colon to trigger the release of the drug in this site of action are needed[221,223]. 
There are several approaches to target drugs into the colon: 
 
4.1. pH-dependent 
pH dependent colonic targeted oral formulations should able to withstand the lower pH values of the 
stomach and of the proximal part of the small intestine, and to disintegrate at neutral or slightly alkaline 
pH in order to deliver the drug at the terminal ileum and colon[224,225]. 
 
The most commonly used pH-dependent polymers for coating of oral dosage forms are methacrylic acid 
copolymers, commonly known as Eudragit®. In this respect, Eudragit® L100-55, L100 and S100 which 
dissolve at pH 5.5, 6.0 and 7.0 respectively have been widely used[226,227]. Commercialized mesalazine 
tablets coated with Eudragit® L-100 available as Claversal, Salofalk, Mesasal and Rowasa. As well, 
Eudragit® S-100 mesalazine tablets are marketed as Asacol. These tablets release the drug at the 
terminal ileum and beyond for topical inflammatory action in the colon[225]. 
 
However, GI fluids might pass through the polymeric coating while the dosage form transits the small 
intestine, leading to premature drug release in the upper parts of the GI tract.  Furthermore, failure of 
the coating to dissolve may also occur when the pH of the colon drops below normal in patients with 
IBD[225]. 
 
Coating formulations consisting of a combination of pH-dependent polymers have been used to 
overcome the issue of high GI pH variability among individuals[226]. Eudragit® L and Eudragit® S have 
frequently been mixed with each other in differing weight ratios in an attempt to fine-tune the overall 
dissolution performance of the coat[227]. There are also formulations based on the combination of pH-
dependent and pH-independent polymers. Eudragit® RS and RL are copolymers of acrylic and 
methacrylic acid esters, which contain a low level of quaternary ammonium groups. Both copolymers are 
insoluble in water but they hydrate in GI fluids independent of pH[225]. The use of these insoluble 
materials combined with pH-dependent polymers, would result in a further delayed and slower release 
of the drug, acting as a pH-controlled pore formers[227]. 
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Fig. 7: Structure of the MMX ™ system[233] 
 
Although polymethacrylates have most widely been employed as pH-dependent coating agents for colon 
delivery, the use of other polymers, such as hydroxypropyl methylcellulose acetate succinate (HPMCAS), 
cellulose acetate phthalate (CAP)[228] and shellac[229], a pharmaceutically used resin of animal origin, was 
also investigated. These polymers possess a pH threshold of around 6.7; 5.8 and 7.3, respectively. 
 
Determinants of luminal pH in the colon include mucosal bicarbonate and lactate production, bacterial 
fermentation of carbohydrates, mucosal absorption of SCFA, and possibly intestinal transit. Alterations in 
these factors as a result of mucosal disease and changes in diet, likely explain abnormal pH measurement 
in IBD[230].  Therefore, pH-sensitive polymers are not completely suitable for colon targeted drug delivery 
systems due to poor site specificity[231,232]. These issues have prompted the development of other types 
of delivery systems[225].  
 
Some examples of pH-dependent technologies are described below: 
 
Multi-matrix system (MMX™): This technology 
permits a sustained and homogeneous release of 
5-ASA throughout the entire colon. It combines an 
outer pH-dependent polymethacrylate coat 
comprising a blend of Eudragit® S and L and an 
inner tablet core containing 5-ASA dispersed 
within a network of hydrophilic and lipophilic 
matrices made of carmellose sodium, carnauba 
wax and stearic acid. Once the outer coat dissolves 
at pH ≥7, normally in the terminal ileum, the 
interaction of intestinal fluids with the 
hydrophilic matrix causes the tablet core to swell and form a viscous gel mass that slows the diffusion of 
5-ASA into the colonic lumen. Small pieces of the gel mass gradually break away in the colon, releasing 5-
ASA in proximity to the colonic mucosa. The lipophilic matrix further slows penetration of intestinal fluids 
into the tablet core, reducing the rate of dissolution and thereby prolonging therapeutic activity[233,234].  
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Fig. 8: Starch TARGIT™capsule component parts 
(lid and body) and assembled to form capsule [235] 
Fig. 9: Schematic representation of the mode of action of 
non-percolating incorporation of disintegrants in a pH-
responsive polymer coating [237] 
Targit™: This technology is based on the application of 
pH-sensitive coating made of a mixture of Eudragit® S 
and L, onto injection-molded starch capsules. The blend 
of pH-sensitive polymers in Targit™ is specifically 
chosen to start dissolving at a relatively low pH to avoid 
the potential drawbacks associated with polymers 
that do not dissolve until a high pH is reached that is, 
incomplete or delayed disintegration. Due to the construction of Targit™, in which the walls of the starch 
capsule separate the enteric coating from the capsule contents, dissolution of the coating is essentially 
independent of the capsule fill. This avoids the need to reformulate the coating when changing from one 
drug compound or formulation to another[235]. 
 
 
Colopulse®: The tablet coating of the 
Colopulse® technology consists of an Eudragit® 
S film with dispersed croscarmellose, in a non-
percolating mode, as a super-disintegrant 
[236,237].Release from the coated ColoPulse® 
system is triggered by the variation in the GI 
pH in the terminal ileum and occurs at pH >7. 
It differs from other pH responsive systems 
because of the non-percolating incorporation 
of a disintegrant in the coating, yielding a 
highly reliable and pulsatile release pattern in 
the targeted region[238]. The mechanisms are 
explained in Figure 9. 
 
4.2. Time-dependent 
In these systems the site of drug release is decided by the transit time of the formulation in the GI tract. 
On an average, an orally administered dosage form takes about 3h to travel through the length of the 
small intestine to the beginning of the colon. Compared to gastric emptying rate, the small intestinal 
transit time is relatively consistent. In principle, time-controlled systems rely on this consistent small 
intestinal transit time[225].  
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Fig. 10: Schematic mechanism of action of Chronotopic™ system [242] 
For this purpose, different combinations of hydrophilic and hydrophobic polymers have been used as 
coating materials on solid formulations[239]. The majority of coated systems intended for time-based 
colonic release consist in enteric dosage forms for pulsatile delivery, wherein erodible, rupturable, 
permeable or semipermeable functional layers are responsible for imparting the appropriate delay phase 
prior to the drug liberation[240]. Swellable systems for example, use hydrophilic polymers that swell when 
coming in contact with water and release the drug based on GIT time transit. Lag time can be adjusted by 
altering the thickness of the coating polymer. Combinations of water insoluble polymers like 
ethylcellulose (EC) and hydrophilic polymers like hydroxypropyl methylcellulose (HPMC), hydroxypropyl 
cellulose (HPC), have been used to produce time-dependent systems[239]. 
 
Generally time-controlled formulations for colonic delivery include a pH-dependent component because 
the transit of a formulation in the GI tract is largely influenced by the gastric emptying time. Enteric 
coating is also used for preventing the rapid swelling and disintegration of the other components in the 
upper GI tract[225]. 
 
Ideally, these formulations are designed such that the site of delivery is not affected by the individual 
differences in the gastric emptying time, pH of the stomach and small intestine or presence of anaerobic 
bacteria in the colon[225].  
 
Due to the inter-subject variation in GI transit times, the onset of initial drug release could sometimes 
occur in the small intestine, or formulations could pass the ascending colon intact[223]. Additionally, the 
performance of a time-dependent formulation can be affected significantly by the pathophysiological 
conditions associated with the GI tract. Accelerated transit through different regions of the colon has 
been observed in the patients with irritable bowel syndrome, diarrhea, and UC. Therefore, these systems 
might not be ideal to deliver drugs colon-specifically for the treatment of colon-related diseases[223]. 
 
Some examples of time-dependent systems are: 
 
Chronotopic™ system:  The system 
consists in a drug-loaded core 
coated with a swellable hydrophilic 
polymer, which is responsible for a 
lag phase preceding the onset of 
release. When in contact with the 
aqueous fluids, the hydrophilic 
polymer undergoes a glassy-rubbery transition and, in the rubbery state, it becomes more permeable, 
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Fig. 11:  Structure of TES  
1: sucrose core; 2: drug; 3: 
swelling agent; 4: polymer 
membrane [from: US 4871549 A 
patent] 
Fig. 12:  Structure of Time-controlled capsule [from US 
5637319 patent] 
dissolves and/or erodes. An outer gastro-resistant film is expected to remain the formulation intact as 
long as it is located in the stomach, overcoming the variability in gastric emptying time. The pH change 
occurring with the passage of the unit from the gastric to the duodenal environment determines the 
dissolution of the enteric coating, thus allowing the interaction between hydrophilic polymer and 
biological fluids to start. This interaction gives rise to the lag phase[241,242]. The delayed release behavior is 
mainly controlled by the viscosity grade and amount of the swellable polymer applied[227].  
 
Time-Controlled Explosion System (TES): The TES could be in the 
form of a bead or granule, which has four-layered spherical 
structure: a core, the drug, the swelling agent and a water 
insoluble polymer membrane. TES is characterized by a rapid drug 
release with a precisely programmed lag time. This is given by the 
expansion of the swelling agent by water penetration through the 
outer membrane, destruction of the membrane by stress due to 
swelling force and subsequent rapid drug release. Low-substituted-
HPC (L-HPC) and EC were used as the swelling agent and for the 
outer insoluble membrane, respectively. The lag time can be 
programmed by changing the outer membrane thickness[243]. 
 
Time-controlled capsule: This capsule is composed 
of four parts: drug container, swellable substance, 
capsule body and cap. At the bottom of the body, 
micropores are made. After oral administration, GI 
fluid permeates through the micropores and causes 
swelling of excipients as L-HPC. This causes an inner 
pressure, which pushes the drug container. When 
the cap made of water-insoluble EC cannot resist 
the swelling pressure, it disintegrates and the drug 
in the container is released from the capsule[244]. 
The disintegration lag-time depends on the balance 
between the tolerability and thickness of the water-insoluble membrane and the amount of swellable 
excipient[245]. 
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Fig. 13:  Schematic mechanism of action of the Time clock® system [246] 
Fig. 14:  Structure of Pulsincap system 
(modified from [221]) 
Fig. 15:  Structure of CTDC[251] 
 
Time clock® system: This system 
is made of a coated solid dosage 
form, either tablet or capsule. 
The coating consists of a 
hydrophobic-surfactant layer, 
applied as aqueous dispersion, to 
which a hydrosoluble polymer is 
added to improve adhesion to the 
core. The coating is made of carnauba wax, beeswax, polyoxyethylene sorbitan monooleate and water. 
The dispersion, dried on the core during coating, retains the capacity to rehydrate and redisperse in an 
aqueous environment in a time proportional to the thickness of the film. Following redispersion, the core 
is available for dissolution[246]. To overcome the problem of inopportune drug release in the small bowel, 
an enteric coating can be applied to the formulation preventing dispersion of the hydrophobic layer in 
the stomach[247,248]. 
 
Pulsincap™ system: The device is composed of a water 
insoluble body capsule enclosing the drug reservoir. The 
half capsule body is sealed at the open end with a 
swellable hydrogel plug that is covered by a water 
soluble cap. The whole unit is coated with an enteric 
polymer to avoid problems of variable gastric emptying. 
When the capsule comes in contact with fluids, the plug 
swells, and after a lag time, the plug pushes itself 
outside the capsule and rapidly releases the drug. The 
length of the plug and its point of insertion into the capsule control the lag time[249,250]. 
 
Colon-targeted delivery capsule (CTDC): 
The system combines time and pH 
approaches to a hard gelatin capsule. It 
contains an organic acid together with 
an active ingredient in a capsule coated 
with a three-layered film consisting of 
an acid-soluble polymer, a water soluble 
polymer, and an enteric polymer. The 
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intermediate layer prevents the direct contact of the cationic and anionic polymeric layer. After ingestion 
of the capsule, drug release is prevented in the stomach due to enteric polymeric layer. After gastric 
emptying, the outer layer and the intermediate layer quickly dissolve, but the inner polymeric layer still 
remains and prevents the drug release in the intestine. However, when the micro-environmental pH 
inside the capsule gradually decreases according to the dissolution of organic acid, and when the inner 
polymeric layer is finally dissolved by the acid fluid, the drug content is quickly released. The onset of the 
drug release, therefore, can be controlled by the thickness of the inner polymeric layer[251].  
 
4.3. Microbial enzyme-dependent 
Colon microbiota is increasingly recognized as a preferable triggering component in the design of colon-
specific drug delivery systems since there is an abrupt increase of the bacterial population and 
corresponding enzyme activities in the colon, which is independent of the GI transit time. The colon has a 
population of 1011 – 1012 colony-forming units (CFU) mL-1 with Bacteroides, Bifidobacterium, 
Eubacterium and Lactobacillus greatly outnumbering other species, converting the large intestine as the 
site of the most abundant microflora in the GI tract[252,253,254]. 
 
Hydrolytical and redox reactions are the predominant metabolic conversions triggered by the intestinal 
microflora. The main hydrolytic enzymes produced by the intestinal bacteria are β-glucuronidase, β-
xylosidase, α-L-arabinosidase and β-galactosidase, whereas the reductive enzymes include 
nitroreductase, deaminase and urea dehydroxylase[253]. 
4.3.1. Prodrugs 
These are therapeutic agents that have to undergo biotransformation before exerting a 
pharmacological action. Once in the colon, enzymes produced by colonic bacteria act on the 
prodrugs to release the active moiety[224]:  
 Azo-bond conjugates: Through cleavage of the azo group by bacterial azoreductases. For 
example: sulfasalazine where sulfapyridine is linked to a salicylate radical by an azo bond; 
olsalazine that is a dimer of 5-ASA linked via an azo bond.  
 Glycoside conjugates:  Steroid glycosides, for example, are hydrophilic and thus poorly absorbed 
from the small intestine. One it reaches the colon it can be cleaved by bacterial glycosidases, 
releasing the free drug to be absorbed by the colonic mucosa.  
 Glucuronide conjugates: Here the deglucuronidation process results in the release of active 
drug and enables its absorption. This is used for narcotic antagonists and steroids. 
 Cyclodextrin conjugates: Cyclodextrins are cyclic oligosaccharides barely capable of being 
hydrolyzed and only slightly absorbed in the upper GI tract. However, they are fermented by 
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colonic microflora into small saccharides. The formation of drug conjugates with cyclodextrins 
might thus be used in colon-targeting delivery. 
 Dextran conjugates: Ester prodrugs of this polysaccharide with naproxen and corticosteroids 
provided a colonic drug release.  
 Polymeric prodrugs: Here, drug is linked directly to a high molecular weight polymeric 
backbone. This linkage is susceptible to enzymatic attack in the large intestine. The large size of 
the prodrug hinders absorption from the upper GIT. Poly-asa, in which sulfapyridine is linked to 
an inert polymer backbone to which 5-ASA is azo linked. The mechanism of colonic 5-ASA 
delivery is essentially that of sulfasalazine: reduction of azo bonds.  
The prodrug approach is not very versatile as its formation depends upon the functional groups 
available on the drug moiety for chemical linkage. Furthermore, prodrugs are new chemical 
entities and need evaluation before being used as drug carriers. Toxicological studies need to be 
performed before their use as drug delivery systems[255]. Thus, dextrans and cyclodextrins remain 
the polysaccharides of choice as drug carriers for the formation of conjugates/prodrugs because of 
a safer toxicological profile[255]. 
4.3.2. Azo-polymeric coatings 
Various azo polymers have also been evaluated as coating materials over drug cores. They are 
similarly susceptible to cleavage by the azoreductase in the colon[255]. Peptide drugs were coated 
with polymers cross-linked with azoaromatic groups to form a film degradable by colonic 
microflora[256].  Azopolymer-coated pellets containing budesonide were effective for colonic delivery 
in a rat model of colitis[257]. 
 
However, it has been shown the azoreductase activity in CD patients is decreased[258]. Furthermore, 
microbial degradation of azo crossed link polymers is generally slow, resulting in incomplete and 
irregular dug absorption. A limitation of azopolymer based formulation is the release of harmful 
substances on long-term use, generating a toxicity concern[239,259].  
 
These limitations can be overcome by the use of natural polymer materials with glycosidic 
linkage[239]. Considering this, the use of naturally occurring polysaccharides has been investigated for 
colonic delivery of drugs. 
 
4.3.3. Polysaccharide delivery systems 
The primary sources of carbon and energy of the vast colonic microflora are polysaccharides 
present in dietary residues that have been left indigested in the small intestine[260]. Therefore, 
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colonic degradable polysaccharides have been employed in colon-targeted systems, generally as 
film or compression coatings or within matrix systems.  
 
In film coating naturally occurring polysaccharides of plant, algal, animal or microbial origin, such as: 
pectin[261], inulin[262], chitosan[263], chondroitin sulphate[264], galactomannan[265], amylose[266], 
cyclodextrin[267] and starch derivatives[268,269], have been preferred as colon delivery aids primarily in 
view of their proven safety and biocompatibility characteristics. It should be noted that, because of 
the water solubility and poor film-forming properties of these polysaccharides, they might have to 
be mixed with other synthetic polymers in order to obtain a polymer film or to decrease the 
aqueous solubility[259]. That is the reason why coatings prepared from cellulosic (Aquacoat® ECD30, 
Surelease®), acrylic (Eudragit® NE30D and RS30D) or vinyl acetate (Kollicoat® SR30D) insoluble 
polymer aqueous dispersions are incorporated in appropriate amounts to polysaccharide solutions. 
This aims to prepare more suitable forms for targeting drugs to the colon. The identified release 
mechanism is drug diffusion through the coating, after leaching out or bacterial degradation of the 
polyssacharide, via the water-filled pores formed within the insoluble polymer network[227]. 
 
COLAL® technology involves a coating for drug pellets, tablets or capsules which is composed of EC 
and a ‘glassy amylose’, derived from starch. Human enzymes do not digest this amylose as the 
preparation moves through the upper GI tract, but is digested by bacterial enzymes found only in 
the colon. This technology was applied to the delivery of prednisolone: COLAL-PRED®. Clinical 
studies showed that prednisolone is consistently delivered in the ileocecal junction/ascending colon, 
regardless of the transit time and that treatment with COLAL-PRED® did not entail major systemic 
exposure to the corticosteroid[270]. COLAL-PRED® is in phase III clinical trials for treatment of mild to 
moderate UC[271]. 
 
Poor film-forming properties of natural substances can be overcome by applying the 
polysaccharides as compression coatings. Pectin[272] and guar gum[273,274] were for example, used as 
direct compression coatings for tablets aiming a colonic delivery.   
 
Another alternative approach involves the compression of blends of the drug, a degradable 
polysaccharide and additives to form a monolithic or multiparticulate solid dosage form.  The drug is 
thus embedded in the matrix core of the degradable polymer. For example bioerodible matrix 
systems of cross-linked chondroitin sulfate[275], guar gum[276], pectin[277], chitosan[278], starch 
derivatives[279] have been studied. However, matrices have the disadvantage that only a limited 
amount of drug can be incorporated[259]. 
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Fig. 16:  Schematic mechanism of action of OROS® system[289] 
Bacterially triggered colonic drug release seems to avoid drawbacks of pH and time dependent 
approaches. These systems have better site specificity and reliability in humans than pH-dependent 
formulations[280] and they are not influenced by the feeding state[281]. Moreover, a system than 
conciliates both, the pH and bacterial approach, provides also colon-specificity[282]. 
 
4.4. Newer technologies 
4.4.1. Pressure-dependent 
Intestinal pressure-controlled colon delivery capsules (PCDCs), rely on the relatively strong 
peristaltic waves in the colon that lead to an increased luminal pressure. It consists of capsular 
shaped suppositories coated with a water-insoluble polymer like EC[283]. The PCDCs were originally 
prepared by coating the inner surface of gelatin capsules where the drug was introduced along with 
a suppository base[283,284]. In these systems, the drug is dissolved with a suppository base such as 
polyethylene glycol[285,284], propylene glycol[283] or an oily base[286]. Therefore, after oral 
administration, the system behaves like an EC balloon containing drug solution, since the 
suppository base liquefies at body temperature. In the upper GI tract, the EC balloon is not directly 
subjected to intestinal luminal pressures since sufficient fluid is present in the stomach and small 
intestine. However, reabsorption of water occurs in the colon and the viscosity of the luminal 
contents increases. As a result, intestinal pressures due to peristalsis directly affect the EC balloon. 
Since the EC balloon cannot tolerate these pressures, it disintegrates and releases the drug in the 
colon. The thickness of the EC membrane is the most important factor for the disintegration of the 
balloon in the colon[287]. Other EC coating methods like dipping[288] or direct suppository 
coating[285,287] have also been studied. 
4.4.2. Osmotic-dependent 
The OROS® system comprises 4 or 5 
push-pull units within a hard gelatin 
capsule. Each push-pull unit is a bilayer 
tablet core containing the drug in the 
top layer and the osmotic push agent 
in the lower layer. The drug 
formulation contains the drug 
combined with osmotic and 
suspending agents. This bilayer tablet 
is coated with a semipermeable membrane that is drilled on the drug side to allow drug delivery 
through the orifice. The outside surface of the semipermeable membrane is then coated with 
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Fig. 17:  Schematic mechanism of action of CODES™[290] 
Eudragit® S-100 to delay the drug release from the devise during the transit through the stomach. 
Upon arrival to the small intestine, when the pump is in operation, both the drug and osmotic layers 
imbibe water from the GI fluids across the membrane by the process of osmosis to formulate a 
suspension form in the drug layer. Simultaneously, by the pulling action of the water in the drug 
compartment, the drug suspension is pushed out of the drilled orifice by the dispersing action of the 
expanding osmotic, resulting in the release of the drug. The drug release kinetics is controlled by the 
rate of influx of water through the semipermeable membrane[289].  
 
 
4.4.3. CODES™ 
This system consists of three 
components: a core containing 
lactulose and the drug, an 
inner acid-soluble material 
layer, and an outer layer of an 
enterosoluble material. The 
concept of CODES™ is shown 
in Figure 17: in the stomach, 
the drug is not released from 
CODES™ with the enteric 
coating layer. In the small 
intestine where the enteric 
coating layer dissolves, the drug is still not released from the tablet core because of its inner acid-
soluble coating layer. However, GI fluids penetrate into the tablet core through the acid-soluble 
coating layer and then lactulose begins to dissolve inside the core during the small intestinal transit. 
When CODES™ arrives at the colon, lactulose leaches through the acid-soluble coating layer and is 
degraded by enterobacteria and produces organic acids. These organic acids should dissolve the 
acid-soluble coating layer to release the drug. The feature that distinguishes CODES™ from other 
strategies is the generation of organic acids by bacterial degradation of lactulose in the colon to 
dissolve the acid-soluble coating layer[290,291]. 
 
 
 
 
 
 
CHAPTER I 
46 
 
References:  
1.  ECDC/EMEA. Technical Report. The bacterial challenge: time to react. Technical Report. European Center for Disease 
Prevention and Control, European Medicines Agency. Stockholm, 2009.  
2.  T. Kirby, Europe to boost development of new antimicrobial drugs. Lancet. 379 (2012) 2229–30.  
3.  M.N. Alekshun, S. B. Levy, Molecular mechanisms of antibacterial multidrug resistance. Cell. 128 (2007) 1037–50.  
4.  J.M.A. Blair, M.A. Webber, A.J. Baylay, D.O. Ogbolu, L.J.V Piddock, Molecular mechanisms of antibiotic resistance. Nat. 
Rev. Microbiol. 13 (2015) 42–51.  
5.  S. Dzidic, V. Bedeković, Horizontal gene transfer-emerging multidrug resistance in hospital bacteria. Acta. Pharmacol. 
Sin. 24 (2003) 519–26.  
6.  S.B. Levy, B. Marshall, Antibacterial resistance worldwide: causes, challenges and responses. Nat. Med. 10 (2004) S122–
9.  
7.  H. Nikaido, Multidrug resistance in bacteria. Annu. Rev. Biochem. 78 (2009) 119–46.  
8.  B.H. Normark, S. Normark, Evolution and spread of antibiotic resistance. J. Intern. Med. 252 (2002) 91–106.  
9.  K. Lewis, Platforms for antibiotic discovery. Nat. Rev. Drug. Discov. 12 (2013) 371–87.  
10.  D.I. Andersson, D. Hughes, Antibiotic resistance and its cost: is it possible to reverse resistance? Nat. Rev. Microbiol. 8 
(2010) 260–71.  
11.  A. Rodríguez-Rojas, J. Rodríguez-Beltrán, A. Couce, J. Blázquez , Antibiotics and antibiotic resistance: a bitter fight against 
evolution. Int. J. Med. Microbiol. 303 (2013) 293–7.  
12.  J.A. Perry, G.D. Wright, The antibiotic resistance “mobilome”: searching for the link between environment and clinic. 
Front. Microbiol. 2013 (4) 138.  
13.  J.L. Martinez, Environmental pollution by antibiotics and by antibiotic resistance determinants. Environ. Pollut. 157 
(2009) 2893–902.  
14.  J. Davies, D. Davies, Origins and evolution of antibiotic resistance. Microbiol. Mol. Biol. Rev. 74 (2010) 417–33.  
15.  K. Kümmerer, Resistance in the environment. J. Antimicrob. Chemother. 54 (2004) 311–20.  
16.  W. Van Schaik, The human gut resistome. Philos. Trans. R. Soc. Lond. B. 370 (2015) 20140087.  
17.  H-H. Chang, T. Cohen, Y.H. Grad, W.P. Hanage, T.F. O’Brien, M. Lipsitch, Origin and proliferation of multiple-drug 
resistance in bacterial pathogens. Microbiol. Mol. Biol. Rev. 79 (2015) 101–16.  
18.  L.B. Rice, Federal funding for the study of antimicrobial resistance in nosocomial pathogens: no ESKAPE. J. Infect. Dis. 
197 (2008) 1079–81.  
19.  H.W. Boucher, G.H. Talbot, J.S. Bradley, J.E. Edwards, D. Gilbert, L.B. Rice, et al., Bad bugs, no drugs: no ESKAPE! An 
update from the Infectious Diseases Society of America. Clin. Infect. Dis. 48 (2009) 1–12.  
20.  G.L. French, The continuing crisis in antibiotic resistance. Int. J. Antimicrob. Agents. 36S3 (2010) S3–7.  
21.  H.C. Lewis, K. Mølbak, C. Reese, F.M. Aarestrup, M. Selchau, M. Sørum, et al., Pigs as source of methicillin-resistant 
Staphylococcus aureus CC398 infections in humans, Denmark. Emerging Infect. Dis. 14 (2008) 1383–9.  
CHAPTER I 
47 
 
22.  N.L. Van der Mee-Marquet, A. Corvaglia, M. Haenni, X. Bertrand, J-B. Franck, J. Kluytmans, et al., Emergence of a novel 
subpopulation of CC398 Staphylococcus aureus infecting animals is a serious hazard for humans. Front. Microbiol. 5 
(2014) 652.  
23.  B. Huttner, S. Harbarth, Think (Gram) negative! Crit. Care. 14 (2010) 171.  
24.  G. Patel, R.A. Bonomo, “Stormy waters ahead”: global emergence of carbapenemases. Front. Microbiol. 4 (2013) 48.  
25.  K.K. Kumarasamy, M.A. Toleman, T.R. Walsh, J. Bagaria, F. Butt, R. Balakrishnan, et al., Emergence of a new antibiotic 
resistance mechanism in India, Pakistan, and the UK: a molecular, biological, and epidemiological study. Lancet Infect. 10 
(2010) 597–602.  
26.  H. Aubry-Damon, K. Grenet, P. Sall-Ndiaye, D. Che, E. Cordeiro, M-E. Bougnoux, et al., Antimicrobial resistance in 
commensal flora of pig farmers. Emerging Infect. Dis. 10 (2004) 873–9.  
27.  L. Briñas, M.A. Moreno, M. Zarazaga, C. Porrero, Y. Sáenz, M. García, et al., Detection of CMY-2, CTX-M-14, and SHV-12 
beta-lactamases in Escherichia coli fecal-sample isolates from healthy chickens. Antimicrob. Agents Chemother. 47 
(2003) 2056–8.  
28.  N. Porres-Osante, Y. Sáenz, S. Somalo, C. Torres, Characterization of Beta-lactamases in Faecal Enterobacteriaceae 
Recovered from Healthy Humans in Spain: Focusing on AmpC Polymorphisms. Microb. Ecol. 70 (2014) 132-40  
29.  M-H. Nicolas-Chanoine, C. Gruson, S. Bialek-Davenet, X. Bertrand, F. Thomas-Jean, F. Bert, et al., 10-Fold increase (2006-
11) in the rate of healthy subjects with extended-spectrum β-lactamase-producing Escherichia coli faecal carriage in a 
Parisian check-up centre. J. Antimicrob. Chemother. 68 (2013) 562–8.  
30.  L. Pallecchi, A. Bartoloni, C. Fiorelli, A. Mantella, T. Di Maggio, H. Gamboa, et al., Rapid dissemination and diversity of 
CTX-M extended-spectrum beta-lactamase genes in commensal Escherichia coli isolates from healthy children from low-
resource settings in Latin America. Antimicrob. Agents Chemother. 51 (2007) 2720–5.  
31.  M. Fernández-Reyes, D. Vicente, M. Gomariz, O. Esnal, J. Landa, E. Oñate, et al., High rate of fecal carriage of extended-
spectrum-β-lactamase-producing Escherichia coli in healthy children in Gipuzkoa, northern Spain. Antimicrob. Agents 
Chemother. 58 (2014) 1822–4.  
32.  D.M. Livermore, Has the era of untreatable infections arrived? J. Antimicrob. Chemother. 64 (2009) i29–36.  
33.  P. Nordmann, J-P. Couard, D. Sansot, L. Poirel, Emergence of an autochthonous and community-acquired NDM-1-
producing Klebsiella pneumoniae in Europe. Clin. Infect. Dis. 54 (2012) 150–1.  
34.  C. Arpin, P. Noury, D. Boraud, L. Coulange, A. Manetti, C. André, et al., NDM-1-producing Klebsiella pneumoniae resistant 
to colistin in a French community patient without history of foreign travel. Antimicrob. Agents Chemother. 56 (2012) 
3432–4.  
35.  C. Urban, H. Tiruvury, N. Mariano, R. Colon-Urban, J.J. Rahal, Polymyxin-resistant clinical isolates of Escherichia coli. 
Antimicrob. Agents Chemother. 55 (2011) 388–9.  
36.  S.E. Cosgrove, The relationship between antimicrobial resistance and patient outcomes: mortality, length of hospital 
stay, and health care costs. Clin. Infect. 42 (2006) S82–9.  
37.  G.L. French, Clinical impact and relevance of antibiotic resistance. Adv. Drug Deliv. Rev. 57 (2005) 1514–27.  
38.  M.S. Niederman, Impact of antibiotic resistance on clinical outcomes and the cost of care. Crit. Care Med. 29 (2001) 
N114–20.  
39.  WHO. World Health Statistics 2014. A wealth of information on global public health. World Health Organization. Geneva, 
2014.  
40.  S.J. Projan, Why is big Pharma getting out of antibacterial drug discovery? Curr. Opin. Microbiol. 6 (2003) 427–30.  
CHAPTER I 
48 
 
41.  J. Carlet, P. Collignon, D. Goldmann, H. Goossens, I.C. Gyssens, S. Harbarth, et al., Society’s failure to protect a precious 
resource: antibiotics. Lancet. 378 (2011) 369–71.  
42.  L.J.Piddock, The crisis of no new antibiotics—what is the way forward? Lancet Infec. Dis. 12 (2012) 249–53.  
43.  S. Harbarth, U. Theuretzbacher, J. Hackett - on behalf of the DRIVE-AB consortium, Antibiotic research and development: 
business as usual? J Antimicrob. Chemother. 70 (2015) 1604-7  
44.  L. Freire-Moran, B. Aronsson, C. Manz, I.C. Gyssens, A.D. So, D.L. Monnet, et al., Critical shortage of new antibiotics in 
development against multidrug-resistant bacteria-Time to react is now. Drug Resist. Updat. 14 (2011) 118–24.  
45.  K.M. Overbye, J.F. Barrett, Antibiotics: Where did we go wrong? Drug Discov. Today 10 (2005) 45–52.  
46.  R. Wise, BSAC Working Party on the Urgent Need: Regenerating Antibacterial Drug Discovery and Development. The 
urgent need for new antibacterial agents. J. Antimicrob. Chemother. 66 (2011) 1939–40.  
47.  H. Wagner, G. Ulrich-Merzenich, Synergy research: Approaching a new generation of phytopharmaceuticals. 
Phytomedicine. 16 (2009) 97–110.  
48.  N.S. Radulović, P.D. Blagojević, Z.Z. Stojanović-Radić, N.M. Stojanović, Antimicrobial plant metabolites: structural 
diversity and mechanism of action. Curr. Med. Chem. 20 (2013) 932–52.  
49.  S.B. Singh, J.F. Barrett, Empirical antibacterial drug discovery—Foundation in natural products. Biochem. Pharmacol. 71 
(2006) 1006–15.  
50.  F.E. Koehn, G.T. Carter, The evolving role of natural products in drug discovery. Nat. Rev. Drug Discov. 4 (2005) 206–20.  
51.  J. Gertsch, Botanical drugs, synergy, and network pharmacology: forth and back to intelligent mixtures. Planta Med. 77 
(2011) 1086–98.  
52.  F. Bakkali, S. Averbeck, D. Averbeck, M. Idaomar, Biological effects of essential oils – A review. Food Chem. Toxicol. 46 
(2008) 446–75.  
53.  F. Nazzaro, F. Fratianni, L. De Martino, R. Coppola, V. De Feo, Effect of Essential Oils on Pathogenic Bacteria. 
Pharmaceuticals. 6 (2013) 1451–74.  
54.  F. Solórzano-Santos, M.G. Miranda-Novales, Essential oils from aromatic herbs as antimicrobial agents. Curr. Opin. 
Biotechnol. 23 (2012) 136–41.  
55.  J. Sikkema, J.A. de Bont, B. Poolman, Mechanisms of membrane toxicity of hydrocarbons. Microbiol. Rev. 59 (1995) 201–
22.  
56.  R.J. Lambert, P.N. Skandamis, P.J. Coote, G.J. Nychas, A study of the minimum inhibitory concentration and mode of 
action of oregano essential oil, thymol and carvacrol. J. Appl. Microbiol. 91 (2001) 453–62.  
57.  I.M. Helander, H-L. Alakomi, K. Latva-Kala, T. Mattila-Sandholm, I. Pol, E.J. Smid, et al., Characterization of the Action of 
Selected Essential Oil Components on Gram-Negative Bacteria. J. Agric. Food Chem. 46 (1998) 3590–5.  
58.  S. Burt, Essential oils: their antibacterial properties and potential applications in foods--a review. Int. J. Food Microbiol. 
94 (2004) 223–53.  
59.  R. Di Pasqua, N. Hoskins, G. Betts, G. Mauriello, Changes in membrane fatty acids composition of microbial cells induced 
by addiction of thymol, carvacrol, limonene, cinnamaldehyde, and eugenol in the growing media. J. Agric. Food. Chem. 
54 (2006) 2745–9.  
60.  J.A. Kwon, C.B. Yu, H.D. Park HD, Bacteriocidal effects and inhibition of cell separation of cinnamic aldehyde on Bacillus 
cereus. Lett. Appl. Microbiol. 37 (2003) 61–5.  
CHAPTER I 
49 
 
61.  R. Di Pasqua, G. Betts, N. Hoskins, M. Edwards, D. Ercolini, G. Mauriello, Membrane toxicity of antimicrobial compounds 
from essential oils. J. Agric. Food Chem. 55 (2007) 4863–70.  
62.  B.J. Juven, J. Kanner, F. Schved, H. Weisslowicz, Factors that interact with the antibacterial action of thyme essential oil 
and its active constituents. J. Appl. Bacteriol. 76 (1994) 626–31.  
63.  P. Domadia, S. Swarup, A. Bhunia, J. Sivaraman, D. Dasgupta, Inhibition of bacterial cell division protein FtsZ by 
cinnamaldehyde. Biochem. Pharmacol. 74 (2007) 831–40.  
64.  C.N. Wendakoon, M. Sakaguchi, Inhibition of Amino Acid Decarboxylase Activity of Enterobacter aerogenes by Active 
Components in Spices. J. Food Prot. 58 (1995) 280–3.  
65.  G. Meades, R.L. Henken, G.L. Waldrop, M.M. Rahman, S.D. Gilman, G.P.P. Kamatou, et al., Constituents of cinnamon 
inhibit bacterial acetyl CoA carboxylase. Planta Med. 76 (2010) 1570–5.  
66.  A. Ultee, E. Smid, Influence of carvacrol on growth and toxin production by Bacillus cereus. Int. J. Food Microbiol. 64 
(2001) 373–8.  
67.  R.S. Feldberg, S.C. Chang, A.N. Kotik, M. Nadler, Z. Neuwirth, D.C. Sundstrom DC, et al., In vitro mechanism of inhibition 
of bacterial cell growth by allicin. Antimicrob. Agents Chemother. 32 (1988) 1763–8.  
68.  R. Di Pasqua, G. Mauriello, G. Mamone, D. Ercolini, Expression of DnaK, HtpG, GroEL and Tf chaperones and the 
corresponding encoding genes during growth of Salmonella Thompson in presence of thymol alone or in combination 
with salt and cold stress. Food Res. Int. 52 (2013) 153–9.  
69.  A.O. Gill, R.A. Holley, Disruption of Escherichia coli, Listeria monocytogenes and Lactobacillus sakei cellular membranes 
by plant oil aromatics. Int. J. Food Microbiol. 108 (2006) 1–9.  
70.  M. Turgis, J. Han, S. Caillet, M. Lacroix, Antimicrobial activity of mustard essential oil against Escherichia coli O157:H7 
and Salmonella typhi. Food Control. 20 (2009) 1073–9.  
71.  A. Ultee, E.P.W. Kets, E.J. Smid, Mechanisms of Action of Carvacrol on the Food-Borne Pathogen Bacillus cereus. Appl. 
Environ. Microbiol. 65 (1999) 4606–10.  
72.  G. Picone, L. Laghi, F. Gardini, R. Lanciotti, L. Siroli, F. Capozzi, Evaluation of the effect of carvacrol on the Escherichia coli 
555 metabolome by using 1H-NMR spectroscopy. Food Chem. 141 (2013) 4367–74.  
73.  S.M.Z. Hossain, B. Bojko, J. Pawliszyn, Automated SPME–GC–MS monitoring of headspace metabolomic responses of E. 
coli to biologically active components extracted by the coating. Anal. Chim. Acta. 776 (2013) 41–9.  
74.  B.L. Bassler, How bacteria talk to each other: regulation of gene expression by quorum sensing. Curr. Opin. Microbiol. 2 
(1999) 582–7.  
75.  G. Brackman, T. Defoirdt, C. Miyamoto, P. Bossier, S. Van Calenbergh, H. Nelis, et al., Cinnamaldehyde and 
cinnamaldehyde derivatives reduce virulence in Vibrio spp. by decreasing the DNA-binding activity of the quorum 
sensing response regulator LuxR. BMC Microbiol. 2008 (8) 149.  
76.  C. Niu, S. Afre, E.S. Gilbert, Subinhibitory concentrations of cinnamaldehyde interfere with quorum sensing. Lett. Appl. 
Microbiol. 43 (2006) 489–94.  
77.  L.L. Silver, Multi-targeting by monotherapeutic antibacterials. Nat. Rev. Drug Discov. 6 (2007) 41–55.  
78.  H. Brötz-Oesterhelt, N.A. Brunner, How many modes of action should an antibiotic have? Curr. Opin. Pharmacol. 8 
(2008) 564–73.  
79.  S. Hemaiswarya, A.K. Kruthiventi, M. Doble, Synergism between natural products and antibiotics against infectious 
diseases. Phytomedicine. 15 (2008) 639–52.  
CHAPTER I 
50 
 
80.  K. Nicolson, G. Evans, P.W. O’Toole, Potentiation of methicillin activity against methicillin-resistant Staphylococcus 
aureus by diterpenes. FEMS Microbiol. Lett. 179 (1999) 233–9.  
81.  L. Dhara L, A. Tripathi, Antimicrobial activity of eugenol and cinnamaldehyde against extended spectrum beta lactamase 
producing enterobacteriaceae by in vitro and molecular docking analysis. Eur. J. Integr Med. 5 (2013) 527–36.  
82.  M. Fadli, A. Saad, S. Sayadi, J. Chevalier, N-E. Mezrioui, J-M. Pagès, et al., Antibacterial activity of Thymus maroccanus 
and Thymus broussonetii essential oils against nosocomial infection – bacteria and their synergistic potential with 
antibiotics. Phytomedicine. 19 (2012) 464–71.  
83.  G. Bamias, M.R. Nyce, S.A. De La Rue, F. Cominelli, American College of Physicians, American Physiological Society. New 
concepts in the pathophysiology of inflammatory bowel disease. Ann. Intern. 143 (2005) 895–904.  
84.  M. Baumgart, B. Dogan, M. Rishniw, G, Weitzman, B. Bosworth, R. Yantiss R, et al., Culture independent analysis of ileal 
mucosa reveals a selective increase in invasive Escherichia coli of novel phylogeny relative to depletion of Clostridiales in 
Crohn’s disease involving the ileum. ISME J. 1 (2007) 403–18.  
85.  R.B. Sartor, Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat. Clin. Pract. 
Gastroenterol. Hepatol. 3 (2006) 390–407.  
86.  E. Cario, Bacterial interactions with cells of the intestinal mucosa: Toll-like receptors and NOD2. Gut. 54 (2005) 1182–93.  
87.  S. Lala, Y. Ogura, C. Osborne, S.Y. Hor, A. Bromfield, S. Davies, et al., Crohn’s disease and the NOD2 gene: a role for 
paneth cells. Gastroenterology. 125 (2003) 47–57.  
88.  M.F. Neurath, I. Fuss, G. Schürmann, S. Pettersson, K. Arnold, H. Müller-Lobeck, et al., Cytokine gene transcription by NF-
kappa B family members in patients with inflammatory bowel disease. Ann. N. Y. Acad. Sci. 859 (1998) 149–59.  
89.  N. Barnich, T. Hisamatsu, J.E. Aguirre, R. Xavier, H-C. Reinecker, D.K. Podolsky, GRIM-19 interacts with nucleotide 
oligomerization domain 2 and serves as downstream effector of anti-bacterial function in intestinal epithelial cells. J. 
Biol. Chem. 280 (2005) 19021–6.  
90.  J. Wehkamp, N.H. Salzman, E. Porter, S. Nuding, M. Weichenthal, R.E. Petras, et al., Reduced Paneth cell alpha-defensins 
in ileal Crohn’s disease. Proc. Natl. Acad. Sci. USA. 102 (2005) 18129–34.  
91.  M. Scharl, G. Rogler, Inflammatory bowel disease: dysfunction of autophagy? Dig. Dis. 30 (2012) 12–9.  
92.  J. Hampe, A. Franke, P. Rosenstiel, A. Till, M. Teuber, K. Huse, et al., A genome-wide association scan of nonsynonymous 
SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat. Genet. 39 (2007) 207–11.  
93.  P.L. Lakatos, S. Fischer, L. Lakatos, I. Gal, J. Papp, Current concept on the pathogenesis of inflammatory bowel disease-
crosstalk between genetic and microbial factors: pathogenic bacteria and altered bacterial sensing or changes in 
mucosal integrity take “toll” ? World J. Gastroenterol. 12 (2006) 1829–41.  
94.  V.D. Peltekova, R.F. Wintle, L.A. Rubin, C.I. Amos, Q. Huang, X. Gu, et al., Functional variants of OCTN cation transporter 
genes are associated with Crohn disease. Nat. Genet. 36 (2004) 471–5.  
95.  C.L. Noble, E.R. Nimmo, H. Drummond, G-T. Ho, A. Tenesa, L. Smith, et al., The contribution of OCTN1/2 variants within 
the IBD5 locus to disease susceptibility and severity in Crohn’s disease. Gastroenterology. 129 (2005) 1854–64.  
96.  W.E. Roediger, S. Nance, Metabolic induction of experimental ulcerative colitis by inhibition of fatty acid oxidation. Br. J. 
Exp. Pathol. 67 (1986) 773–82.  
97.  H. Nakamura, T. Sudo, H. Tsuiki, H. Miyake, T. Morisaki, J. Sasaki, et al., Identification of a novel human homolog of the 
Drosophila dlg, P-dlg, specifically expressed in the gland tissues and interacting with p55. FEBS Lett. 433 (1998) 63–7.  
98.  P.C. Stokkers, P.H. Reitsma, G.N. Tytgat, S.J. van Deventer, HLA-DR and -DQ phenotypes in inflammatory bowel disease: 
a meta-analysis. Gut. 45 (1999) 395–401.  
CHAPTER I 
51 
 
99.  S.R. Brant, C.M.I. Panhuysen, D. Nicolae, D.M. Reddy, D.K. Bonen, R. Karaliukas, et al., MDR1 Ala893 polymorphism is 
associated with inflammatory bowel disease. Am. J. Hum. Genet. 73 (2003) 1282–92.  
100. A.L. Hart, H.O. Al-Hassi, R.J. Rigby, S.J. Bell, A.V. Emmanuel, S.C. Knight, et al., Characteristics of intestinal dendritic cells 
in inflammatory bowel diseases. Gastroenterology. 129 (2005) 50–65.  
101. E. Cario, D.K. Podolsky, Differential alteration in intestinal epithelial cell expression of toll-like receptor 3 (TLR3) and 
TLR4 in inflammatory bowel disease. Infect. Immun. 68 (2000) 7010–7.  
102. D.A. Van Heel, S. Ghosh, K.A. Hunt, C.G. Mathew, A. Forbes, D.P. Jewell, et al., Synergy between TLR9 and NOD2 innate 
immune responses is lost in genetic Crohn’s disease. Gut. 54 (2005) 1553–7.  
103. J. Wehkamp, J. Harder, M. Weichenthal, M. Schwab, E. Schäffeler, M. Schlee, et al., NOD2 (CARD15) mutations in 
Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut. 53 (2004) 1658–64.  
104. S. Danese, C. Fiocchi, Etiopathogenesis of inflammatory bowel diseases. World. J. Gastroenterol. 12 (2006) 4807–12.  
105. R.P. MacDermott, G.S. Nash, M.J. Bertovich, M.V. Seiden, M.J. Bragdon, M.G. Beale, Alterations of IgM, IgG, and IgA 
Synthesis and secretion by peripheral blood and intestinal mononuclear cells from patients with ulcerative colitis and 
Crohn’s disease. Gastroenterology. 81 (1981) 844–52.  
106. F. Takahashi, K.M. Das, Isolation and characterization of a colonic autoantigen specifically recognized by colon tissue-
bound immunoglobulin G from idiopathic ulcerative colitis. J. Clin. Invest. 76 (1985) 311–8.  
107. J.K. Kolls, A, Lindén, Interleukin-17 family members and inflammation. Immunity. 21 (2004) 467–76.  
108. C. Becker, S. Wirtz, M. Blessing, J. Pirhonen, D. Strand, O. Bechthold, et al. Constitutive p40 promoter activation and IL-
23 production in the terminal ileum mediated by dendritic cells. J. Clin. Invest. 112 (2003) 693–706.  
109. C. Schmidt, T. Giese, B. Ludwig, I. Mueller-Molaian, T. Marth, S. Zeuzem, et al., Expression of interleukin-12-related 
cytokine transcripts in inflammatory bowel disease: elevated interleukin-23p19 and interleukin-27p28 in Crohn’s disease 
but not in ulcerative colitis. Inflamm. Bowel Dis. 11 (2005) 16–23.  
110. S. Fujino, A. Andoh, S. Bamba, A. Ogawa, K. Hata, Y. Araki, et al,. Increased expression of interleukin 17 in inflammatory 
bowel disease. Gut. 52 (2003) 65–70.  
111. I.J. Fuss, M. Neurath, M. Boirivant, J.S. Klein, C. de la Motte, S.A. Strong, et al,. Disparate CD4+ lamina propria (LP) 
lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of 
IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J. Immunol. 157 (1996) 1261–70.  
112. W.S. Selby, G. Janossy, D.Y. Mason, D.P. Jewell, Expression of HLA-DR antigens by colonic epithelium in inflammatory 
bowel disease. Clin. Exp. Immunol. 53 (1983) 614–8.  
113. L. Mayer, D. Eisenhardt. Lack of induction of suppressor T cells by intestinal epithelial cells from patients with 
inflammatory bowel disease. J. Clin. Invest. 86 (1990) 1255–60.  
114. B. Von Lampe, B. Barthel, S.E. Coupland, E.O. Riecken, S. Rosewicz, Differential expression of matrix metalloproteinases 
and their tissue inhibitors in colon mucosa of patients with inflammatory bowel disease. Gut. 47 (2000) 63–73.  
115. J.D. Vogel, G.A. West, S. Danese, C. De La Motte, M.H. Phillips, S.A. Strong, et al., CD40-mediated immune-nonimmune 
cell interactions induce mucosal fibroblast chemokines leading to T-cell transmigration. Gastroenterology. 126 (2004) 
63–80.  
116. D.G. Binion, G.A. West, K. Ina, N.P. Ziats, S.N. Emancipator, C. Fiocchi, Enhanced leukocyte binding by intestinal 
microvascular endothelial cells in inflammatory bowel disease. Gastroenterology. 112 (1997) 1895–907.  
117. D.G. Binion, G.A. West, E.E. Volk, J.A. Drazba, N.P. Ziats, R.E. Petras, et al., Acquired increase in leucocyte binding by 
intestinal microvascular endothelium in inflammatory bowel disease. Lancet. 352 (1998) 1742–6.  
CHAPTER I 
52 
 
118. S. Danese, C. de la Motte, A. Sturm, J.D. Vogel, G.A. West, S.A. Strong, et al., Platelets trigger a CD40-dependent 
inflammatory response in the microvasculature of inflammatory bowel disease patients. Gastroenterology. 124 (2003) 
1249–64.  
119. S. Danese, M. Sans, C. Fiocchi, Inflammatory bowel disease: the role of environmental factors. Autoimmun. Rev. 3 (2045) 
394–400.  
120. E.V. Loftus, Clinical epidemiology of inflammatory bowel disease: Incidence, prevalence, and environmental influences. 
Gastroenterology. 126 (2004) 1504–17.  
121. A.M. Riordan, C.H. Ruxton, J.O. Hunter, A review of associations between Crohn’s disease and consumption of sugars. 
Eur. J. Clin. Nutr. 52 (1998) 229–38.  
122. R. Shoda, K. Matsueda, S. Yamato, N. Umeda, Epidemiologic analysis of Crohn disease in Japan: increased dietary intake 
of n-6 polyunsaturated fatty acids and animal protein relates to the increased incidence of Crohn disease in Japan. Am. J. 
Clin. Nutr. 63 (1996) 741–5.  
123. B.J. Geerling, P.C. Dagnelie, A. Badart-Smook, M.G. Russel, R.W. Stockbrügger, R.J. Brummer, Diet as a risk factor for the 
development of ulcerative colitis. Am. J. Gastroenterol. 95 (2000) 1008–13.  
124. D.P. Perl, U. Fogarty, N. Harpaz, D.B. Sachar, Bacterial-metal interactions: the potential role of aluminum and other trace 
elements in the etiology of Crohn’s disease. Inflamm. Bowel. Dis. 10 (2004) 881–3.  
125. T. Birrenbach, U. Böcker, Inflammatory bowel disease and smoking: a review of epidemiology, pathophysiology, and 
therapeutic implications. Inflamm. Bowel. Dis. 10 (2004) 848–59.  
126. L.E. Derby, H. Jick, Appendectomy protects against ulcerative colitis. Epidemiology. 9 (1998) 205–7.  
127. E.J. Boyko, M.K. Theis, T.L. Vaughan, B. Nicol-Blades, Increased risk of inflammatory bowel disease associated with oral 
contraceptive use. Am. J. Epidemiol. 140 (1994) 268–78.  
128. J.I. Wurzelmann, C.M. Lyles, R.S. Sandler, Childhood infections and the risk of inflammatory bowel disease. Dig. Dis. Sci. 
39 (1994) 555–60.  
129. R.B. Sartor, S.K. Mazmanian, Intestinal Microbes in Inflammatory Bowel Diseases. Am. J. Gastroenterol. 1 (2012) 15–21.  
130. P.B. Eckburg, D.A. Relman, The Role of Microbes in Crohn’s Disease. Clin. Infect. Dis. 44 (2007) 256–62.  
131. R.B. Sartor, Microbial influences in inflammatory bowel diseases. Gastroenterology. 134 (2008) 577–94.  
132. A. Swidsinski, A. Ladhoff, A. Pernthaler, S. Swidsinski, V. Loening-Baucke, M. Ortner, et al., Mucosal flora in inflammatory 
bowel disease. Gastroenterology. 122 (2002) 44–54.  
133. G. Loh, M. Blaut, Role of commensal gut bacteria in inflammatory bowel diseases. Gut Microbes. 3 (2012) 544–55.  
134. M. Mylonaki, N.F. Rayment, D.S. Rampton, B.N. Hudspith, J. Brostoff, Molecular characterization of rectal mucosa-
associated bacterial flora in inflammatory bowel disease. Inflamm. Bowel. Dis. 11 (2005) 481–7.  
135. D.N. Frank, A.L. St Amand, R.A. Feldman, E.C. Boedeker, N. Harpaz, N.R. Pace, Molecular-phylogenetic characterization 
of microbial community imbalances in human inflammatory bowel diseases. Proc. Natl. Acad. Sci. USA. 104 (2007) 
13780–5.  
136. J.R. Marchesi, E. Holmes, F. Khan, S. Kochhar, P. Scanlan, F. Shanahan, et al., Rapid and noninvasive metabonomic 
characterization of inflammatory bowel disease. J. Proteome Res. 6 (2007) 546–51.  
137. R.J. Chiodini, Crohn’s disease and the mycobacterioses: a review and comparison of two disease entities. Clin. Microbiol. 
Rev. 2 (1989) 90–117.  
CHAPTER I 
53 
 
138. J. Rumsey, J.F. Valentine, S.A. Naser, Inhibition of phagosome maturation and survival of Mycobacterium avium 
subspecies paratuberculosis in polymorphonuclear leukocytes from Crohn’s disease patients. Med. Sci. Monit. 12 (2006) 
BR130–9.  
139. M.A. Behr, E. Schurr, Mycobacteria in Crohn’s disease: a persistent hypothesis. Inflamm. Bowel Dis. 12 (2006) 1000–4.  
140. M. Feller, K. Huwiler, R. Stephan, E. Altpeter, A. Shang, H. Furrer, et al., Mycobacterium avium subspecies 
paratuberculosis and Crohn’s disease: a systematic review and meta-analysis. Lancet Infect. Dis. 7 (2007) 607–13.  
141. N. Barnich, A. Darfeuille-Michaud, Adherent-invasive Escherichia coli and Crohn’s disease. Curr. Opin. Gastroenterol. 23 
(2007) 16–20.  
142. H. Kim, S.H. Rhee, C. Pothoulakis, J.T. Lamont, Inflammation and apoptosis in Clostridium difficile enteritis is mediated 
by PGE2 up-regulation of Fas ligand. Gastroenterology. 133 (2007) 875–86.  
143. S. Rabizadeh, K-J. Rhee, S. Wu, D. Huso, C.M. Gan, J.E. Golub, et al., Enterotoxigenic bacteroides fragilis: a potential 
instigator of colitis. Inflamm. Bowel Dis. 13 (2007) 1475–83.  
144. M. Issa, A. Vijayapal, M.B. Graham, D.B. Beaulieu, M.F. Otterson, S. Lundeen, et al., Impact of Clostridium difficile on 
inflammatory bowel disease. Clin. Gastroenterol. Hepatol. 5 (2007) 345–51.  
145. J.D. Rioux, R.J. Xavier, K.D. Taylor, M.S. Silverberg, P. Goyette, A. Huett, et al., Genome-wide association study identifies 
new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat. Genet. 39 (2007) 596–
604.  
146. S.H. Lee, Intestinal permeability regulation by tight junction: implication on inflammatory bowel diseases. Intest. Res. 13 
(2015) 11–8.  
147. J.R. Korzenik, Is Crohn’s disease due to defective immunity? Gut. 56 (2007) 2–5.  
148. S. Nuding, K. Fellermann, J. Wehkamp, E.F. Stange, Reduced mucosal antimicrobial activity in Crohn’s disease of the 
colon. Gut. 56 (2007) 1240–7.  
149. T. Hisamatsu, M. Suzuki, H-C. Reinecker, W.J. Nadeau, B.A. McCormick, D.K. Podolsky, CARD15/NOD2 functions as an 
antibacterial factor in human intestinal epithelial cells. Gastroenterology. 124 (2003) 993–1000.  
150. E. Israeli, I. Grotto, B. Gilburd, R.D. Balicer, E. Goldin, A. Wiik, et al., Anti-Saccharomyces cerevisiae and antineutrophil 
cytoplasmic antibodies as predictors of inflammatory bowel disease. Gut. 54 (2005) 1232–6.  
151. S.R. Targan, C.J. Landers, H. Yang, M.J. Lodes, Y. Cong, K.A. Papadakis, et al., Antibodies to CBir1 flagellin define a unique 
response that is associated independently with complicated Crohn’s disease. Gastroenterology. 128 (2005) 2020–8.  
152. T.A. Kraus, L. Toy, L. Chan, J. Childs, L. Mayer. Failure to induce oral tolerance to a soluble protein in patients with 
inflammatory bowel disease. Gastroenterology. 126 (2004) 1771–8.  
153. D. Polymeros, D.P. Bogdanos, R. Day, D. Arioli, D. Vergani, A. Forbes, Does cross-reactivity between mycobacterium 
avium paratuberculosis and human intestinal antigens characterize Crohn’s disease? Gastroenterology. 131 (2006) 85–
96.  
154. J.A. Katz, Management of inflammatory bowel disease in adults. J. Dig. Dis. 8 (2007) 65–71.  
155. B.G. Feagan, J.K. Macdonald, Oral 5-aminosalicylic acid for maintenance of remission in ulcerative colitis. Cochrane 
Database Syst Rev. 10 (2012) CD000544.  
156. B.G. Feagan, J.K. Macdonald, Oral 5-aminosalicylic acid for induction of remission in ulcerative colitis. Cochrane 
Database Syst Rev. 10 (2012) CD000543.  
CHAPTER I 
54 
 
157. W-C. Lim, S. Hanauer, Aminosalicylates for induction of remission or response in Crohn’s disease. Cochrane Database 
Syst Rev. 12 (2010) CD008870.  
158. J.W. Singleton, S.B. Hanauer, G.L. Gitnick, M.A. Peppercorn, M.G. Robinson, L.D. Wruble, et al., Mesalamine capsules for 
the treatment of active Crohn’s disease: results of a 16-week trial. Pentasa Crohn’s Disease Study Group. 
Gastroenterology. 104 (1993) 1293–301.  
159. A.C. Ford, C.N. Bernstein, K.J. Khan, MT. Abreu, J.K. Marshall, N.J. Talley, et al., Glucocorticosteroid therapy in 
inflammatory bowel disease: systematic review and meta-analysis. Am. J. Gastroenterol. 106 (2011) 590–9.  
160. C.N. Bernstein, Treatment of IBD: where we are and where we are going. Am. J. Gastroenterol. 110 (2015) 114–26.  
161. S.P.L. Travis, S. Danese, L. Kupcinskas, O. Alexeeva, G. D’Haens, P.R. Gibson, et al., Once-daily budesonide MMX in active, 
mild-to-moderate ulcerative colitis: results from the randomised CORE II study. Gut. 63 (2014) 433–41.  
162. K.J. Khan, M.C. Dubinsky, A.C. Ford, T.A. Ullman, N.J. Talley, P. Moayyedi, Efficacy of immunosuppressive therapy for 
inflammatory bowel disease: a systematic review and meta-analysis. Am J Gastroenterol. 2011 Apr;106(4):630–42.  
163. B.G. Feagan, J. Rochon, R.N. Fedorak, E.J. Irvine, G. Wild, L. Sutherland, et al., Methotrexate for the treatment of Crohn’s 
disease. The North American Crohn’s Study Group Investigators. N. Engl. J. Med. 332 (1995) 292–7.  
164. B.G. Feagan, R.N. Fedorak, E.J. Irvine, G. Wild, L. Sutherland, A.H. Steinhart, et al., A comparison of methotrexate with 
placebo for the maintenance of remission in Crohn’s disease. North American Crohn’s Study Group Investigators. N. 
Engl. J. Med. 342 (2000) 1627–32.  
165. S. Lichtiger, D.H. Present, A. Kornbluth, I. Gelernt, J. Bauer, G. Galler, et al., Cyclosporine in severe ulcerative colitis 
refractory to steroid therapy. N. Engl. J. Med. 330 (1994) 1841–5.  
166. J. Brynskov, L. Freund, S.N. Rasmussen, K. Lauritsen, O.S. Muckadell, N. Williams, et al, A placebo-controlled, double-
blind, randomized trial of cyclosporine therapy in active chronic Crohn’s disease. N. Engl. J. Med. 321 (1989) 845–50.  
167. A. Amiot, L. Peyrin-Biroulet, Current, new and future biological agents on the horizon for the treatment of inflammatory 
bowel diseases. Therap. Adv. Gastroenterol. 8 (2015) 66–82.  
168. S.B Hanauer, B.G Feagan, G.R. Lichtenstein, L.F. Mayer, S. Schreiber, J.F. Colombel, et al., Maintenance infliximab for 
Crohn’s disease: the ACCENT I randomised trial. Lancet. 359 (2002) 1541–9.  
169. P. Rutgeerts, W.J. Sandborn, B.G. Feagan, W. Reinisch, A. Olson, J. Johanns, et al,. Infliximab for induction and 
maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353 (2005) 2462–76.  
170. F. Baert, M. Noman, S. Vermeire, G. Van Assche, G. D’ Haens, A. Carbonez, et al., Influence of immunogenicity on the 
long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. 348 (2003) 601–8.  
171. S.B. Hanauer, W.J. Sandborn, P. Rutgeerts, R.N. Fedorak, M. Lukas, D. MacIntosh, et al., Human anti-tumor necrosis 
factor monoclonal antibody (adalimumab) in Crohn’s disease: the CLASSIC-I trial. Gastroenterology. 130 (2006) 323–33; 
quiz 591.  
172. W.J. Sandborn, S.B. Hanauer, P. Rutgeerts, R.N. Fedorak, M. Lukas, D.G. MacIntosh, et al., Adalimumab for maintenance 
treatment of Crohn’s disease: results of the CLASSIC II trial. Gut. 56 (2007) 1232–9.  
173. W. Reinisch, W.J. Sandborn, D.W. Hommes, G. D’Haens, S. Hanauer, S. Schreiber, et al., Adalimumab for induction of 
clinical remission in moderately to severely active ulcerative colitis: results of a randomised controlled trial. Gut. 60 
(2011) 780–7.  
174. J. Keane, S. Gershon, R.P. Wise, E. Mirabile-Levens, J. Kasznica, W.D. Schwieterman, et al., Tuberculosis associated with 
infliximab, a tumor necrosis factor alpha-neutralizing agent. N. Engl. J. Med. 345 (2001) 1098–104.  
CHAPTER I 
55 
 
175. B.G. Feagan, P. Rutgeerts, B.E. Sands, S. Hanauer, J-F. Colombel, W.J. Sandborn, et al., Vedolizumab as induction and 
maintenance therapy for ulcerative colitis. N. Engl. J. Med. 369 (2013) 699–710.  
176. W.J. Sandborn, B.G. Feagan, P. Rutgeerts, S. Hanauer, J-F. Colombel, B.E. Sands, et al., Vedolizumab as induction and 
maintenance therapy for Crohn’s disease. N. Engl. J. Med. 369 (2013) 711–21.  
177. S. Vermeire, S. O’Byrne, M. Keir, M. Williams, T.T. Lu, Mansfield JC, et al. Etrolizumab as induction therapy for ulcerative 
colitis: a randomised, controlled, phase 2 trial. Lancet. 384 (2014) 309–18.  
178. W.J. Sandborn, B.G. Feagan, R.N. Fedorak, E. Scherl, M.R. Fleisher, S. Katz, et al., A randomized trial of Ustekinumab, a 
human interleukin-12/23 monoclonal antibody, in patients with moderate-to-severe Crohn’s disease. Gastroenterology. 
135 (2008) 1130–41.  
179. W.J. Sandborn, C. Gasink, L-L. Gao, M.A. Blank, J. Johanns, C. Guzzo, et al., Ustekinumab induction and maintenance 
therapy in refractory Crohn’s disease. N. Engl. J. Med. 367 (2012) 1519–28.  
180. H. Ito, IL-6 and Crohn’s disease. Curr. Drug. Targets Inflamm. Allergy. 2 (2003) 125–30.  
181. H. Ito, M. Takazoe, Y. Fukuda, T. Hibi, K. Kusugami, A. Andoh, et al., A pilot randomized trial of a human anti-interleukin-
6 receptor monoclonal antibody in active Crohn’s disease. Gastroenterology. 126 (2004) 989–96.  
182. S. Danese, J. Rudziński, W. Brandt, J-L. Dupas, L. Peyrin-Biroulet, Y. Bouhnik, et al., Tralokinumab for moderate-to-severe 
UC: a randomised, double-blind, placebo-controlled, phase IIa study. 64 (2015) 243–9.  
183. W.J. Sandborn, S. Ghosh, J. Panes, I. Vranic, C. Su, S. Rousell, et al., Tofacitinib, an oral Janus kinase inhibitor, in active 
ulcerative colitis. N. Engl. J. Med. 367 (2012) 616–24.  
184. R.B. Sartor, Therapeutic manipulation of the enteric microflora in inflammatory bowel diseases: antibiotics, probiotics, 
and prebiotics. Gastroenterology. 126 (2004) 1620–33.  
185. K.J. Khan, T.A. Ullman, A.C. Ford, M.T. Abreu, A. Abadir, A. Abadir, et al., Antibiotic therapy in inflammatory bowel 
disease: a systematic review and meta-analysis. Am. J. Gastroenterol. 106 (2011) 661–73.  
186. P. Rutgeerts, M. Hiele, K. Geboes, M. Peeters, F. Penninckx, R. Aerts, et al., Controlled trial of metronidazole treatment 
for prevention of Crohn’s recurrence after ileal resection. Gastroenterology. 108 (1995) 1617–21.  
187. P. Rutgeerts, G. Van Assche, S. Vermeire, G. D’Haens, F. Baert, M. Noman, et al., Ornidazole for prophylaxis of 
postoperative Crohn’s disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology. 128 
(2005) 856–61.  
188. G.R. D’Haens, S. Vermeire, G. Van Assche, M. Noman, I. Aerden, G. Van Olmen, et al., Therapy of metronidazole with 
azathioprine to prevent postoperative recurrence of Crohn’s disease: a controlled randomized trial. Gastroenterology. 
135 (2008) 1123–9.  
189. G.P. Pineton de Chambrun, J. Torres, A. Darfeuille-Michaud, J-F. Colombel, The Role of Anti(myco)bacterial Interventions 
in the Management of IBD: Is There Evidence at All? Digestive Diseases. 30 (2012) 358–67.  
190. R. Bringiotti, E. Ierardi, R. Lovero, G. Losurdo, A. Di Leo, M. Principi, Intestinal microbiota: The explosive mixture at the 
origin of inflammatory bowel disease? World J. Gastrointest. Pathophysiol. 5(2014) 550–9.  
191. A-P. Bai, Q. Ouyang, Probiotics and inflammatory bowel diseases. Postgrad. Med. J. 82 (2006) 376–82.  
192. R. Bibiloni, R.N. Fedorak, G.W. Tannock, K.L. Madsen, P. Gionchetti, M. Campieri, et al., VSL#3 probiotic-mixture induces 
remission in patients with active ulcerative colitis. Am. J. Gastroenterol. 100 (2005) 1539–46.  
193. Y. Tsuda, Y. Yoshimatsu, H. Aoki, K. Nakamura, M. Irie, K. Fukuda, et al., Clinical effectiveness of probiotics therapy (BIO-
THREE) in patients with ulcerative colitis refractory to conventional therapy. Scand. J. Gastroenterol. 42 (2007) 1306–11.  
CHAPTER I 
56 
 
194. M.A. Zocco, L.Z. dal Verme, F. Cremonini, A.C. Piscaglia, E.C. Nista, M. Candelli, et al., Efficacy of Lactobacillus GG in 
maintaining remission of ulcerative colitis. Aliment. Pharmacol. Ther. 23 (2006) 1567–74.  
195. W. Kruis W, Schütz E, Fric P, Fixa B, Judmaier G, Stolte M. Double-blind comparison of an oral Escherichia coli 
preparation and mesalazine in maintaining remission of ulcerative colitis. Aliment Pharmacol Ther. 1997 Oct;11(5):853–
8.  
196. B.J. Rembacken, A.M. Snelling, P.M. Hawkey PM, D.M. Chalmers, A.T. Axon, Non-pathogenic Escherichia coli versus 
mesalazine for the treatment of ulcerative colitis: a randomised trial. Lancet. 354 (1999) 635–9.  
197. A.D. Butterworth, A.G. Thomas, A.K. Akobeng, Probiotics for induction of remission in Crohn’s disease. Cochrane 
Database Syst. Rev. 3(2008) CD006634.  
198. P. Marteau, M. Lémann, P. Seksik, D. Laharie, J-F. Colombel, Y. Bouhnik, et al., Ineffectiveness of Lactobacillus johnsonii 
LA1 for prophylaxis of postoperative recurrence in Crohn’s disease: a randomised, double blind, placebo controlled 
GETAID trial. Gut. 55 (2006) 842–7.  
199. A. Van Gossum, O. Dewit, E. Louis, G. de Hertogh, F. Baert, F. Fontaine, et al., Multicenter randomized-controlled clinical 
trial of probiotics (Lactobacillus johnsonii, LA1) on early endoscopic recurrence of Crohn’s disease after lleo-caecal 
resection. Inflamm. Bowel. Dis. 13 (2007) 135–42.  
200. C. Prantera, M.L. Scribano, G. Falasco, A. Andreoli, C. Luzi, Ineffectiveness of probiotics in preventing recurrence after 
curative resection for Crohn’s disease: a randomised controlled trial with Lactobacillus GG. Gut. 51 (2002) 405–9.  
201. H.A. Malchow, Crohn’s disease and Escherichia coli. A new approach in therapy to maintain remission of colonic Crohn’s 
disease? J. Clin. Gastroenterol. 25 (1997) 653–8.  
202. S. Guandalini, Use of Lactobacillus-GG in paediatric Crohn’s disease. Dig. Liver. Dis. 34 (2002) S63–5.  
203. M. Guslandi, G. Mezzi, M Sorghi, P.A. Testoni, Saccharomyces boulardii in maintenance treatment of Crohn’s disease. 
Dig Dis Sci. 45 (2000) 1462–4.  
204. H. Braat, P. Rottiers, D.W. Hommes, N. Huyghebaert, E. Remaut, J-P. Remon, et al., A phase I trial with transgenic 
bacteria expressing interleukin-10 in Crohn’s disease. Clin. Gastroenterol. Hepatol. 4 (2006) 754–9.  
205. J.O. Lindsay, K. Whelan, A.J. Stagg, P. Gobin, H.O. Al-Hassi, N. Rayment, et al., Clinical, microbiological, and 
immunological effects of fructo-oligosaccharide in patients with Crohn’s disease. Gut. 55 (2006) 348–55.  
206. J.L. Benjamin, C.R.H. Hedin, A. Koutsoumpas, S.C. Ng, N.E. McCarthy, A.L. Hart, et al., Randomised, double-blind, 
placebo-controlled trial of fructo-oligosaccharides in active Crohn’s disease. Gut. 60 (2011) 923–9.  
207. T. Bamba, O. Kanauchi, A. Andoh, Y. Fujiyama, A new prebiotic from germinated barley for nutraceutical treatment of 
ulcerative colitis. J. Gastroenterol. Hepatol. 17 (2002) 818–24.  
208. O. Kanauchi, T. Suga, M. Tochihara, T. Hibi, M. Naganuma, T. Homma, et al., Treatment of ulcerative colitis by feeding 
with germinated barley foodstuff: first report of a multicenter open control trial. J. Gastroenterol. 37 (2002) 67–72.  
209. O. Kanauchi, K. Mitsuyama, T. Homma, K. Takahama, Y. Fujiyama, A. Andoh, et al., Treatment of ulcerative colitis 
patients by long-term administration of germinated barley foodstuff: multi-center open trial. Int. J. Mol. Med. 12 (2003) 
701–4.  
210. J. Critch, A.S. Day, A. Otley, C. King-Moore, J.E. Teitelbaum, H. Shashidhar, et al., Use of enteral nutrition for the control 
of intestinal inflammation in pediatric Crohn disease. J. Pediatr. Gastroenterol. Nutr. 54 (2012) 298–305.  
211. C.L. Wall, A.S. Day, R.B. Gearry, Use of exclusive enteral nutrition in adults with Crohn’s disease: a review. World J. 
Gastroenterol. 19 (2013) 7652–60.  
CHAPTER I 
57 
 
212. A. Levine, E. Wine, Effects of enteral nutrition on Crohn’s disease: clues to the impact of diet on disease pathogenesis. 
Inflamm. Bowel Dis. 19 (2013) 1322–9.  
213. R.B. Heuschkel, C.C. Menache, J.T. Megerian, A.E. Baird, Enteral nutrition and corticosteroids in the treatment of acute 
Crohn’s disease in children. J. Pediatr. Gastroenterol. Nutr. 31 (2000) 8–15.  
214. P. Lionetti, M.L. Callegari, S. Ferrari, M.C. Cavicchi, E. Pozzi, M. de Martino, et al., Enteral nutrition and microflora in 
pediatric Crohn’s disease. J. Parenter. Enteral Nutr. 29(2005) S173–5.  
215. C. O’Moráin, A.W. Segal, A.J. Levi, Elemental diet as primary treatment of acute Crohn’s disease: a controlled trial. Br. 
Med. J. 288 (1984) 1859–62.  
216. T.J. Borody, A. Khoruts, Fecal microbiota transplantation and emerging applications. Nat. Rev. Gastroenterol. Hepatol. 9 
(2012) 88–96.  
217. J.L. Anderson, R.J. Edney, K. Whelan, Systematic review: faecal microbiota transplantation in the management of 
inflammatory bowel disease. Aliment. Pharmacol. Ther. 36 (2012) 503–16.  
218. B. Cui, Q. Feng, H. Wang, M. Wang, Z. Peng, P. Li, et al., Fecal microbiota transplantation through mid-gut for refractory 
Crohn’s disease: safety, feasibility, and efficacy trial results. J. Gastroenterol. Hepatol. 30 (2015) 51–8.  
219. P. Moayyedi, M.G. Surette, P.T. Kim, J. Libertucci, M. Wolfe, C. Onischi, et al., Fecal Microbiota Transplantation Induces 
Remission in Patients with Active Ulcerative Colitis in a Randomized, Controlled Trial. Gastroenterology. 149 (2015) 102-
9  
220. S. Angelberger, W. Reinisch, A. Makristathis, C. Lichtenberger, C. Dejaco, P. Papay, et al., Temporal bacterial community 
dynamics vary among ulcerative colitis patients after fecal microbiota transplantation. Am. J. Gastroenterol. 108 (2013) 
1620–30.  
221. R. Kinget, W. Kalala, L. Vervoort, G. van den Mooter, Colonic drug targeting. J. Drug Target. 6 (1998) 129–49.  
222. A. Rubinstein, Colonic drug delivery. Drug Discov. Today: Technologies. 2 (2005) 33–7.  
223. L. Yang, J.S. Chu, J.A. Fix, Colon-specific drug delivery: new approaches and in vitro/in vivo evaluation. Int. J. Pharm. 235 
(2002) 1–15.  
224. M.K. Chourasia, S.K. Jain, Pharmaceutical approaches to colon targeted drug delivery systems. J. Pharm. Pharm Sci. 6 
(2003) 33–66.  
225. B.N. Singh, Modified-release solid formulations for colonic delivery. Recent Pat. Drug. Deliv. Formul. 1 (2007) 53–63.  
226. M.Z.I. Khan, Z. Prebeg, N. Kurjaković, A pH-dependent colon targeted oral drug delivery system using methacrylic acid 
copolymers: I. Manipulation of drug release using Eudragit® L100-55 and Eudragit® S100 combinations. J. Control. 
Release. 58 (1999) 215–22.  
227. A. Maroni, M.D. Del Curto, L. Zema, A. Foppoli, A. Gazzaniga, Film coatings for oral colon delivery. Int. J. of Pharm. 457 
(2013) 372–94.  
228. M. Marvola, P. Nykänen, S. Rautio, N. Isonen, A. Autere, Enteric polymers as binders and coating materials in multiple-
unit site-specific drug delivery systems. Eur. J. Pharm. Sci. 7 (1999) 259–67.  
229. Y. Farag, C.S. Leopold, Development of shellac-coated sustained release pellet formulations. Eur. J. Pharm. Sci. 42 (2011) 
400–5.  
230. S.G. Nugent, D. Kumar, D.S. Rampton, D.F. Evans, Intestinal luminal pH in inflammatory bowel disease: possible 
determinants and implications for therapy with aminosalicylates and other drugs. Gut. 48 (2001) 571–7.  
CHAPTER I 
58 
 
231. M. Ashford, J.T. Fell, D. Attwood, H. Sharma, P.J. Woodhead, An in vivo investigation into the suitability of pH dependent 
polymers for colonic targeting. Int. J. Pharm. 95 (1993) 193–9.  
232. V.C. Ibekwe, H.M. Fadda, E.L. McConnell, M.K. Khela, D.F. Evans, A.W. Basit, Interplay between intestinal pH, transit time 
and feed status on the in vivo performance of pH responsive ileo-colonic release systems. Pharm Res. 25 (2008) 1828–
35.  
233. M.Y. Hu, M.A. Peppercorn, MMX mesalamine: a novel high-dose, once-daily 5-aminosalicylate formulation for the 
treatment of ulcerative colitis. Expert Opin. Pharmacother. 9 (2008) 1049–58.  
234. G.R. Lichtenstein, M.A. Kamm, P. Boddu, N. Gubergrits, A. Lyne, T. Butler, et al., Effect of once- or twice-daily MMX 
mesalamine (SPD476) for the induction of remission of mild to moderately active ulcerative colitis. Clin. Gastroenterol. 
Hepatol. 5 (2007) 95–102.  
235. P. Watts, A. Smith, TARGIT technology: coated starch capsules for site-specific drug delivery into the lower 
gastrointestinal tract. Expert Opin. Drug. Deliv. 2 (2005) 159–67.  
236. R.C.A. Schellekens, J.H. Baltink, E.M. Woesthuis, F. Stellaard, J.G.W. Kosterink, H.J. Woerdenbag, et al., Film coated 
tablets (ColoPulse technology) for targeted delivery in the lower intestinal tract: influence of the core composition on 
release characteristics. Pharm. Dev. Technol. 17 (2012) 40–7.  
237. R.C.A. Schellekens, F. Stellaard, D. Mitrovic, F.E. Stuurman, J.G.W. Kosterink, H.W. Frijlink, Pulsatile drug delivery to ileo-
colonic segments by structured incorporation of disintegrants in pH-responsive polymer coatings. J. Control. Release. 
132 (2008) 91–8.  
238. J.M. Maurer, R.C.A. Schellekens, H.M. van Rieke, F. Stellaard, K.D. Wutzke, D.J. Buurman, et al., ColoPulse tablets 
perform comparably in healthy volunteers and Crohn’s patients and show no influence of food and time of food intake 
on bioavailability. J. Control. Release.172 (2013) 618–24.  
239. V. Bansal, R. Malviya, T. Malaviya, P.K. Sharma, Novel prospective in colon specific drug delivery system. Polim. Med. 44 
(2014) 109–18.  
240. A. Maroni, L. Zema, G. Loreti, L. Palugan, A. Gazzaniga, Film coatings for oral pulsatile release. Int. J. Pharm. 457 (2013) 
362–71.  
241. M. Sangalli, A. Maroni, L. Zema, C. Busetti, F. Giordano, A. Gazzaniga, In vitro and in vivo evaluation of an oral system for 
time and/or site-specific drug delivery. J. Control. Release. 73 (2001) 103–10.  
242. A. Gazzaniga, L. Palugan, A. Foppoli, M.E. Sangalli, Oral pulsatile delivery systems based on swellable hydrophilic 
polymers. Eur. J. Pharm. Biopharm. 68 (2008) 11–8.  
243. S. Ueda, T. Hata, S. Asakura, H. Yamaguchi, M. Kotani, Y. Ueda, Development of a novel drug release system, time-
controlled explosion system (TES). I. Concept and design. J. Drug Target.2 (1994) 35–44.  
244. K. Niwa, T. Takaya, T. Morimoto, K Takada, Preparation and evaluation of a time-controlled release capsule made of 
ethylcellulose for colon delivery of drugs. J. Drug. Target. 3 (1995) 83–9.  
245. T. Takaya, K. Niwa, M. Muraoka, I. Ogita, N. Nagai, R. Yano, et al., Importance of dissolution process on systemic 
availability of drugs delivered by colon delivery system. J. Control. Release. 50 (1998) 111–22.  
246. F. Pozzi, P. Furlani, A. Gazzaniga, S.S. Davis, I.R. Wilding, The time clock system: a new oral dosage form for fast and 
complete release of drug after a predetermined lag time. J. Control. Release. 31 (1994) 99–108.  
247. I.R. Wilding, S.S. Davis, F. Pozzi, P. Furlani, A. Gazzaniga, Enteric coated timed release systems for colonic targeting. Int. J. 
Pharm. 111 (1994) 99–102.  
CHAPTER I 
59 
 
248. K. Steed, G. Hooper, N. Monti, M. Strolin Benedetti, G. Fornasini, I. Wilding, The use of pharmacoscintigraphy to focus 
the development strategy for a novel 5-ASA colon targeting system (“TIME CLOCK®” system). J. Control. Release. 49 
(1997) 115–22.  
249. D. Jain, R. Raturi, V. Jain, P. Bansal, R. Singh, Recent technologies in pulsatile drug delivery systems. Biomatter. 1 (2011) 
57–65.  
250. H.N.E. Stevens, C.G. Wilson, P.G. Welling, M. Bakhshaee, J.S. Binns, A.C. Perkins, et al., Evaluation of Pulsincap to provide 
regional delivery of dofetilide to the human GI tract. Int. J. Pharm. 236 (2002) 27–34.  
251. T. Ishibashi, H. Hatano, M. Kobayashi, M. Mizobe, H. Yoshino, Design and evaluation of a new capsule-type dosage form 
for colon-targeted delivery of drugs. Int. J. Pharm. 168 (1998) 31–40.  
252. S.L. Gorbach, Microbiology of the Gastrointestinal Tract. In: S. Baron, editor, Medical Microbiology. Fourth Edition. 
Galveston (Texas), USA, 1996 . 
253. R.R. Scheline, Metabolism of foreign compounds by gastrointestinal microorganisms. Pharmacol. Rev. 25 (1973) 451–
523.  
254. G.L. Simon, S.L. Gorbach, Intestinal flora in health and disease. Gastroenterology. 86 (1984) 174–93.  
255. V.R. Sinha, R. Kumria, Microbially triggered drug delivery to the colon. Eur. J. Pharm. Sci. 18 (2003) 3–18.  
256. M. Saffran, G.S. Kumar, C. Savariar, J.C. Burnham, F. Williams, D.C. Neckers, A new approach to the oral administration 
of insulin and other peptide drugs. Science. 233 (1986) 1081–4.  
257. H. Tozaki, T. Fujita, J. Komoike, S.I. Kim, H. Terashima, S. Muranishi, et al., Colon-specific delivery of budesonide with 
azopolymer-coated pellets: therapeutic effects of budesonide with a novel dosage form against 2,4,6-
trinitrobenzenesulphonic acid-induced colitis in rats. J .Pharm. Pharmacol. 51 (1999) 257–61.  
258. O. Carrette, C. Favier, C. Mizon, C. Neut, A. Cortot, J-F. Colombel, et al., Bacterial enzymes used for colon-specific drug 
delivery are decreased in active Crohn’s disease. Dig. Dis. Sci. 40 (1995) 2641–6.  
259. G. Van den Mooter, Colon drug delivery. Expert Opin. Drug Deliv. 3 (2005) 111–25.  
260. D.L. Topping, P.M. Clifton, Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch 
polysaccharides. Physiol. Rev. 81 (2001) 1031–64.  
261. L-F. Fan, W. He, M. Bai, Q. Du, B. Xiang, Y-Z. Chang, et al., Biphasic drug release: permeability and swelling of 
pectin/ethylcellulose films, and in vitro and in vivo correlation of film-coated pellets in dogs. Chem. Pharm. Bull. 56 
(2008) 1118–25.  
262. A. Akhgari, H.A. Garekani, F. Sadeghi, Combination of inulin and time dependent polymethacrylates as a coating system 
to achieve colonic delivery of indomethacin. J. Pharm. Sci. 17 (2009) 199–208.  
263. L-F. Fan, W. He, Y-Z. Chang, B. Xiang, Q. Du, F. Wang, et al., Studies of chitosan/Kollicoat SR 30D film-coated tablets for 
colonic drug delivery. Int J Pharm. 375 (2009) 8–15.  
264. G. Kaur, V. Rana, S. Jain, A.K. Tiwary, Colon delivery of budesonide: evaluation of chitosan-chondroitin sulfate 
interpolymer complex. AAPS PharmSciTech. 11 (2010) 36–45.  
265. C. Ji, H. Xu, W. Wu, In vitro evaluation and pharmacokinetics in dogs of guar gum and Eudragit FS30D-coated colon-
targeted pellets of indomethacin. J. Drug. Target. 15 (2007) 123–31.  
266. C. Tuleu, A.W. Basit, W.A. Waddington, P.J. Ell, J.M. Newton, Colonic delivery of 4-aminosalicylic acid using amylose-
ethylcellulose-coated hydroxypropylmethylcellulose capsules. Aliment. Pharmacol. Ther. 16 (2002) 1771–9.  
CHAPTER I 
60 
 
267. A. Fetzner, S. Böhm, S. Schreder, R. Schubert, Degradation of raw or film-incorporated beta-cyclodextrin by enzymes and 
colonic bacteria. Eur. J. Pharm. Biopharm. 58 (2004) 91–7.  
268. Y. Karrout, L. Dubuquoy, C. Piveteau, F. Siepmann, E. Moussa, D. Wils, et al., In vivo efficacy of microbiota-sensitive 
coatings for colon targeting: A promising tool for IBD therapy. J. Control. Release. 197 (2014) 121–30.  
269. Y. Karrout, C. Neut, D. Wils, F. Siepmann, L. Deremaux, M.P. Flament, et al., Peas starch-based film coatings for site-
specific drug delivery to the colon. J. Appl. Polym. Sci. 119 (2011) 1176–84.  
270. R. Thompson, J. Bloor, C. Hawkey, B. Hawthorne, F. Muller, R. Palmer, Preserved endogenous cortisol levels during 
treatment of ulcerative colitis with COLAL-PRED, a novel oral system consistently delivery prednisolone 
metasulphobenzoate to the colon [abstract]. Gastroenterology. 2002 (122) T1207.  
271. E.L. McConnell, H.M. Fadda, A.W. Basit, Gut instincts: Explorations in intestinal physiology and drug delivery. Int. J. 
Pharm. 364 (2008) 213–26.  
272. M. Ashford, J. Fell, D. Attwood, H. Sharma, P. Woodhead, An evaluation of pectin as a carrier for drug targeting to the 
colon. J. Control. Release. 26 (1993) 213–20.  
273. Y.S. Krishnaiah, S. Satyanarayana, Y.V. Prasad, Studies of guar gum compression-coated 5-aminosalicylic acid tablets for 
colon-specific drug delivery. Drug. Dev. Ind. Pharm. 25 (1999) 651–7.  
274. Y.S.R. Krishnaiah, S. Satyanarayana, Y.R.V. Prasad, S.N. Rao, In vivo evaluation of 99mTc-DTPA and 99mTc-sulphur colloid 
as tracers in colonic drug delivery systems using gamma scintigraphy in volunteers. J Pharm. Pharm. Sci. 5 (2002) 24–8.  
275. A. Rubinstein, D. Nakar, A. Sintov, Chondroitin sulfate: A potential biodegradable carrier for colon-specific drug delivery. 
Int. J. Pharm. 84 (1992) 141–50.  
276. Y.S. Krishnaiah, P. Veer Raju, B. Dinesh Kumar, V. Satyanarayana, R. Karthikeyan, P. Bhaskar, Pharmacokinetic evaluation 
of guar gum-based colon-targeted drug delivery systems of mebendazole in healthy volunteers. J. Control. Release. 88 
(2003) 95–103.  
277. S.F. Ahrabi, G. Madsen, K. Dyrstad, S.A. Sande, C. Graffner, Development of pectin matrix tablets for colonic delivery of 
model drug ropivacaine. Eur. J. Pharm. Sci. 10 (2000) 43–52.  
278. J.R. Amrutkar, S.G. Gattani, Chitosan-chondroitin sulfate based matrix tablets for colon specific delivery of 
indomethacin. AAPS PharmSciTech. 10 (2009) 670–7.  
279. S. Krenzlin, F. Siepmann, D. Wils, L. Guerin-Deremaux, M.P. Flament, J. Siepmann, Non-coated multiparticulate matrix 
systems for colon targeting. Drug Dev. Ind. Pharm. 37 (2011) 1150–9.  
280. E.L. McConnell, M.D. Short, A.W. Basit, An in vivo comparison of intestinal pH and bacteria as physiological trigger 
mechanisms for colonic targeting in man. J. Control. Release. 130 (2008) 154–60.  
281. A.W. Basit, M.D. Short, E.L. McConnell, Microbiota-triggered colonic delivery: robustness of the polysaccharide approach 
in the fed state in man. J. Drug Target. 17 (2009) 64–71.  
282. V.C. Ibekwe, M.K. Khela, D.F. Evans, A.W. Basit, A new concept in colonic drug targeting: a combined pH-responsive and 
bacterially-triggered drug delivery technology. Aliment. Pharmacol. Ther. 28 (2008) 911–6.  
283. T. Takaya, C. Ikeda, N. Imagawa, K. Niwa, K. Takada, Development of a colon delivery capsule and the pharmacological 
activity of recombinant human granulocyte colony-stimulating factor (rhG-CSF) in beagle dogs. J. Pharm. Pharmacol. 47 
(1995) 474–8.  
284. M. Muraoka, Z. Hu, T. Shimokawa, S. Sekino, R. Kurogoshi, Y. Kuboi, et al., Evaluation of intestinal pressure-controlled 
colon delivery capsule containing caffeine as a model drug in human volunteers. J. Control. Release. 52 (1998) 119–29.  
CHAPTER I 
61 
 
285. Z. Hu, S. Mawatari, T. Shimokawa, G. Kimura, Y. Yoshikawa, N. Shibata, et al., Colon delivery efficiencies of intestinal 
pressure-controlled colon delivery capsules prepared by a coating machine in human subjects. J. Pharm. Pharmacol. 52 
(2000) 1187–93.  
286. N. Shibata, T. Ohno, T. Shimokawa, Z. Hu, Y. Yoshikawa, K. Koga, et al., Application of pressure-controlled colon delivery 
capsule to oral administration of glycyrrhizin in dogs. J. Pharm. Pharmacol. 53 (2001) 441–7.  
287. Z. Hu, G. Kimura, S. Mawatari, T. Shimokawa, Y. Yoshikawa, K. Takada,  New preparation method of intestinal pressure-
controlled colon delivery capsules by coating machine and evaluation in beagle dogs. J. Control. Release. 56 (1998) 293–
302.  
288. Y-I. Jeong, T. Ohno, Z. Hu, Y. Yoshikawa, N. Shibata, S. Nagata, et al., Evaluation of an intestinal pressure-controlled colon 
delivery capsules prepared by a dipping method. J. Control. Release. 71 (2001) 175–82.  
289. D.R. Swanson, B.L Barclay, P.S.L. Wong, F. Theeuwes, Nifedipine gastrointestinal therapeutic system. Am. J. Med. 83 
(1987) 3–9.  
290. M. Katsuma, S. Watanabe, H. Kawai, S. Takemura, Y. Masuda, M. Fukui, Studies on lactulose formulations for colon-
specific drug delivery. Int. J. Pharm. 249 (2002) 33–43.  
291. M. Katsuma, S. Watanabe, S. Takemura, K. Sako, T. Sawada, Y. Masuda, et al., Scintigraphic evaluation of a novel colon-
targeted delivery system (CODES) in healthy volunteers. J. Pharm. Sci. 93 (2004) 1287–99.  
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
ABOUT THE BACTERIOLOGICAL CHARACTERIZATION 
OF CIN-102  
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER II 
63 
 
1. Introduction 
Antimicrobial resistance is an increasingly global threat to public health and novel antimicrobials are urgently 
needed. In spite of this, in recent decades pharmaceutical companies have largely abandoned the discovery 
and development in this area. The perceived lack of return on investment is one of the main reasons for the 
abandon of this pipeline. However, antibiotics are essential for life because they are the cornerstone of 
infectious disease therapy and medical care rely on their effectiveness for successful clinical outcomes[1]. A 
group of bacteria (ESKAPE) has emerged that escape the lethal action of antibiotics: vancomycin-resistant 
Enterococcus faecium, methicillin-resistant Staphylococcus aureus (MRSA), extended-spectrum β-lactamase 
(ESBL) producing Escherichia coli and Klebsiella pneumoniae, carbapenemase-hydrolyzing β-lactamases 
producing K. pneumoniae (KPC), multi-drug resistant (MDR) Acinetobacter baumannii, Pseudomonas 
aeruginosa and Enterobacter species.  These bacteria which are a threat to immunocompromised patients, 
are no longer exclusively associated with the nosocomial environment[2]. 
 
Even though infections caused by resistant Gram-positive bacteria like MRSA and vancomycin-resistant 
Enterococcus spp. (VRE) have been partially controlled, the actual increased burden of multidrug-resistant 
Gram-negative bacteria is a real phenomenon. These bacteria remain a considerable threat  not only because 
of their faster dissemination  compared to Gram-positive, but also because few antimicrobial agents are 
reliably active and very little is expected to be available in the near future[3]. Of particular interest is that 
much of this dissemination is undetected, with resistant clones carried in the normal human flora and only 
becoming evident when they are the source of endogenous infections[4]. Asymptomatic fecal carriage of ESBL-
producing enterobacteria in healthy people[5,6], as well as the alarming spread of New Delhi metallo-β-
lactamase (NDM)-producing enterobacteria[4] and colistin resistance in community infections[7] have been 
reported. These facts show that the community is a reservoir of multi-resistant bacteria that might constitute 
a sustaining source for nosocomial infections and compromise the efficacy of hospital infection-control 
measures[5].  All of these findings highlight the urgent need for new antimicrobials able to target these 
microorganisms.  
 
Bush et al.[8], pointed out that in battle against antimicrobial resistant, the vast reservoir of bioactive 
compound available in nature merit to be exploited for novel antibiotic discovery Plant secondary metabolites 
(PSMs), like essential oils (EOs), do not appear to participate in plant growth and development; instead they 
possess inherent antimicrobial activity important for protection against microbial infections, permitting plants 
to compete for an ecological niche. EOs are complex mixtures characterized by 2 or 3 major components and 
composed of terpenes, terpenoids and phenylpropanoids[9].  EOs are of main interest since they possess 
antibacterial properties and have been screened as potential sources of novel antimicrobial compounds[10]. 
Furthermore, the presence of multiple compounds and a possible multiplicity of action in EOs is favorable 
since drugs that interact with multiple targets can delay development of bacterial resistance[11].  
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The pharmaceutical company Septeos (Paris, France) followed the aim of antibiotic discovery based on 
natural products. After an initial screening of the antibacterial activity of 33 EOs alone and in combination, 
cinnamon EOs were selected because of their broad-spectrum of action. However, the purpose was the 
fabrication of a reproducible synthetic blend that respects the concentrations of the compounds naturally 
found in cinnamon EOs. For that, chemical standards of the main components of these EOs were purchased 
and the known toxic compounds were excluded from the blend composition. This resulted in a reconstituted 
blend at well-defined concentrations of each compound to respect synergies observed in EOs combinations. 
Then, this blend and closely related ones were evaluated in order to confirm that all of the components were 
involved in the synergistic antibacterial effect. The one presenting the highest efficacy, called CIN-102 
represents an interesting new antibacterial candidate with potential to treat infections caused by resistant 
bacteria (See Annexe 1). 
 
In this work we confirm the broad-spectrum of activity of CIN-102 against a wide range of different subsets of 
bacteria, many of them multi-resistant. The logarithmic reduction time, the post-antibiotic effect and the 
impact of sub-inhibitory concentrations of CIN-102 on bacterial growth were also evaluated. Finally, an 
extensive study of the interactions between CIN-102 and several antibiotics is presented. 
 
2. Materials and methods 
2.1. Antibacterial agents and growth media 
CIN-102 (Septeos, Paris, France) (Composition in Table 1); polyethylene sorbitan monooleate (Tween 80; 
Panreac, Barcelona, Spain); propylene glycol (Cooper, Melun Cedex, France); Ringer solution (Merck, 
Darmstadt, Germany); Rosenow broth (Bio-Rad, Marnes-la-Coquette, France); Mueller-Hinton agar; 
Columbia agar base (Oxoid; Hampshire, England); Brain-Heart broth; Brucella agar and Dey-Engley 
neutralizing broth (Becton, Dickinson and Company, Le Pont de Claix, France). Antibiotics were obtained 
from Sigma-Aldrich (Saint-Quentin-Fallavier, France). 
    
Table 1: CIN-102 composition 
 
 
 
  
 
 
 
 
 
Component % (w/w) 
Trans-cinnamaldehyde 86.7 
Trans-2-methoxycinnamaldehyde 5.35 
Cinnamyl acetate 2.5 
Linalool 2.4 
β-Caryophyllene 1.7 
Cineol 1 
Benzyl benzoate 0.35 
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2.2. Microorganisms, storage and growth conditions 
Strains were isolated from human clinical samples and are listed in Table 2 and 3. Strains were stored at -
20˚C in Brain-Heart (BH) and Rosenow broth for aerobic and anaerobic isolates, respectively. 
 
Table 2: Aerobic bacterial strains 
 
Bacterial strain Wild or acquired resistance 
N° of strains 
tested 
Enterobacteria 
Escherichia. coli 
ATCC 25922 1 
Wild (8137, 8141, 8150, 8151, 8155, 8156) 6 
Penicillinase (8138, 8154) 2 
Penicillinase and nalidixic acid-resistant (8142) 1 
Penicillinase and fluoroquinolone-resistant (8157) 1 
ESBL (09003),  NDM-1 (10269, 10385, 10386), KPC-2 (10269), CTX-
M1 (11003), CTX-M3 (11004), CTX-M14 (11005), CTX-M15 (11006), 
TEM-12 (11007), SHV-2A (11008), SHV-12 (11009), OXA-30 (11010), 
CMY-2 (11011), OXA-48 (10012), VIM-1 (11013), VIM-2 (11014), 
VIM-19 (11015) 
18 
   
Enterobacter 
aerogenes 
TEM-24 (09004) 1 
   
Enterobacter 
cloacae 
GES-5 (10274), KPC-2 (10281), NDM-1 (11053), NMC-A (11054), 
OXA-43 (11055) 
5 
Wild (11050) 1 
Cephalosporinase (11051, 11052) 2 
   
Serratia 
marcescens 
KPC-2 (10267), SME-1 (10271), SME-2(10279)  3 
Wild (11056) 1 
Cephalosporinase high-level (11057, 11058) 2 
   
Citrobacter freundii 
KPC-2 (10268), TEM-3 (11028), CTX-M1 (11044), CTX-M15 (11045), 
NDM-1 (11046) 
5 
Wild (11041) 1 
Cephalosporinase high-level (11016) 1 
   
Klebsiella 
pneumoniae 
VIM (10270), OXA-48 (10272), KPC-2 (10277), ACT-1 (11018), DHA-2 
(11019), LAT-1 (11020), CTX-M2 (11021), CTX-M3 (11022), CTX-M14 
(11023), CTX-M15 (11024), SHV-2A (11025), SHV (11026), SHV-12 
(11027), TEM-3 (11028), TEM-2 (11029), KPC-3 (11030), NMD-1 
(11031, 11032) 
18 
Wild (11016) 1 
Penicillinase (11017) 1 
   
Salmonella spp. 
Wild  (11033, 11034, 11035, 11036) 4 
CMY-2 (11037) 1 
   
Providencia stuartii 
Wild (11038, 11039) 2 
TEM-24 (11040) 
 
1 
Proteus mirabilis 
Wild (11059, 11060) 2 
Penicillinase  (11061) 1 
TEM-21 (11062), TEM-52 (11063), ACC-1 (11064) 3 
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Klebsiella oxytoca 
Wild (11047) 1 
OXY (11048) 1 
CTX-M15 (11049) 1 
Non-fermentative Gram-negative 
Pseudomonas 
aeruginosa 
Fluoroquinolone-resistant (8127) 1 
Multi-resistant (8128, 8132) 2 
Cephalosporinase high-level (8129) 1 
Penicillinase (8130, 8136) 2 
Wild (8131, 8133, 8135) 3 
Fluoroquinolone- and aminoglycoside-resistant (8134) 1 
VIM-2 (09007), ESBL (09008), PER-1 (10276), GES-2 (10278), VIM-2 
(10280) 
5 
ATCC 27583 1 
   
Acinetobacter 
baumanii 
VEB-1 (09010), VIM-4 (10275) 2 
Multi-resistant (09011) 1 
   
Burkholderia 
cepacia 
Wild (10282) 1 
Gram-positive 
Staphylococcus 
spp. 
Methicillin-, kanamycin- and tobramycin-resistant (8143) 1 
Methicillin- and kanamycin-resistant (8146) 1 
Wild (8147, 8149, 8237, 8238) 4 
MRSA and fluoroquinolone-resistant (8148, 8240) 2 
MRSA (8239, 10168) 2 
Methicillin-, kanamycin-, tobramycin- and fluoroquinolone-
resistant(8241) 
1 
   
Enterococcus spp. 
Multi-resistant (09001, 09002) 2 
MLSB (8153) 1 
Aminoglycoside-resistant (8152) 1 
ATCC: American Type Culture Collection 
Other strains: Collection from the College of Pharmacy (University Lille Nord de France) 
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Table 3: Anaerobic bacterial strains 
 
Bacterial strain Wild or acquired resistance 
N° of strains 
tested 
Gram-positive cocci 
Peptostreptococcus micros  Wild (11129, 11124) 2 
   
Peptostreptococcus magnus  Clindamycin-resistant (11123) 1 
Wild (11135, 11131) 2 
   
Anaerococcus prevotii  Wild (11104, 11125, 11313, TB47-B10) 4 
   
Peptoniphilus asaccharolyticus  Wild (10315, 11315) 2 
   
Peptostreptococcus anaerobius  Wild (11310) 1 
   
Ruminococcus spp.  Wild (T46-B17, Y67-4) 2 
Gram-positive bacilli 
Clostridium difficile  ATCC 700057 1 
Wild (11178, 11179, 11180) 3 
   
Clostridium ramosum  Wild (9361) 1 
   
Clostridum perfringens  Wild (11115, 11116, Y66F6-4, 11117, 11126, 
ATCC 13124) 
6 
   
Clostridium scindens  Clindamycin- and penicillin G-resistant (11323) 
1 
Wild (11318, 11321) 2 
   
Clostridium innocuum  Clindamycin resistant (11327) 1 
   
Bifidobacterium bifidum  Wild (Y56-7) 1 
   
Clostridium clostridioforme  Wild (Y67-9) 1 
   
Clostridium sporogenes  Clindamycin-resistant (11127) 1 
Gram-negative bacilli 
Fusobacterium nucleatum  Wild (11324, 8029, JD7) 3 
   
Bacteroides fragilis  ATCC 25285 1 
Clindamycin-resistant (11105, 11108) 
2 
   
Bacteroides thetaiotamicron  ATCC 29742 1 
Clindamycin- and piperacilin + 
tazobactam-resistant (11134) 1 
   
Fusobacterium necrophorum  Clindamycin-resistant (11320) 1 
Wild (8246) 1 
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Bacteroides distasonis  Clindamycin-resistant (11092) 1 
Wild (Y67-10, 11107) 2 
   
Bacteroides vulgatus  Clindamycin-resistant (11118, 11326) 2 
   
Bacteroides uniformis  Wild (11316, 9074) 2 
   
Prevotella spp.  Wild (Y67-6) 1 
Gram-negative cocci 
Veillonella spp.  Wild (T18.8) 1 
           ATCC: American Type Culture Collection 
    Other strains: Collection from the College of Pharmacy (University Lille Nord de France) 
 
2.3. Determination of the Minimal Inhibitory Concentration (MIC) 
MICs of CIN-102 were determined following the reference agar dilution procedures of the Clinical and 
Laboratory Standards Institute (CLSI)[12,13]. The stock solution (1% v/v) of CIN-102, was prepared by 
solubilizing CIN-102 in a blend of Tween 80 : Propylene glycol 10% (38 : 62), then only propylene glycol 
10% was used for the further dilutions. The absence of antibacterial activity of the surfactants at the 
concentrations used to perform the dilutions of CIN-102 was first verified. The inocula (2 to 3 µL) were 
delivered using a Steers replicator (Mast Systems, London, UK) giving a final 104 colony-forming units 
(CFU) per spot of inoculation onto Mueller-Hinton agar (MHA) plates and 105 CFU per spot onto Brucella 
blood agar plates for aerobes and anaerobes, respectively. The lowest concentration of CIN-102 that 
inhibits growth of bacteria is reported as the MIC 
2.4. Time of logarithmic reduction 
Inocula were prepared by making a suspension on Ringer solution of overnight sub-cultured bacteria in 
BH broth from 26 enterobacteria, 20 non-fermentative Gram-negative and 11 Gram-positive isolates 
with known MICs for CIN-102. Testing tubes containing 8mL of Ringer solution were inoculated with 1mL 
of the previous bacterial suspension (approximately 107 CFU mL-1). Then, 1 mL of the dilution 
corresponding to either 1% or 4xMIC of CIN-102 was added. Next, aliquots were removed from the 
incubation mixture after 15, 60 min and 24h to assess the bacterial growth logarithmic reduction in time. 
For that, aliquots were ten-fold diluted in Dey-Engley neutralizing broth. Aliquots from the neutralized 
mixture were further diluted 1:10 and 1:100 in Ringer solution. Viable counts were performed by 
inoculation of these aliquots onto MHA plates subsequently incubated at 37°C for 24h. 
2.5. Post-Antibiotic Effect (PAE) 
The PAE describes the phenomenon of suppression of microbial growth that persists after antimicrobial 
exposure. The technique involves the measurement of microbial growth kinetics after rapid removal of 
the antimicrobial agent. The PAE of CIN-102 was determined by the viable plate count method described 
by Craig and Gudmundsson[14] for aerobes: K. pneumoniae-OXA 48 (enterobacteria), B. cepacia (non-
fermentative, Gram-negative), multiresistant E. faecium (Gram-positive) and anaerobes: C. perfringens. 
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Testing tubes were prepared as previously but 1 mL of the dilution corresponding to either the MIC or 
4xMIC of CIN-102 was added.  They were incubated at 37°C for 2 hours and at the end of the exposure 
period cultures were diluted 1000-fold with Mueller-Hinton (MH) broth in order to remove CIN-102. 
Next, tubes were re-incubated at 37°C. Viable counts on MHA plates were determined before exposure 
to CIN-102, immediately after dilution (zero hour) and every 1 or 2h after dilution until turbidity 
developed and reached an intensity comparable at least to that of the control group (turbidity reached a 
1 McFarland standard). Please note that for anaerobes all the culture media and Ringer solution used 
were previously reduced. As well, viable counts were performed in Columbia agar plates incubated 
under anaerobic conditions. The PAE was defined as PAE = T – C, where the T represents the time 
required for the viability count of CIN-102 exposed culture to increase by 1 log10 above the count 
obtained immediately after dilution and C represents the corresponding time for the growth control. 
2.6. Bacterial growth at sub-inhibitory (subMIC) concentrations 
The impact of subMICs of CIN-102 on bacterial growth was studied for aerobes: E. coli (enterobacteria), 
P. aeruginosa (non-fermentative Gram-negative,) S. aureus (Gram-positive) and anaerobes: C. 
perfringens. To evaluate bacterial growth at sub-inhibitory concentrations, we proceeded as previously, 
CIN-102 at either the CMI/2 or CMI/4 was added. Tubes were placed at 37°C and viable counts were 
determined before exposure to CIN-102 (zero time) and every hour after exposure on MHA plates. For 
anaerobes the methodology was modified as formerly mentioned. 
2.7. Interaction with antibiotics 
To perform the CIN-102 – antibiotic combinations assays, a checkerboard procedure was applied[15]. 
Antibiotic tested were: aminoglycosides (amikacin and gentamicin), polymyxin (colistin), lincosamide 
(clindamycin), macrolide (erythromycin), ß-lactam (imipenem), glycylcycline (tigecycline) and 
glycopeptide (vancomycin). Serial two-fold dilutions of the antibiotics and CIN-102 were used (final 
concentrations from 1- to 0.002-fold MIC for the antibiotic; and from 10 000 to 5 mg L-1 for CIN-102). All 
combinations of any antibiotic and CIN-102 concentrations were inoculated using a Steers replicator. 
After inoculation, plates were incubated for 24h at 37°C. For each combination, the fractional inhibitory 
concentration (FIC) index was calculated using the following formula: ƩFIC index = FIC A + FIC B = (MIC of 
A in combination / MIC of A alone) + (MIC of B in combination / MIC of B alone). ƩFIC index ≤ 0.5 
indicates synergism; > 0.5 and ≤ 1 addition; >1 and ≤ 4 indifference and > 4 antagonism. 
 
3. Results and discussion 
3.1. MIC and spectrum of action of CIN-102 
CIN-102 was tested against 123 aerobic bacterial strains many of them multi-resistant bacteria isolated 
from nosocomial infections. The lipophilic nature of CIN-102 demanded the adaptation and validation of 
a new solubilization procedure. All strains are inhibited by CIN-102 at 1250 mg L-1 (Table 4). For aerobic 
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bacteria MIC ranges between 15 and 600 mg/L (average MIC of 300 mg L-1), B. cepacia is the most 
susceptible (75 mg L-1) and P. aeruginosa has the highest MIC (1250 mg L-1). Experimental animal models 
still under investigation (data not shown) allow us to assess that active concentrations are obtained in 
infected tissues Furthermore, 52 anaerobic bacterial strains were also tested (Table 5), they have lower 
CIN-102 MICs, within a range of 5 to 150 mg L-1. C. scindens and F. necrophorum strains have the lowest 
MICs (5 to 37.5 mg L-1) and C. perfringens strains the highest (75 to 150 mg L-1).  CIN-102 is confirmed as 
an antibacterial agent with a broad spectrum of action. A remarkable aspect is the relative stability of 
CIN-102 MICs within different isolates of the same species.  
 
Table 4:  MIC of CIN-102 against aerobic bacteria 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 5: MIC of CIN-102 against anaerobic bacteria 
  
Bacterial strain N° of strains tested   MIC Range  (mgL-1) 
Enterobacteria 
Escherichia coli   29 300 
Enterobacter aerogenes 1 300 
Enterobacter cloacae 8 300 
Serratia marcescens 6 300-600 
Citrobacter freundii 7 300 
Klebsiella pneumoniae 20 300-600 
Salmonella spp. 5 150-300 
Providencia stuartii 3 300 
Proteus mirabilis 6 300 
Klebsiella oxytoca 3 300 
Non-fermentative Gram-negative 
Pseudomona aeruginosa 16 600-1250 
Acinetobacter baumanii 3 150-300 
Burkholderia cepacia 1 75 
Gram-positive 
Staphylococcus aureus 11 300 
Enterococcus spp. 4 300-600 
Bacterial strain N° of strains tested MIC Range (mgL-1) 
Gram-positive cocci 
Peptostreptococcus micros 2 37.5 
Peptostreptococcus magnus 3 37.5 – 75 
Anaerococcus prevotii 4 75 
Peptoniphilus asaccharolyticus 2 75 
Peptostreptococcus anaerobius 1 75 
Ruminococcus sp 2 5 – 37.5 
Gram-positive bacilli 
Clostridium difficile 4 75 
Clostridium ramosum 1 75 
Clostridum perfringens 6 75 – 150 
Clostridium scindens 3 5 – 37.5 
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The relative increased tolerance of P. aeruginosa towards CIN-102 correlated with the observations of 
Longbottom et al.[16], explaining the increased resistance of this bacteria towards essential oil 
compounds due to the barrier and energy functions of its outer membrane and a possible participation 
of efflux systems.  
 
Cinnamaldehyde, a phenylpropanoid, is the major compound of CIN-102 and its antibacterial mechanism 
of action is not yet totally understood. Cinnamaldehyde does not seem to cause disruption of the 
bacterial membrane, indicating that it might interfere with intracellular targets[17,18]. However, it has also 
been observed that as cinnamaldehyde concentration increases, damage caused to membrane integrity 
and permeability might become more serious[19]. Domadia et al. [20] showed that cinnamaldehyde is able 
to bind FtsZ, the prokaryotic homolog of the eukaryotic tubulin, perturbing the assembly of the Z-ring, 
essential for bacterial division. Given the widespread conservation of FtsZ in the bacterial kingdom[21], it 
might be possible that the broad-spectrum activity of CIN-102 is due to the inhibition of cell division 
through binding of cinnamaldehyde to FtsZ. Furthermore, cinnamaldehyde inhibits quorum sensing (QS) 
processes[22] and alter gene expression in bacteria[23]. 
 
This evidence suggest that the antibacterial activity of cinnamaldehyde might not be attributed to only 
one mechanism. However, to elucidate the mechanism of action of CIN-102, the presence of the other 
minor compounds must also be taken into account. β-caryophyllene, cineole and linalool are terpenoids, 
and the accumulation of terpene hydrocarbons in lipid bilayers of the cytoplasmic membrane causes loss 
of membrane integrity, increased permeability and even proteins embedded in the membrane can be 
affected[24]. The presence of these compounds in the formulation of CIN-102 might favor the penetration 
of cinnamaldehyde into the bacterial cell to exert its activity, interact synergistically to perform a multi-
targeted action against intra-cellular components and/or affect membrane permeability. Indeed, 
Clostridium innocuum 1 75 
Bifidobacterium bifidum 1 150 
Clostridium clostridioforme 1 37.5 
Clostridium sporogenes 1 75 
Gram-negative bacilli 
Fusobacterium nucleatum 3 20 – 37.5 
Bacteroides fragilis 3 37.5 
Bacteroides thetaiotamicron 2 37.5 
Fusobacterium necrophorum 2 5 – 37.5 
Bacteroides distasonis 3 37.5 
Bacteroides vulgatus 2 20 – 37.5 
Bacteroides uniformis 2 37.5 – 75 
Prevotella spp. 1 37.5 
Gram-negative cocci 
Veillonella spp. 1 75 
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targeting bacterial membranes is of especial interest in treating persistent infections involving slow-
growing or non-growing bacteria[25]. Further studies are needed to elucidate the mechanism of action of 
CIN-102. 
3.2. Logarithmic reduction time of CIN-102 
The rapidity of the cidal effect of CIN-102 (time, in minutes, necessary to reduce bacterial counts by 1 
log), at 1% and 4-fold the MIC of CIN-102 was investigated against 57 isolates. As shown in Figure 1, 
there is a dramatic and fast killing more important with Gram-negative bacilli. 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
Figure 1: One log reduction time: The time to reduce bacterial counts by 1 log was tested at 1% and 4×MIC of 
CIN-102. Bacteria tested comprised: enterobacteria (E. coli, Enterobacter spp., S. marcescens and K. 
pneumoniae), non-fermentative Gram-negative (P. aeruginosa, A. baumannii) and Gram-positive 
(Staphylococcus spp)  (mean values +/- SD are indicated). 
 
 
 
The rapid log reduction time of CIN-102 might be related with disruption of cell wall or cell membranes 
caused by high concentrations of this agent. The advantages of bactericidal agents appear obvious, as 
rapid elimination of bacteria and decrease possibility of resistance development or recurrence of 
infection. Indeed, infectious of the central nervous system, endocarditis or infections in patients with 
cancer are some specific settings where the use of antibacterials with in vitro bactericidal activity is more 
important than a bacteriostatic activity[26]. However, some in vitro and experimental evidence suggest 
that rapid killing of bacteria may be undesirable when release of endotoxins could induce inflammatory 
responses[27,28]. 
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3.3. PAE of CIN-102 
The PAE of CIN-102 for K. pneumoniae (strain10272) is of 3.3h at the MIC and 4.0h at 4-fold the MIC (Fig. 
2A). For B. cepacia (strain 10282), CIN-102 has a PAE of 2.17h at the MIC and, it is prolonged until 21.57h 
at 4-fold the MIC (Fig. 2B). E. faecium (strain 9002) has a PAE of 0.4h and 3.6h at the MIC and 4-fold the 
MIC of CIN-102, respectively (Fig. 2C). For C. perfringens (strain 11116) the PAE of CIN-102 is 1.7h at the 
MIC and 1.9h at 4-fold the MIC (Fig. 2D). The PAE for this strain does not seem to depend upon the 
concentration of CIN-102 used, as little variation between the PAE at the MIC and 4-fold the MIC is 
observed.  
 
The PAE could represent the prolonged antibiotic persistence at the site of action, the time necessary to 
recover the normal metabolic activities of bacteria, or even to repair cell membrane damage that might 
occur[14].  Severe damage to the cellular wall as well as irreversible binding might explain the long PAE of 
an antibiotic[29]. Given the marked susceptibility of B. cepacia to CIN-102 reflected by its low MIC, it is 
possible that the damage produced by high CIN-102 concentrations caused more serious alterations than 
for the other bacterial strains and so the time required to recover a normal growth is longer.  
 
The determination of the PAE is of importance for an optimal dosing frequency. If a drug produces a very 
short or no PAE, organism regrowth will begin soon after concentrations fall below the MIC and the goal 
of a dosing regimen might be to maximize the time of exposure. In contrast, for drugs producing PAE 
widely-spaced dosing intervals should be possible, since the PAE would prevent bacterial regrowth when 
levels fall below the MIC[14].  
 
These results permit to state that CIN-102 present a PAE against different subsets of bacteria: Gram-
negative and Gram-positive, aerobic and anaerobic, which can be of importance in the dosing of this 
agent. 
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Figure 2: PAE of CIN-102: Growth curves of A) K. pneumoniae, B) B. cepacia, C) E. faecium and D) C. perfringens 
following a 2h exposure to CIN-102, at MIC and 4×MIC, which was then removed by dilution into fresh broth. 
Dashed lines denote the duration of the PAE for both concentrations. 
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3.4. Bacterial growth a CIN-102 subMICs 
E. coli (strain 8154) (Fig. 3A) exposed to CIN-102 at MIC/2 presents a prolongation of the lag phase, but 
about 20h later the concentration of bacteria at the stationary phase reaches that of the control. At the 
MIC/4 the prolongation of the lag phase is shorter than at the MIC/2, the logarithmic growth is slower 
than the control, and also reaches a similar bacterial concentration at the stationary phase at about 18h. 
For P. aeruginosa (strain 09007) (Fig. 3B), it is observed that at the MIC/2 of CIN-102 the rate of the 
logarithmic growth is slower than in the control and there is also a decrease in the size of the population 
at the stationary phase. At the MIC/4, there is reduction in the concentration of bacteria at the 
stationary phase compared to control. S. aureus (strain 10168) (Fig. 3C), when exposed to CIN-102 at the 
MIC/2 and at the MIC/4 presents a decrease in the rate of logarithmic growth, however bacteria exposed 
at MIC/4 reach the same bacterial count of the control at the stationary phase. For C. perfringens (strain 
11116), CIN-102 at the MIC and at the MIC/2 inhibits bacterial growth. At the MIC/4 a long lag phase of 
more than 20 hours is obtained (Fig. 3D).  
 
It has been shown that subMICs of antibiotics cannot kill bacteria but can affect microorganisms in 
various ways like slower bacterial growth, induction of morphological changes, alterations of the cell 
surface structure, inhibition of enzyme and toxin production, reduction of bacterial adhesion and biofilm 
formation, sensitivity to stress conditions.  These effects can consequently interfere with process of host-
bacteria interaction like phagocytosis[30].  Cinnamaldehyde at subMICs causes bacterial cell elongation[23], 
interferes with the QS[22] and gene expression[23] altering virulent factors as biofilm formation, toxin 
production and/or susceptibility to stress. Therefore, in addition to the PAE, the success of discontinuous 
dosing regimens may be attributed to both the function of a normal host defense and to the effects of 
subMICs[30]. 
 
These results demonstrated that CIN-102 is able to slow down bacterial growth of Gram-positive, Gram- 
negative, aerobic and anaerobic bacteria even at sub-inhibitory concentrations (CMI/2 and CMI/4). It 
would be of interest to study if subMICs of CIN-102 can alter other characteristics of bacteria.   
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Figure 3: Effect of subMICs of CIN-102: Growth curves of A) E. coli, B) P. aeruginosa, C) S. aureus and D) C. 
perfringens exposed to CIN-102 at the MIC/2 and MIC/4. For reasons of comparison, CIN-102 at the MIC is also 
presented. 
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3.5. Interaction of CIN-102 with antibiotics 
As clinicians would prefer to use a new antibacterial in combination with known antibiotics, rather than 
introducing a new wide spectrum monotherapy, the interaction of CIN-102 with commercialized 
antibiotics was studied. Among all the antibiotics tested in combination, no antagonism has been 
detected, and it was observed that colistin and aminoglycosides (gentamicin and amikacin) have often 
synergistic interactions with CIN-102 (Table 6). 
 
Table 6: CIN-102 and antibiotic combinations (%) 
 
 
 Amikacin 
N°strains=62 
 
 
Gentamicin 
N°strains=57 
 
Tigecycline 
N°strains=62 
 
Vancomycin 
N°strains=62 
 S A I An  S A I An  S A I An  S A I An 
Enterob 81 19 0 0  56 44 0 0  4 44 52 0  44 56 0 0 
Non-ferm 45 40 10 0  47 47 7 0  20 20 60 0  55 45 0 0 
Gpositive 93 7 0 0  87 13 0 0  7 87 7 0  13 73 13 0 
Total 73 24 3 0  61 37 2 0  10 46 44 0  40 57 3 0 
 Clindamycin 
N°strains=65 
 
Erythromycin 
N°strains=62 
 
Imipenem 
N°strains=61 
 
Colistin 
N°strains=65 
 S A I An  S A I An  S A I An  S A I An 
Enterob 73 20 7 0  22 78 0 0  38 42 19 0  93 7 0 0 
Non-ferm 35 65 0 0  45 30 25 0  5 35 60 0  45 50 0 0 
Gpositive 53 40 7 0  47 53 0 0  13 47 47 0  73 27 0 0 
Total 57 38 5 0  36 56 8 0  21 41 38 0  74 25 1 0 
 S=synergy; A=addition; I=indifference; An=Antagonism; Enterob=Enterobacteria; Non-fermen=Non-
fermentative Gram-negative bacteria and Gpositive=Gram-positive bacteria 
 
 
Colistin possess a detergent-like mechanism, interfering with the structure and function of the outer and 
cytoplasmic membranes of bacteria. The insertion of colistin and its self-promoted uptake disrupts the 
outer membrane, release lipopolysaccharides and leads to leakage of intracellular components with 
subsequent death[31]. Possible mechanisms of synergism between CIN-102 and colistin might be a 
potentiation of the outer membrane disruption and cytoplasmic membrane permeabilization, leading to 
an important leakage of intracellular components. Another explanation could be the enhancement of the 
penetration CIN-102 components that would bind their intracellular targets, as a result of an increased 
membrane permeability by colistin. However, it has been shown that polymyxin-mediated cell death 
takes place apparently prior to cytoplasmic membrane depolarization. This suggests that there are 
multiple potential anionic targets, some of which are cytoplasmic[32]. Perhaps a possible synergism 
between the intracellular targets of CIN-102 and colistin exists besides outer membrane 
permeabilization.   
 
CHAPTER II 
78 
 
Aminoglycosides cross the outer membrane by a self-promoted uptake and bind to the 30S ribosomal 
subunit leading to the production of misread proteins that cause membrane damage when incorporated 
into the membrane, which further stimulates the influx of the antibiotic. A rapid expanding cycle is 
triggered and the intracellular antibiotic eventually reaches a concentration that blocks all the initiating 
ribosomes preventing further protein synthesis[33]. The uptake of aminoglycosides could favor the 
penetration of CIN-102 components, which would be enhanced as the misreading proteins are further 
inserted into the membranes. In the same way, CIN-102 hydrophobic compounds could favor the 
penetration of aminoglycosides. Synergy might also occur from the different intracellular targets of 
aminoglycosides and CIN-102. Cinnamaldehyde can alter gene regulation reducing the expression of 
protein, RNA, 50S and 30S ribosomal protein synthesis[23], and this could potentiate the mechanism of 
aminoglycosides. In addition, it has been shown that gentamicin can interact with the outer membrane 
causing increased permeabilization[34]. This would further favor the penetration of CIN-102 components 
or lead to a more serious damage of the membranes when interacting with the terpenoid compounds of 
CIN-102.  It has been proved that sub-lethal concentrations of amikacin interfere with cell division 
through an impairment in the formation of the Z ring[35]. This could explain the synergistic activity 
between amikacin and CIN-102, as cinnamaldehyde is able to bind FtsZ preventing the assembly of the Z 
ring[20].  
 
Nevertheless, the most remarkable aspect for MDR strains, is that when antibiotics are combined with 
CIN-102, resistance is overpassed. To better illustrate these results, the CIN-102 – antibiotic interactions 
from 8 multi-resistant bacterial strains tested are represented in Table 7 and 8. First, the MIC of the 
antibiotics and CIN-102 alone are presented (Table 7).  Then the MICs of a single combination CIN-102 – 
antibiotic and the respective Ʃ FIC index is shown (Table 8). 
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Table 7: MIC of antibiotics and CIN-102 for MDR strains 
 
  MIC (mgL-1) 
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Escherichia coli 300 16* 64* 64 64 64 4* 64* 1 
Klebsiella pneumoniae 600 16* 64* 64 64 64 16* 16 2 
Serratia marcescens 600 64* 8* 64 64 64 32* 64 2 
Enterobacter cloacae 300 16* 64* 64 64 64 8* 16 2 
Pseudomonas aeruginosa 1250 16* 64* 64 64 64 8* 4 32 
Acinetobacter baumannii 300 2 64* 64 4 64 8* 32* 4 
Staphylococcus aureus 300 0.25 1 1 8* 32* 32 16 0.5 
Enterococcus faecium 600 64* 64 64* 64* 64 32 64 1* 
*: Resistant Bacteria, according to: The European Committee on Antimicrobial Susceptibility Testing 
(EUCAST)[36]. 
 
Table 8: Interaction CIN-102 – Antibiotics for MDR strains 
 
 
MIC (mg/L) in combination (CIN-102/Antibiotic) 
Ʃ FIC index 
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Escherichia  
coli 
37.5/4 
0.38 
5/16 
0.27 
300/0.03 
1.00 
150/4 
0.56 
150/0.03 
0.50 
20/1 
0.32 
37.5/0.5 
0.13 
5/0.5 
0.52 
Klebsiella 
pneumoniae 
150/4 
0.50 
150/1 
0.27 
300/0.03 
0.50 
300/0.03 
0.50 
150/0.03 
0.25 
37.5/2 
0.19 
37.5/0.06 
0.07 
300/0.03 
0.52 
Serratia 
marcescens 
150/16 
0.50 
150/1 
0.38 
150/0.06 
0.25 
300/4 
0.56 
150/0.25 
0.25 
75/4 
0.25 
75/0.06 
0.13 
300/0.03 
0.52 
Enterobacter 
cloacae 
37.5/4 
0.38 
5/0.25 
0.02 
300/0.03 
1.00 
150/16 
0.75 
150/0.03 
0.50 
75/1 
0.38 
5/0.25 
0.03 
300/0.03 
1.02 
Pseudomonas 
aeruginosa 
600/8 
0.98 
600/1 
0.50 
600/0.25 
0.48 
600/0.5 
0.49 
1250/0.03 
1.00 
150/4 
0.62 
600/0.06 
0.5 
5/16 
0.50 
Acinetobacter 
baumannii 
5/1 
0.52 
150/0.03 
0.50 
150/0.25 
0.50 
150/0.25 
0.56 
150/0.25 
0.50 
37.5/2 
0.38 
75/4 
0.38 
300/0.03 
1.01 
Staphylococcus 
aureus 
5/0.125 
0.52 
5/0.25 
0.27 
150/0.06 
0.56 
75/0.03 
0.25 
75/8 
0.50 
75/1 
0.28 
5/4 
0.27 
5/0.25 
0.52 
Enterococcus 
faecium 
600/0.03 
1.00 
150/0.25 
0.25 
150/2 
0.28 
150/4 
0.31 
600/0.03 
1.00 
600/0.03 
1.00 
150/1 
0.27 
5/0.5 
0.51 
Synergy : ƩFIC index ≤0.5 
 
 
CHAPTER II 
80 
 
As seen in Table 7, all these four enterobacteria (E. coli, K. pneumoniae, S. marcescens and E. cloacae) 
are resistant to imipenem, gentamicin and colistin, whose MICs decreases between 4- and 256- fold 
when combined with subMICs of CIN-102, resulting in synergistic interactions. For E. coli, also amikacin-
resistant, a synergistic interaction with CIN-102 subMIC decreases the MIC of amikacin by a factor of 128. 
For non-fermentative Gram-negative bacteria: P. aeruginosa imipenem, gentamicin and colistin-resistant 
shows a decrease of 2-, 64- and 2-fold their MICs respectively in association with CIN-102 subMICs.  And 
even though A. baumannii is resistant to colistin and amikacin, these antibiotics present synergistic 
interactions with subMICs of CIN-102, decreasing their MICs by a factor of 4 and 8 respectively. 
Furthermore, antibiotics like vancomycin, erythromycin and clindamycin with marginal activity against 
Gram-negative, exhibit an enhanced activity against these bacteria when associated with CIN-102, shown 
by a decrease between 4- and 2133-fold in their MICs. Multi-resistant Gram-positive bacteria (S. aureus 
and E. faecium) become susceptible when CIN-102 is combined with these antibiotics, reducing their 
MICs between 4- and 2133-fold. Additionally, against Gram-positive bacteria, antibiotics like gentamicin, 
colistin and amikacin decrease their MICs between 4- and 1066-fold when associated with subMICs of 
CIN-102. 
 
PSMs are good sources for combination therapy with antibiotics, as there is evidence that they act as 
multidrug resistance modifiers, restoring the activity of antibiotics against resistant bacteria. These 
compounds can reduce the expression of modified targets, inhibit enzymes able to degrade the 
antibiotic, increase the permeability of the OM and inhibit efflux pumps facilitating the accumulation of 
antibiotic within bacterial cell[37]. Further studies are needed to understand how the components of CIN-
102 can improve the effectiveness of antibiotics which might involve several targets. In this regard, 
Dhara et al.[38] have shown that cinnamaldehyde might be able to interact with ESBLs like TEM-2, SHV-2, 
CTXM-9 by cleaving this enzymes through hydrogen bonds with catalytic and other crucial amino acid 
residues in these proteins. 
 
These interactions show that CIN-102 improves the effectiveness and restores the action of antibiotics. 
Through these combinations, the MICs of antibiotics can be reduced and then the potential side effects 
of antibiotics can be minimized or even the emergence of antibiotic resistance using monotherapy could 
be prevented. 
 
4. Conclusion 
CIN-102 is a broad-spectrum antibacterial agent of. All bacteria tested, including several multi-resistant 
clinical isolates, are susceptible to CIN-102. The MICs are higher as those found for antibiotics but animal 
studies carried out suggested that the active concentrations of CIN-102 are effective in infection models and 
seem to be compatible with a therapeutic use (data not shown).  This activity is associated with a rapid 1 log-
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reduction of the bacterial inoculum, an important PAE and the capacity of sub-inhibitory concentrations to 
slow down bacterial growth. The most important fact is that CIN-102 in combination, could allow the re-
utilization of antibiotics that are ineffective against multi-resistant bacteria. Nowadays, aminoglycosides and 
colistin are sometimes the only antibiotics that possess activity against MDR bacteria. If these antibiotics 
would remain ineffective or if the resistance would become more important, CIN-102 alone or in combination 
could be an encouraging alternative. The promising in vitro activity has to be confirmed by further clinical 
studies. 
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1. Introduction 
 Research on Intestinal Bowel Diseases (IBD) suggests that these disorders occur as an inappropriate immune 
response in genetically susceptible individuals as a result of a complex interaction between environmental 
and microbial factors and the intestinal immune system. However, the exact causes and mechanisms of IBD 
are not yet completely understood[1]. Nevertheless, bacteria seem to play an important role in the 
pathogenesis of IBD, as patients suffering from these diseases show an increased number of bacteria in their 
intestinal mucus layer. Also, lesions are preferentially observed in segments with the highest concentrations 
of bacteria; and IBD patients show an enhanced systemic and mucosal immunological reactivity against 
bacterial antigens[2]. There is indeed major evidence that IBD is due to an abnormal immune response to the 
bacterial flora[3]. The perturbations in the homeostasis between the immune system and the commensal flora 
can lead to gastro intestinal tract inflammation. In this situation the commensal flora appears to act as a 
pathogenic community, starting a lifelong inflammation because the host responses are incapable of 
controlling the flora[4]. The increasing evidence that gastro intestinal bacteria play a role in the pathogenesis 
and the development of IBD and the persistence of inflammation, provides the rational for research on the 
use of antibacterial agents in the treatment of these diseases: as modulator of the gastro intestinal flora or as 
adjuvants in the treatment of gastro intestinal tract inflammation[2,5].  In this respect, antibiotics may act via 
different pathways: They may for instance inhibit bacteria linked to the pathological process of the disease, or 
they may lower the luminal and/or mucosal bacterial overgrowth. The modification of the intestinal flora may 
reduce the strength of certain symptoms, including pain and diarrhea. Research in this field suggests that 
antibiotics can indeed improve clinical outcomes in patients suffering from an acute relapse of IBD[6]. For 
example, significant beneficial clinical effects have been reported for ciprofloxacin[7] and rifaximin[8] (versus 
placebo) in the treatment of IBD patients. 
 
However, antimicrobial resistance is a major concern for any antibiotic treatment. It is considered as an 
increasing threat to public health, with enormous economic and human costs, that requires a global action 
from the governments, academia and industry[9]. Despite the urgent need for new antimicrobials, there is a 
decline in the antibiotic research and in the industrial development pipeline, as evidenced by the decrease in 
discovery research and in antibacterial trials conducted by the pharmaceutical industry[10]. The perceived lack 
of return on investment in the field of antibacterial research has led industry to focus more on markets of 
chronic diseases, rather than acute infectious diseases. It seems that antibiotics are not perceived as being 
essential to health, however, they have saved millions of lives since these drugs were introduced in the early 
1930s, permitting individuals to live for many years after infection[11]. 
 
As stated by Bush et al.[9], in the battle against antimicrobial resistance, natural products appear as a vast 
reservoir of bioactive compounds available in nature that merit to be exploited. Plant secondary metabolites, 
like essential oils, are provided of an inherent antimicrobial activity as defense mechanism to survive in a 
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competing environment. These antimicrobial defenses are the result of a long evolutionary process. 
Therefore, they should be reconsidered as a good starting point in the development of new antimicrobial 
agents[12]. Furthermore, it is known that antibiotics that act on more than one target are advantageous to 
avoid the development of bacterial resistances[13]. This is an inherent major advantage of many multi-
component essential oils[14]. Although the antimicrobial activity of essential oils seems to be a property of the 
assembly of their components, it might be necessary to “reengineer” these botanical mixtures in order to 
render their production more reproducible[15]. Following this aim of antibiotic discovery based on natural 
products, a chemically well-defined, synergistic blend (called “CIN-102”) has been developed by Septeos. The 
composition of CIN-102 resembles the composition of cinnamon essential oils (Table 1). Its major component 
is cinnamaldehyde (86.7 % w/w). CIN-102 has a broad-spectrum antibacterial activity and no resistance has 
been observed so far (unpublished data). 
 
The hypothesis of this study was that the delivery of the broad-spectrum antibiotic CIN-102 to the lower 
gastrointestinal tract can ameliorate the state of colitis via a reduction in the total bacterial loads and/or the 
number of bacterial pathogens in the colon. Preliminary studies in trinitrobenzene sulfonic acid (TNBS) 
treated rats revealed that oral gavage of pure CIN-102 had only slight effects on bacterial flora (data not 
shown). Thus, it was concluded that adequate controlled oral drug delivery systems are required to assure 
minimal effective antibiotic concentrations at the site of action – the colon. The aim of these dosage forms is 
to minimize undesired premature drug release in the upper gastro intestinal tract and to control drug release 
in the colon[16,17,18,19,20]. Different types of multiparticulate dosage forms were prepared, offering major 
advantages compared to single unit dosage forms, such as a more homogeneous distribution within the 
contents of the gastro intestinal tract and a reduced risk of dose dumping[21]. Coated pellets as well as 
uncoated mini-tablets were studied. In the first case, an outer polymeric film coating (sensitive to colonic 
bacterial enzymes) was used to assure the onset of drug release at the site of action. In the case of mini-
tablets, the incorporation of inulin (which is preferentially degraded by colonic bacterial enzymes[22] is 
intended to provide the site-specific delivery of CIN-102 along the gastro intestinal tract. A particular 
formulation challenge was the fact that CIN-102 is a volatile hydrophobic liquid. 
 
The objective of this study was to prepare multiparticulate dosage forms for CIN-102, able to minimize 
undesired drug release in the upper gastro intestinal tract and to control the release of the novel broad 
spectrum antibacterial agent in the colon. The systems were tested in vitro as well as in vivo (in mice suffering 
from colitis). The idea was to reduce the animals’ bacterial loads, especially in the intestinal mucosa in order 
to improve the state of intestinal inflammation. 
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2. Materials and methods 
2.1. Materials 
CIN-102, a well-defined blend of trans-cinnamaldehyde, trans-2-methoxycinnamaldehyde, cinnamyl 
acetate, linalool, β-caryophyllene, cineol and benzyl benzoate (see Table 1 for the exact composition) 
(Septeos, Paris, France); ethylcellulose powder (Ethocel Standard 10 FP Premium; Dow, Knoxville, TN; 
USA); microcrystalline cellulose (MCC, Avicel PH 101) and an aqueous ethylcellulose dispersion 
(Aquacoat ECD 30D, 30 % solids content) (FMC Biopolymer, Brussels, Belgium); an aqueous dispersion of 
poly(vinyl acetate) (27 %), containing also poly(vinyl pyrrolidone) (2.7 %) and sodium lauryl sulfate (0.3 
%) [30 % solids content, Kollicoat SR 30D; BASF, Ludwigshafen, Germany]; triethyl citrate (TEC; Alfa 
Aesar, Karlsruhe, Germany); magnesium aluminometasilicate (Neusilin US2, neutral grade; Fuji Chemical 
Industry, Toyama, Japan); polyethylene sorbitan monooleate (Tween 80; Panreac, Barcelona, Spain); 
poly(vinyl alcohol) (Opadry; Colorcon, Dartford Kent, UK); lactose (Lactochem fine powder; Domo, 
Veghel, The Netherlands); inulin (Orafti HP; Beneo Orafti, Oreye, Belgium); peas starch (Peas starch; 
Roquette Freres, Lestrem, France); silicon dioxide (Syloid 244 FP; Grace Davison, Worms, Germany); 
glyceryl tristearate (Dynasan 118; Sasol, Witten, Germany); dextran sodium sulfate (DSS; TdB, Uppsala, 
Sweden); acetonitrile (VWR, Fontenay-sous-Bois, France); methanol (Fisher Scientific, Loughborough, 
UK); cysteinated Ringer’s solution (Merck, Darmstadt, Germany). 
 
Table 1: Composition of CIN-102 
 
 
 
 
 
 
 
 
 
2.2. Preparation of coated pellets 
2.2.1. Preparation of drug-laded pellet starter cores 
Three types of CIN-102-loaded pellet cores were prepared by extrusion-spheronization. Table 2 
shows their theoretical compositions. The respective excipients, CIN-102 and purified water (400, 
600 and 800 mL for 1 kg MCC/lactose/Tween, MCC/lactose/Syloid, and MCC/Ethocel/Neusilin cores) 
were blended in a high speed granulator (Gral 10; Collette, Antwerp, Belgium). The mixtures were 
Component % (w/w) 
Trans-cinnamaldehyde 86.7 
Trans-2-methoxycinnamaldehyde 5.35 
Cinnamyl acetate 2.5 
Linalool 2.4 
β-Caryophyllene 1.7 
Cineol 1 
Benzyl benzoate 0.35 
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passed through a cylinder extruder (SK M/R; 1 mm diameter holes, rotation speed = 96 rpm; 
Alexanderwerk, Remscheid, Germany). The extrudates were subsequently spheronized at 520 rpm 
for 30 s (Spheronizer Model 15; Calveva, Dorset, UK) and dried in a fluidized bed at 30°C for 30 min 
(Strea 1; Aeromatic, Bubendorf, Switzerland). Pellets in the size range of 710-1000 µm were 
obtained by sieving. 
 
2.2.2.  Pellet coating 
Pellets were coated with peas starch: ethylcellulose or inulin: Kollicoat SR blends. Aquacoat ECD 30D 
was used as an aqueous ethylcellulose dispersion. Kollicoat SR 30D is an aqueous dispersion of 
poly(vinyl acetate) (27 %), containing also poly(vinyl pyrrolidone) (2.7 %) and sodium lauryl sulfate 
(0.3 %). Aquacoat ECD 30D and Kollicoat SR 30D were plasticized overnight with triethyl citrate (25 
and 10 % w/w of the solid contents, respectively) under magnetic stirring. Peas starch and inulin 
were dissolved in purified water (5 and 7% w/w, respectively) and mixed with plasticized Aquacoat 
ECD 30 D or Kollicoat SR 30D dispersion at different ratios (w/w polymer mass, as indicated). The 
blends were stirred for 2 h prior to coating. Optionally, an Opadry sub-coating was applied. For this 
Opadry was dissolved in purified water (15% w/w). 
 
CIN-102-loaded pellet cores were coated in a fluidized bed (Strea 1), equipped with a Wurster 
insert. The process parameters for polymer blends were as follows: inlet temperature = 38 °C, 
product temperature = 40 °C, spray rate = 1.5 g/min, atomization pressure = 1.2 bar, nozzle 
diameter = 1.2 mm. Pellets were coated until a weight gain of 15, 20, 25 or 30 % (w/w) was achieved 
(as indicated). Finally, the pellets were cured in an oven at 60 °C for 24 h. The process parameters 
for the Opadry sub-coating were as follows: inlet temperature = 30 °C, product temperature = 35°C, 
spray rate = 0.7 g/min, atomization pressure = 1.2 bar, nozzle diameter = 1.2 mm. In this case, the 
coating level was 7 % (w/w). At the end, the pellets were further fluidized in the coater without 
spraying any liquid during 15 min (for drying). 
 
2.3.  Preparation of mini-tablets 
Mini-tablets were prepared by direct compression. Table 3 shows the theoretical compositions of the 
investigated systems (further compositions are described in the text). CIN-102 was adsorbed onto 
Neusilin to obtain a powder (upon manual mixing in a mortar). Ethocel, Dynasan 118 and/or inulin were 
added under continuous manual mixing. The obtained blends were compressed using a Frank 
Universalpruefmaschine 81816 (Karl Frank, Weinheim-Birkenau, Germany) into flat-faced cylinders 
(diameter = 2 mm, height = 2 mm). The compression force was 300 N and the compression time 10 s, 
unless otherwise stated. 
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2.4. In vitro drug release 
To monitor the release of CIN-102, the release of its main component (cinnamaldehyde, 86.7 % w/w) 
was measured. In the case of coated pellets, 500, 80 and 85 mg samples (MCC/lactose/Tween, 
MCC/lactose/Syloid and MCC/Ethocel/Neusilin cores) were placed into 120 mL cylindrical flasks, filled 
with 100 mL release medium: 0.1 M HCl during the first 2 h, which was completely exchanged with 
phosphate buffer pH 7.4 for the following 6 h. The flasks were agitated in a horizontal shaker (80 rpm; 
GFL 3033, Gesellschaft fuer Labortechnik, Burgwedel, Germany) at 37°C. At pre-determinated time 
points, 3 mL samples were withdrawn, replaced with fresh medium, and analyzed UV-
spectrophotometrically (λ = 290 nm in 0.1 M HCl and λ = 291 nm in phosphate buffer pH 7.4) (Shimadzu 
UV-1650, Champs sur Marne, France). In the case of mini-tablets, 1 mini tablet was placed in a 2.5 mL 
Eppendorf tube, filled with 2 mL 0.1 M HCl during the first 2 h, followed by phosphate buffer pH 7.4 for 
the subsequent 6 h. The tubes were horizontally shaken at 37°C (80 rpm, GFL 3033). At pre-determined 
time points, the release medium was completely replaced. The cinnamaldehyde content in the 
withdrawn samples was measured by UV-spectrophotometry, as described above. After the last 
measurement time point, the amount of cinnamaldehyde potentially remaining within the mini-tablet 
remnants was determined as follows: The residues were dissolved in 2 mL acetonitrile, and the 
cinnamaldehyde content in the liquid was determined by HPLC analysis (Varian ProStar 230, 410 
autosampler, 325 UV-Vis detector, Galaxie software; Varian, Les Ulis, France). A reversed phase C18 
column (Luna 5µm, 110 Å, 150mm x 4.6mm, Phenomenex, France) was used. The mobile phase consisted 
of an acetonitrile:methanol:water mixture (20:35:45, v/v/v). Thirty µL samples were injected, the flow 
rate was 1 mL/min, the detection wavelength 290 nm. Each experiment was conducted in triplicate and 
sink conditions were maintained throughout all experiments. 
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Table 2 
Theoretical composition of the investigated pellet cores loaded with CIN-102 (%, w/w) 
 
 
 
 
 
 
 
 
 
Table 3 
Theoretical composition of the investigated mini-tablets loaded with CIN-102 (%, w/w) (further compositions are described in the text) 
  MCC/lactose/Tween  MCC/lactose/Syloid  MCC/Ethocel/Neusilin  
CIN-102 1 14.5 10 
MCC 45 38.75 55 
Lactose 45 38.75 - 
Tween 80 9 - - 
Syloid 244 FP - 8 - 
Ethocel - - 25 
Neusilin - - 10 
    
 
Compound 
Neusilin/Dynasan Neusilin/Inulin/Dynasan Neusilin/Ethocel/Inulin/Dynasan 
CIN-102 4 4 4 4 
Neusilin 1.33 1.33 1.33 1.33 
Ethocel   25 50 
Inulin  1 5 10 25 5 10 15 20 25 5 10 15 20 25 
Dynasan 94.67 93.67 89.67 84.67 69.67 64.67 59.67 54.67 49.67 44.67 39.67 34.67 29.67 24.67 19.67 
Core type 
Compound 
Mini-tablet 
type 
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2.5. Equilibrium solubility measurements 
The solubility at equilibrium of cinnamaldehyde was determined in agitated flasks in 0.1 M HCl and 
phosphate buffer pH 7.4 at 37 °C. An excess amount of CIN-102 was exposed to 100 mL bulk fluid 
under horizontal shaking (80 rpm; GFL 3033). Every day, samples were withdrawn, filtered and 
analyzed by UV for their cinnamaldehyde content (as described above) until equilibrium was 
reached. Each experiment was conducted in triplicate. 
 
2.6. mDSC analysis 
Modulated Differential Scanning Calorimetry (mDSC) experiments of polymeric film samples were 
performed with a DSC Q200 (TA Instruments, Guyancourt, France). Temperature and enthalpy 
readings were calibrated using pure indium at the same scan rates and with the same kind of pans 
as used for the measurements. Thin films were obtained by spraying the same formulations as used 
for the preparation of the coated pellets, onto Teflon plates and subsequent controlled drying at 60 
°C for 24 h. Approximately 5 mg samples were heated in open pans (containers without lids) from 
−20 to 100 °C at 5 °C/min using a modulation amplitude of  ±0.663 °C and a modulation period of 50 
s. The samples were flushed with highly purified nitrogen gas. Two heating cycles were run, the 
reported data was obtained from the second cycle. 
 
2.7. Mouse study 
An in vivo study with seven-week-old, male mice (C57BL6; Janvier Laboratory, Le Genest St. Isle, 
France) was conducted in the animal facilities "Animalerie Haute Technologie" at the School of 
Medicine of the University of Lille (Lille, France), respecting all governmental guidelines (including 
n°2010/63/UE; Décret 2013-118; EC Directive 86/609/EEC) and ethical rules. The animals were 
housed with free access to commercial rodent food and water. Fig. 1 shows the study design. At the 
beginning of the experiment (Day 1), the mice were divided into 3 groups (10 animals in each 
group): (i) One group received only standard chow (negative control). (ii) One group received 
standard chow mixed with CIN-102-loaded coated pellets (50 mg cinnamaldehyde/kg/day) 
[MCC/Ethocel/Neusilin cores; 7 % Opadry sub-coating; 30 % inulin:Kollicoat SR (1:4) outer coating]; 
(iii) One group received standard chow mixed with CIN-102-loaded mini-tablets (50 mg 
cinnamaldehyde/kg/day) [4 % CIN-102 (theoretical), 1.33 % Neusilin, 50 % Ethocel, 25 % inulin, 
19.67 % Dynasan]. The disease was induced from Day 4 on by adding 2.5 % (w/v) dextran sodium 
sulfate to the drinking water. The course of the colitis was evaluated by monitoring the body 
weight, presence of blood in stools and occurrence of diarrhea. On Day 12 the animals were 
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sacrificed. Samples of the luminal content and of sections of the colon were used for bacteriological 
analysis and colonic tissue samples for immunological analysis. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 1: In vivo mouse study design: Oral administration of coated pellets and mini-tablets began on Day 1. 
Colitis was induced by adding dextran sodium sulfate in drinking water from Day 4 on. The animals were 
sacrificed on Day 12. The course of colitis was evaluated by monitoring the body weight, presence of blood 
in stools and diarrhea, as well as by bacteriological and immunological analysis. 
 
The colonic tissue and luminal content samples were introduced into pre-weighed vials containing 
1.5 mL cysteinated Ringer’s solution. After manual physical disruption, 10-fold dilutions were made 
in the same diluent (until 10-4 for colonic section samples and 10-6 for luminal content samples, 
respectively). Each dilution was spread onto plates of non-selective blood agar: modified Columbia 
agar [Columbia blood agar base (Oxoid, Basingstoke, England), glucose (5 g L-1), agar (5 g L-1), 
cysteine hydrochloride (0.5 g L-1) supplemented with defibrinated horse blood (5%)][23] and 
incubated at 37°C for 1 week under anaerobic conditions. McConkey (selective for enterobacteria) 
as well as Dcoccosel (selective for enterococci) plates (BioMerieux, Marcy l’Etoile, France) were 
incubated at 37 °C for 48 h under aerobic conditions. Man, Rogosa, Sharpe (selective for lactobacilli) 
plates were incubated at 37 °C for 48 h under CO2-enriched conditions. Total counts were 
performed, and different types of colonies were sub-cultured and identified based on established 
morphological and biochemical criteria. Quantitative results are expressed in “log colony forming 
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units per gram” (CFU g−1). The threshold of detection was 2.5 x 103 CFU g−1 for colonic section 
samples and 4.8 x 102 CFU g-1 for luminal content samples, respectively.  
 
Total RNA was extracted from colonic tissue samples using the NucleoSpin RNAII commercial kit 
(Macherey-Nagel, Hoerd, France), following the manufacturer’s instructions. cDNA was prepared 
using the High Capacity cDNA Archive kit (Macherey-Nagel, Hoerd, France), and quantitative 
Polymerase Chain Reaction (qPCR) was performed using SyBrGreen (Applied Biosystems, Saint-
Aubin, France). Expression levels of TNFα, IL-1β, IL-6, IL-10 were measured. Polr2A was used as a 
reference gene. 
 
Two tail paired t-tests were used to determine if the mean of measurements from one condition is 
different from the mean of another condition, using 95% confidence intervals. 
 
3. Results and discussion 
In order to provide controlled release of CIN-102 in the lower part of the gastro intestinal tract, this 
volatile hydrophobic liquid blend was incorporated into: (i) pellet starter cores, which were subsequently 
coated with appropriate polymer blends, or (ii) mini-tablets. For reasons of simplicity, only the release of 
the main compound of the liquid mixture CIN-102 was monitored during the in vitro drug release 
studies: the release of cinnamaldehyde (the main compound with antibacterial activity, constituting 86.7 
% w/w of the blend). 
3.1. CIN-102-loaded coated pellets 
Pellet starter cores were prepared by extrusion-spheronization and subsequently coated in a 
fluidized bed with blends of a water-insoluble polymer and a polymer, which is known to be 
preferentially degraded by bacterial enzymes in the colon. Since CIN-102 is volatile, 30-50 % of the 
liquid drug got lost during the manufacturing procedure (e.g., during pellet core drying in a fluidized 
bed for 30 min at 30°C, and pellet curing subsequent to coating in an oven at 60 °C for 24 h). Fig. 2A 
shows the resulting cinnamaldehyde release kinetics from pellets consisting of: (i) cores prepared 
with 1 % CIN-102, 45 % MCC, 45 % lactose and 9 % Tween 80, and a (ii) coating based on a peas 
starch:ethylcellulose (1:2) blend. The coating level was 15 or 20 % (as indicated). The release 
medium was initially 0.1 M HCl. After 2 h, it was completely exchanged against phosphate buffer pH 
7.4. An ideal formulation should release no or only negligible amounts of cinnamaldehyde under 
these conditions, simulating the transit through the upper gastro intestinal tract. However, as it can 
be seen, the investigated formulations released more than 50 % of the drug within the first 2 h. The 
rest was rapidly released upon medium change. This was true for both coating levels and indicates 
that these pellets are not suitable for controlled CIN-102 delivery to the lower gastro intestinal 
CHAPTER III 
94 
 
tract. The reasons for their failure probably include: limited drug affinity to the pellets' core, high 
affinity of the drug to the film coating, and high permeability of the drug through the film coating. 
In addition, the presence of the surfactant Tween 80 likely facilitates water penetration into the 
system, drug dissolution and drug release. The significant increase in the release rate of 
cinnamaldehyde upon medium change might be attributable to the fact that the aqueous 
ethylcellulose dispersion Aquacoat ECD was used for film coating, containing small amounts of 
sodium lauryl sulfate (SLS): This surfactant is protonated (and non-charged) at low pH, while un-
protonated (and negatively charged) at pH 7.4. It has been reported in the literature that in the case 
of films prepared from aqueous polymer dispersions, the presence of SLS can be responsible for pH-
depended drug release if the polymer particles are not completely fused together: At pH 7.4, the 
SLS (being negatively charged) more effectively facilitates the penetration of water into the system, 
water being mandatory for drug dissolution and subsequent drug release[24]. It has to be pointed 
out that for all the investigated formulations, sink conditions were provided throughout the 
experiments: The solubility of cinnamaldehyde in 0.1 M HCl and phosphate buffer pH 7.4 was 
determined to be equal to 1.1 ± 0.04 g L-1 and 1.4 ± 0.05 g L-1 at 37 °C, respectively. The higher drug 
solubility at neural pH can also partially explain the observed increase in the drug release rate upon 
medium change (Fig. 2A), but it cannot be the only reason. 
 
In order to slow down cinnamaldehyde release, the surfactant Tween 80 was omitted, and parts of 
the MCC and lactose in the pellets' cores were replaced by Syloid (highly porous silicon dioxide 
particles with a high surface area and adsorption capacity) to increase the affinity of the drug to the 
core. At the same time, the theoretical CIN-102 content was increased to 14.5 %, in order to 
compensate drug loss during preparation. However, as it can be seen in Fig. 2B, these strategies did 
not work out: The release rates became even faster, irrespective of the coating level. This might at 
least partially be explained by the fact that after extrusion-spheronization the surface of the pellets' 
cores appeared to be oily, indicating that the drug was not effectively taken up the Syloid. Also, the 
increased drug loading might facilitate drug release[25]. 
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Fig. 2: Cinnamaldehyde release from CIN-102-loaded pellets, coated with peas starch:ethylcellulose (1:2) in 0.1 M HCl 
for 2 h, followed by phosphate buffer pH 7.4. The coating level was 15 or 20 % (as indicated), the pellet cores 
contained: A) MCC/lactose/Tween, or B) MCC/lactose/Syloid (exact compositions see Table 2) (mean values +/- SD 
are indicated). 
 
 
A 
B 
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To effectively slow down cinnamaldehyde release in 0.1 M HCl and phosphate buffer pH 7.4, the 
relative amount of ethylcellulose in the film coating was increased, the film coating thickness was 
increased, an Opadry-sub-coating was introduced, lactose omitted, Ethocel (ethylcellulose powder) 
introduced into the core, the drug and MCC loadings reduced, and Syloid replaced by Neusilin 
(magnesium aluminometasilicate, with a high adsorption capacity for oily compounds). The aim of 
the Opadry sub-coating [based on poly(vinyl alcohol)] was to reduce the risk of drug migration into 
the outer peas starch:ethylcellulose film coating. The introduction of ethylcellulose into the pellets' 
cores was intended to hinder water penetration into the system. Fig. 3 shows that these strategies 
were at least partially successful: Cinnamaldehyde release was sustained for 8 h at both coating 
levels. In addition, drug release was no more pH dependent (indicating improved film formation). 
But cinnamaldehyde release was still significant under these conditions.  
 
Fig. 3: Cinnamaldehyde release from CIN-102-loaded pellets, coated with peas starch:ethylcellulose (1:3) 
(and an Opadry sub-coating) in 0.1 M HCl for 2 h, followed by phosphate buffer pH 7.4. The coating level 
was 30 and 35 % (as indicated), the pellet cores contained MCC/Ethocel/Neusilin (exact composition see 
Table 2) (mean values +/- SD are indicated). 
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Thus, the coated pellets were further optimized: The controlled release film coating was replaced 
by a blend of inulin and Kollicoat SR (1:4). The pellet cores and the Opadry sub-coating remained 
unaltered. As it can be seen in Fig. 4, even at lower coating levels (20 and 30 %, respectively) drug 
release could be effectively further slowed down. This is probably due to a lower cinnamaldehyde 
affinity to these film coatings and/or a lower permeability of the latter for the drug. Fig. 5 shows 
the reversible signal of the mDSC scans of samples of thin film pieces of the same composition as 
the inulin:Kollicoat SR (1:4) outer film coatings. For reasons of comparison, inulin (pure substance) 
and Kollicoat SR films (plasticized or not) were also studied. As it can be seen, the plasticized 
inulin:Kollicoat SR films used for pellet coating showed a single glass transition temperature (Tg) at 
33 °C. This corresponds to the Tg of the plasticized Kollicoat SR. Inulin did not show any thermal 
event in the investigated temperature range. This likely indicates that the polymeric pellet coating 
is in an amorphous state. Since water acts as an efficient plasticizer for many polymers[26], it can 
further be expected that the polymeric film coating is in the rubbery state during drug release. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 4: Cinnamaldehyde release from CIN-102-loaded pellets, coated with inulin:Kollicoat SR (1:4) (and an Opadry sub-
coating) in 0.1 M HCl for 2 h, followed by phosphate buffer pH 7.4. The coating level was 20 and 30 % (as indicated), 
the pellet cores contained MCC/Ethocel/Neusilin (exact composition see Table 2) (mean values +/- SD are indicated). 
 
. 
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Fig. 5: mDSC Thermograms of film samples consisting of Kollicoat SR, plasticized Kollicoat SR, 
plasticized inulin:Kollicoat SR (1:4) or inulin (pure substance). The arrows mark glass transition 
temperatures 
 
Based on these results, pellets containing MCC/Ethocel/Neusilin cores, a 7 % Opadry sub-coating 
and an inulin:Kollicoat SR (1:4) outer coating (30 %) were selected for in vivo studies. 
 
3.2. CIN-102 mini-tablets 
Mini-tablets were prepared by direct compression. To transform the liquid drug into a solid powder, 
CIN-102 was first adsorbed onto Neusilin (magnesium aluminometasilicate, with a high adsorption 
capacity for oily compounds). Then, Dynasan 118 (glyceryl tristearate) was added and flat-faced 
cylinders (diameter = 2 mm, height = 2 mm) prepared using a Frank Universalpruefmaschine 81816. 
The compression force was either 300 or 2000 N, the holding time either 10 or 120 s. Fig. 6 shows 
the resulting cinnamaldehyde release kinetics from these mini-tablets in 0.1 M HCl, followed by 
phosphate buffer pH 7.4. As it can be seen, drug release was slow in all cases and the impact of the 
investigated variations in the compression force and holding time were only minor. Based on these 
results, a compression at 300 N for 10 s was selected for all further experiments. Note that also in 
the case of mini-tablets, substantial amounts of CIN-102 (approximately 40 % in all cases) were lost 
during tablet preparation. This is due to the high volatility of the liquid blend. The analysis of the 
mini-tablet remnants at the end of the observation period revealed that the amounts of released 
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and non-released CIN-102 added up to 100 % of the practical tablet loading. This was true for all the 
investigated mini-tablets. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 6 Impact of the compression force and holding time (indicated in the diagram) on cinnamaldehyde 
release from CIN-102-loaded mini-tablets in 0.1 M HCl for 2 h, followed by phosphate buffer pH 7.4. The 
mini-tablets consisted of 4 % CIN-102 (theoretical), 1.33 % Neusilin and 94.67 % Dynasan (mean values +/- 
SD are indicated). 
 
 
In order to provide an onset of drug release in the colon, different amounts of inulin were 
incorporated into the mini-tablets. As it can be seen in Fig. 7A, the introduction of up to 25 % inulin 
led to an undesired increase in the resulting drug release rate (due to the higher permeability of this 
hydrogel forming polymer compared to glyceryl tristearate). To reduce the cinnamaldehyde release 
rate in media simulating the upper gastro intestinal tract, Ethocel (ethylcellulose powder) was 
added to the mini-tablets. Figs. 7B and C show the observed drug release profiles from mini-tablets 
containing 25 or 50 % Ethocel and up-to 25 % inulin. Clearly, the release rate decreased upon 
Ethocel addition. Based on these results, mini-tablets consisting of 4 % CIN-102 (theoretical), 1.33 % 
Neusilin, 50 % Ethocel, 25 % inulin and 19.67 % Dynasan were considered as most promising 
formulation.  
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Fig. 7: Impact of the composition of CIN-102-loaded mini-tablets on cinnamaldehyde release in 0.1 M HCl 
for 2 h, followed by phosphate buffer pH 7.4. The mini-tablets contained 4 % CIN-102 (theoretical), 1.33 % 
Neusilin and: A) 1-25 % inulin and 70-94 % Dynasan; B) 25 % Ethocel, 5-25 % inulin and 65-45 % Dynasan; or 
C) 50 % Ethocel, 5-25 % inulin and 20-40 % Dynasan (as indicated) (mean values +/- SD are indicated; note 
that the SD are often too small to be visible). 
A 
B 
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In order to evaluate the impact of increasing initial drug contents on the resulting release kinetics, 
the CIN-102 content was increased up to 12 %. To be able to effectively adsorb the increasing 
amounts of liquid drug, the Neusilin content was increased accordingly. Fig. 8 shows the release of 
cinnamaldehyde from mini-tablets consisting of: (i) 4 % CIN-102 (theoretical), 1.33 % Neusilin, 50 % 
Ethocel, 25 % inulin and 19.67 % Dynasan, (ii) 8 % CIN-102 (theoretical), 2.67 % Neusilin, 50 % 
Ethocel, 25 % inulin and 14.33 % Dynasan, or (iii) 12 % CIN-102 (theoretical), 4 % Neusilin, 50 % 
Ethocel, 25 % inulin and 9 % Dynasan. As expected the release rate increased with increasing initial 
drug content, due to the reasons discussed above. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 8: Impact of the CIN-102 contents (indicated in the diagram) on cinnamaldehyde release from CIN-102-
loaded mini-tablets in 0.1 M HCl for 2 h, followed by phosphate buffer pH 7.4. The mini-tablets consisted of 
4-12 % CIN-102 (theoretical), 1.33-4 % Neusilin, 50 % Ethocel, 25 % inulin and 9-20 % Dynasan (as indicated) 
(mean values +/- SD are indicated; note that the SD are often too small to be visible). 
 
Based on these results, mini-tablets consisting of 4 % CIN-102 (theoretical), 1.33 % Neusilin, 50 % 
Ethocel, 25 % inulin and 19.67 % Dynasan were selected for in vivo studies. No in vitro release 
studies were performed upon exposure to media simulating the conditions in the colon, since 
cinnamaldehyde rapidly degrades upon contact with fecal samples (the peak obtained by HPLC 
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analysis rapidly decreased and multiple new peaks appeared). This does not necessarily mean that 
CIN-102 has no chance to become active in a living colon: The survival time might be sufficient 
and/or the degradation products might be active. It was beyond the scope of this study to 
investigate this aspect in more detail. Instead, we focused on the in vivo efficiency of the most 
promising coated pellet and mini-tablet formulations. 
3.3. In vivo evaluation 
The objective of the CIN-102 treatment was two-fold: (i) to reduce total bacterial loads in the colon 
of the animals, and (ii) to reduce the pathogenic bacteria involved in colitis. Preliminary studies in 
TNBS treated rats revealed that oral gavage of the pure drug had only slight effects on bacterial 
flora (data not shown). In this study, colitis was induced by oral gavage of dextran sodium sulfate 
(DSS). The DSS treatment did not lead to a significant change in the bacterial counts of the total 
flora, which was true for the luminal and mucosal colonic bacteria (data not shown). However, the 
DSS-induced colitis was accompanied by a significant increase in the population of enterobacteria 
(luminal and mucosal) (data not shown). This is in good agreement with previous reports on colitis, 
where inflammation supported a high colonization by these bacteria on intestinal microbiota[27] and 
in IBD patients, the diversity of the microbiota was altered leading to an increase of the Gram-
negative bacteria[28]. Also, an increase of enterobacteria in stool samples of patients suffering from 
IBD has been reported[29]. The critical role of this bacterial family in the pathogenesis of IBD might 
be explained based on the fact that lipopolysaccharides (present in enterobacteria) are specific 
significant contributors to Toll-like-receptors 4 (TLR4), and these receptors are abundantly 
expressed in intestinal epithelial cells in IBD[30], this interaction triggering important inflammatory 
cascades[31]. 
Fig. 9 shows the bacterial counts (luminal and mucosal) in mice, which were treated with the 
selected coated pellets and mini-tablets. For reasons of comparison, also mice not receiving CIN-
102 were studied. Fig. 9A shows the bacterial counts of the total flora, Fig. 9B the bacterial counts 
of the enterobacteria. As it can be seen, the CIN-102 treatment (using coated pellets or mini-
tablets) did not significantly alter the total flora counts (luminal or mucosal), but significantly 
decreased the enterobacteria counts: P = 0.0003 and 0.02 for luminal and mucosal counts (non-
treated vs. coated pellets); P = 0.0002 and 0.02 for luminal and mucosal counts (non-treated vs. 
mini-tablets). This clearly demonstrates the in vivo efficacy of the novel CIN-102 formulations. It has 
to be pointed out that the decrease in the mucosal enterobacteria counts is particularly promising, 
since bacteria associated with the gastro intestinal tract wall are considered to be a more critical 
factor than luminal bacteria for the promotion of IBD pathogenesis, given their immediate 
proximity to affected tissues[32]. For example, increased enterobacterial levels were found in 
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mucosal tissue biopsies from Crohn disease patients, correlating with the severity of the 
inflammation[33]. Based on all these results, it can be expected that the reduction of enterobacteria 
by CIN-102 in stools (luminal bacteria) and more importantly, in the colonic mucosa, will have a 
positive impact on the IBD treatment. The explanation of the fact that the CIN-102 treatment did 
not significantly affect the total flora counts requires further research. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. 9: Antibacterial activity of CIN-102-loaded coated pellets and mini-tablets (compositions see text) in a 
colitis mouse model, with respect to the: A) total flora, B) enterobacteria. For reasons of comparison, a 
control mouse group did not receive CIN-102 ("non-treated") (mean values +/- SD are indicated). 
 
A 
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Importantly, the reduction in the enterobacteria counts upon treatment with CIN-102-loaded 
coated pellets and mini-tablets was accompanied by improved clinical scores of the DSS-colitis 
mice: Fig. 10 shows the percentages of animals with bloody stools and suffering from diarrhea as a 
function of time and treatment type. Very clearly, the presence of blood in stools and occurrence of 
diarrhea was much less frequent in mice receiving CIN-102-loaded pellets and mini-tablets 
compared to mice receiving standard chow only. However, there was no difference in the body 
weight loss between non-treated and CIN-102 treated mice (data not shown). It can be 
hypothesized that the observed amelioration of the course of the colitis is related to the above 
described reduction in the number of colonic enterobacteria. It has indeed been shown that broad-
spectrum antibiotics or broad-spectrum antibiotic combinations are able to prevent, treat and/or 
reduce the severity of the inflammation in colitis animal models[34,35,36]. Also, in clinical practice 
antibiotic therapy has been reported to be promising for the treatment of acute Crohn’s 
disease[37,38] and to be beneficial for the treatment of ulcerative colitis in combination with 
corticosteroids[39]. 
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Fig. 10 Evolution of the course of colitis in the mouse model: A) Presence of blood in stools, and 
B) Occurrence of diarrhea. Ten mice were in each group, 100 % correspond to all 10 mice in the respective 
group. The mice received standard chow only ("non-treated"), standard chow with coated pellets, or 
standard chow with mini-tablets (as indicated). 
 
To know whether the observed amelioration of the clinical course of colitis in the investigated mice 
was potentially related to immunomodulatory effects (as a consequence of the reduction in the 
levels of colonic enterobacteria), the colonic expression of several cytokines was measured. It has 
been shown that cinnamaldehyde is capable to decrease inflammatory mediators and to increase 
anti-inflammatory mediators[40]. As it can be seen in Fig. 11, the mRNA levels of the pro-
inflammatory cytokines IL-1β and TNF-α in colonic tissue samples decreased upon CIN-102 
treatment (in the case of coated pellets and mini-tablets). In contrast, the expression of IL-6, a 
cytokine involved in intestinal healing after inflammatory injury[41], increased upon CIN-102 
treatment (in the case of coated pellets and mini-tablets). However, due to the high standard 
deviations the differences were not statistically significant. The levels of IL-10, an anti-inflammatory 
cytokine involved in intestinal homeostasis[42], remained about constant. 
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Fig. 11: Effects of CIN-102 treatment on the state of inflammation in the mouse colitis model: IL-1β, TNF-α, 
IL-6, and IL-10 mRNA expression levels in colonic tissue samples obtained on Treatment Day 12 (mean 
values +/- SD are indicated). 
 
 
4. Conclusion 
The proposed CIN-102 coated pellets and mini-tablets show a promising potential for the treatment of 
colitis. The controlled release of the new broad spectrum antibiotic was demonstrated to effectively 
reduce the luminal and mucosal enterobacteria in mice, accompanied by an amelioration of the clinical 
course of the intestinal inflammation (presence of blood in stools and occurrence of diarrhea). Further 
studies are needed to better understand the mechanisms of action of CIN-102 during colitis. 
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1. Introduction 
Intestinal Bowel Diseases (IBD), comprising  Crohn’s disease (CD) and ulcerative colitis (UC), are chronic, 
relapsing, inflammatory pathologies that are immunologically mediated and with multi-factorial etiology. 
These idiopathic disorders appear to be caused by overly aggressive acquired immune responses to a 
subset of commensal enteric bacteria in genetically susceptible hosts, and that environmental factors 
precipitate their onset or reactivation. Indeed, increasing evidence suggest that the intestinal microbiota 
play a role in initiating, maintaining and determining the phenotype of these diseases[1]. 
 
The main goals of therapy in patients with IBD are to induce a clinical remission and then maintain that 
remission over time[2]. Mesalazine (5-aminosalicylic acid or 5-ASA) has a well-established role in the 
management of UC and a less clear role in the management of CD, and is likely to have multiple anti-
inflammatory effects[3]. 5-ASA inhibit the production of prostaglandins and leukotrienes by interfering 
with cyclooxygenase and lipoxygenase pathways[4,5]. Mesalazine also inhibits tumor necrosis factor 
(TNF)-α effects on intestinal epithelial cell proliferation and activation of mitogen-activated protein 
(MAP) kinase and nuclear transcription factor κB (NF-kB)[6]. Furthermore, it has recently been 
demonstrated that the peroxisome proliferator-activated receptor-γ (PPARγ) is the key receptor that 
mediates the main effects of 5-ASA in the colon[7] .  
 
The heterodimer of PPARγ with the retinoid X receptor (RXR) plays a crucial role in adipogenesis and 
insulin sensitization, has important immunomodulatory activities and affect cell 
proliferation/differentiation pathways. Adipose tissue, large intestine and hematopoietic cells express 
high levels of PPARγ[8].  PPARγ/RXR could inhibit two of the most important signaling pathways 
regulating expression of pro-inflammatory genes: NF-κB and stress kinase pathways[9].  
 
This receptor seems to play a crucial role in the regulation of intestinal inflammation. In fact, PPARγ+/- 
mice have an exacerbation of intestinal inflammation[10,11] and PPARγ expression is reduced in colonic 
tissue of DSS-colitic mice[12] and in epithelial colonic cells from UC patients[13]. Furthermore, in murine 
models of colitis, PPARγ ligands like thiazolidinediones can inhibit the inflammatory response[10,11,14,15] 
and PPARγ gene therapy can restore or/and enhance endogenous anti-inflammatory processes[12]. In UC 
patients, PPARγ ligands as therapy were effective[16,17]. Furthermore, there is a close link between 
intestinal microbiota and regulation of PPARγ expression by colonic epithelial cells[18].  
 
These facts have led to the development of 5-ASA analogs with stronger affinity for PPARγ and fewer 
side effects. In this context, a molecule belonging to the aminophenyl-methoxy-propionic acid family: 
GED-0507-34-Levo, has appeared as a new a new drug candidate with potent anti-inflammatory and 
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analgesic properties. GED-0507-34-Levo showed 100- to 150-fold higher PPARγ activation than 5-ASA in 
vitro; and 30-fold higher anti-inflammatory effect than 5-ASA in experimental models of colitis[19]. As 
well, no side-effects have been observed in phase I study in healthy subjects[20] and it is currently used in 
phase II clinical trials for IBD[21].  
 
Given the fundamental role of intestinal bacteria in IBD and the increasing attention of PPARγ as a target 
against these diseases, a broad-spectrum evaluation of the inherent antibacterial activity of PPARγ 
ligands is presented in this work. These findings could give complementary information about the 
mechanism of action of PPARγ ligands used to combat intestinal inflammation. Moreover, the activity of 
several antibiotic families commonly used in IBD treatment were also submitted to a broad-spectrum 
evaluation for reasons of comparison.  
 
2. Materials and methods 
2.1. Antibacterial agents and growth media 
Antibiotics, pioglitazone and 5-aminosalicylic acid were obtained from Sigma-Aldrich, France. GED-
0507-34-Levo (INSERM U995, Lille, France); Columbia agar base and Defibrinated horse blood 
(Oxoid; Hampshire, England); Brucella agar base (Becton, Dickinson and Company; Le Pont de Claix, 
France). 
 
2.2. Microorganisms, storage and growth conditions 
Thirty two clinical isolates (see Table 1) and three standard strains: Escherichia coli ATCC 25922, 
Bacteroides fragilis ATCC 25285 and Bacteroides thetaiotamicron ATCC 29741 were considered in 
this study. They were stored at -20˚C in Rosenow broth. For the determination of the minimal 
inhibitory concentration all bacteria were thawed, subcultured in Wilkins West broth and then 
incubated under anaerobic conditions for 48 hours at 37°C. The day of the test, a suspension of 
approximately 106 CFU/mL was prepared in Brucella broth. 
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            Table 1: Anaerobic strains 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.3. Determination of the Minimal Inhibitory Concentration (MIC) 
The MICs of all the 9 products tested (amoxicillin, amoxicillin + clavulanic acid, imipenem, 
ciprofloxacin, erythromycin, metronidazole, pioglitazone, 5-ASA, GED-0507-34-Levo) were 
determined by the agar dilution procedure described by the Clinical and Laboratory Standard 
Institute (CLSI)[22]. The tested concentrations of antibiotics, pioglitazone, 5-ASA and GED-0507-34-
Levo were prepared by making serial two-fold dilution in water, ranging from 128 to 0.03 mg/L. Each 
concentration was added to molten Columbia blood agar, mixed, poured into a Petri dish, and 
allowed to solidify. The inocula from the Brucella broth bacterial suspension was delivered using a 
Steers replicator (Mast Systems, London, UK) onto the Columbia blood agar plates. Inoculated 
control plates (without the agents to be tested) were included at the beginning (pre-O2: to check for 
aerobic contamination; and pre-Ana: anaerobic growth control) and at the end of the test (post-O2 
Bacterial strains 
N° of 
strains 
Escherichia coli 3 
Klebsiella pneumoniae 1 
Enterobacter cloacae 1 
Proteus mirabilis 1 
Bacteroides fragilis 2 
Bacteroides thetaoitamicron 2 
Bacteroides vultagus 2 
Bacteroides distasonis 1 
Bacteroides uniformis 1 
Fusobacterium nucleatum 1 
Fusobacterium necrophorum 1 
Veillonella spp 1 
Enterococcus faecalis 1 
Staphylococcus aureus 2 
Clostridium perfringens 2 
Clostridium clostridioforme 1 
Clostridium difficile 1 
Clostridium innocuum 1 
Clostridium ramosum 1 
Ruminococcus spp 1 
Finegoldia magna 1 
Anaerococcus prevotii 1 
Peptoniphilus asaccharolyticus 1 
Bifidobacterium bifidum 1 
Bifidobacerium spp 2 
Propionibacterium acnes 2 
CHAPTER IV 
114 
 
and post-Ana). Finally, plates were incubated under anaerobic conditions at 37°C for 48h, with the 
exception of control pre-O2 and post-O2 which were incubated under aerobic conditions at 37°C for 
48h. The lowest concentration of each product tested that inhibits growth of bacteria was reported 
as the MIC of the agent.  
 
3. Results 
The antibacterial activity of 5-ASA and GED-0507-34-Levo was explored against a group of clinical 
anaerobic isolates regrouping different intestinal bacteria. For reasons of comparison, the activity of 
different subsets of antibiotics: β-lactam (amoxicillin), β-lactam + β-lactamase inhibitor (amoxicillin + 
clavulanic acid), carbapenem (imipenem), macrolide (erythromycin), fluoroquinolone (ciprofloxacin) and 
nitroimidazole (metronidazole); as well as the kwon PPARγ activator: pioglitazone, was also studied. 
  
Concerning Gram-positives (Table 2), there is a general good activity of β-lactams, including imipenem. 
Only the E. faecalis isolate was resistant to these antibiotics. Erythromycin was not active against E. 
faecalis, C. innocuum, and F. magna (MIC>128 mg/L).  Ciprofloxacin showed poor activity against all 
isolates from Clostridium, and also against Ruminococcus, A. prevotii and some Bifidobacterium isolates. 
For metronidazole, facultative anaerobes like Enterococcus and Staphylococcus were resistant; as well as 
the strict anaerobes: Ruminococcus. Bifidobacterium and Propionibacterium. For the PPARγ agonists 5-
ASA and GED-0507-34-Levo there was an absence of antibacterial activity against all Gram positive 
anaerobes (MICs >128 g/mL). However, C. clostridioforme and F. magna were the only isolates 
susceptible to pioglitazone.  
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Table 2: MIC (mg/L) for Gram-positive strains 
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Enterococcus  faecalis 64* 32* 128* >128 4 >128 >128 >128 >128 
Staphylococcus aureus 0.5 0.125 0.03 2 0.5 >128 >128 >128 >128 
Staphylococcus aureus 1 0.125 0.03 2 0.5 >128 >128 >128 >128 
Clostridium perfringens 0.25 0.25 0.25 0.25 8 0.25 >128 >128 >128 
Clostridium perfringens 0.125 0.25 0.125 0.25 4 0.125 >128 >128 >128 
Clostridium clostridioforme 0.5 0.5 0.25 0.5 64 0.125 >128 >128 1 
Clostridium difficile 0.5 0.5 4 1 8 0.25 >128 >128 >128 
Clostridium innocuum 0.25 0.25 1 >128 4 0.5 >128 >128 >128 
Clostridium ramosum 0.25 0.25 0.25 1 >128 0.5 >128 >128 >128 
Ruminococcus sp 0.25 0.125 0.06 0.03 64 8* >128 >128 >128 
Finegoldia magna 0.25 0.125 0.06 >128 0.25 0.125 >128 >128 0.25 
Anaerococcus prevotii 0.06 0.03 0.03 2 8 0.5 64 >128 >128 
Peptoniphilus asaccharolyticus 0.25 0.25 0.03 4 2 0.5 >128 >128 >128 
Bifidobacterium bifidum 0.03 0.03 0.03 0.03 8 4 >128 >128 >128 
Bifidobacterium sp 0.03 0.03 0.03 0.03 8 >128* >128 >128 >128 
Bifidobacterium sp 0.03 0.03 0.03 0.03 0.5 8* >128 >128 >128 
Propionibacterium acnes 0.06 0.03 0.03 0.03 0.5 >128* >128 >128 >128 
Propionibacterium acnes 0.25 0.03 0.03 0.06 2 >128* >128 >128 >128 
*: Resistant Bacteria, according to: The European Committee on Antimicrobial Susceptibility Testing 
(EUCAST)[23] 
 
Concerning the Gram-negative anaerobic-facultative enterobacteria (Tabe 3), E. coli ATCC and the P. 
mirabilis isolates were sensitive to β-lactams, and imipenem was only active against E. coli isolates. For 
ciprofloxacin, isolates of E. coli, K. pneumoniae and E. cloacae were resistant. As was expected, all of the 
facultative anaerobic enterobacteria were resistant to erythromycin and metronidazole. PPARγ agonists 
did not shown any antibacterial activity against these strains (MIC > 128 g/mL). Concerning the Gram-
negative strict anaerobes (Table 3), most of the Bacteroides, as well as F. nucleatum and Veillonella spp. 
were resistant to amoxicillin, whereas only B. thetaiotaomicron and B. distasonis were resistant to 
amoxicillin + clavulanic acid. All of these clinical isolates were susceptible to imipenem and 
metronidazole, with the exception of one metronidazole-resistant strain of Veillonella spp. As expected, 
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erythromycin and ciprofloxacin did not show a good antibacterial activity against these isolates. All of 
these strains were not susceptible to 5-ASA nor GED-0507-34-Levo, however, pioglitazone was active 
against Bacteroides and Fusobacterium. 
 
Table 3: MIC (mg/L) for Gram-negative strains 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
*: Resistant Bacteria, according to: The European Committee on Antimicrobial Susceptibility Testing (EUCAST)[23] 
 
 
4. Discussion 
In recent years, PPARγ has become an interesting potential target in IBD, and there is an emerging 
interest by its role in intestinal homeostasis[18]. Given the importance of intestinal bacteria in the 
pathogenesis of IBD[1] and also in the expression of PPAR in colonic epithelial cells[13], an in vitro study of 
the inherent antibacterial activity of PPAR γ ligands is presented.  
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Escherichia coli >128* >128* 0.5 >128 >128* >128 >128 >128 >128 
Escherichia coli LF-82 >128* >128* 1 >128 0.125 >128 >128 >128 >128 
Escherichia coli ATCC 8 4 1 >128 0.06 >128 >128 >128 >128 
Klebsiella pneumoniae >128* >128* 128* >128 4* >128 >128 >128 >128 
Enterobacter cloacae >128* >128* 16* >128 8* >128 >128 >128 >128 
Proteus mirabilis 2 1 16* >128 0.06 >128 >128 >128 >128 
Bacteroides fragilis ATCC 32* 0.125 0.06 8 4 0.25 >128 >128 >128 
Bacteroides thetaiotaomicron ATCC 16* 0.5 0.125 8 16 1 >128 >128 1 
Bacteroides fragilis 16* 0.25 0.06 >128* 8 0.25 >128 >128 32 
Bacteroides thetaiotaomicron >128* 16* 2 >128* 64 0.25 >128 >128 0.125 
Bacteroides vulgatus 2 2 0.25 32* 8 0.5 >128 >128 16 
Bacteroides vulgatus 4* 0.03 0.06 >128* 4 0.125 128 >128 0.03 
Bacteroides distasonis >128* 64* 0.5 >128* >128 0.25 >128 >128 128 
Bacteroides uniformis 64* 0.25 0.25 8 >128 0.5 >128 >128 2 
Fusobacterium nucleatum 0.125 0.03 0.06 128* 16 0.25 >128 >128 1 
Fusobacterium necrophorum 16* 0.03 0.06 32* 4 0.125 >128 >128 0.125 
Veillonella sp 0.5 0.5 0.5 128* 2 >128 >128 >128 >128 
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We have showed that 5-ASA did not possess antibacterial activity in vitro against a large range of 
anaerobic intestinal isolates. Nevertheless, in vivo studies have shown an antibacterial effect when 5-
ASA was administered. In a murine model of colitis, 5-ASA decreased bacterial richness and diversity of 
luminal and mucosal intestinal bacteria[24]. In the same way, colonic mucosal bacteria of IBD patients[25] 
and fecal bacteria of Intestinal Bowel Syndrome patients (IBS)[26] were decreased when they were 
treated with 5-ASA. 
However, the mechanism through which 5-ASA alter intestinal microbiota in vivo is still not clear. Our 
results correlate with the observations of Swidsinski et al.[25], for a lack of suppression of anaerobic or 
aerobic bacterial growth when 5-ASA was added to suspensions of fecal bacteria. It might be possible 
that the in vivo changes in the intestinal flora upon 5-ASA treatment are secondary to its effects on 
mucosal immune functions. Furthermore, it has been shown that 5-ASA in vitro altered bacterial gene 
expression involved in metabolism, invasiveness and antibiotic/stress resistance, without inhibiting 
bacterial growth. These changes could result in altered bacterial physiology, with a wider impact on the 
gastrointestinal bacterial community[27]. However, in vitro antimicrobial activity of 5-ASA against 
Mycobacterium avium subspecies paratuberculosis, an organism that may be an etiological factor for 
IBD, has been demonstrated[28]. 
For the novel PPARγ agonist GED-0507-34-Levo, this is the first study of its antibacterial properties in 
vitro. Pioglitazone, a kwon PPARγ agonist, was studied for reasons of comparison. However it has shown 
a beneficial role in a DSS model of colitis[11] and also a potential chemopreventive property in colon 
carcinogenesis[15,29]. In this work we have showed a narrow-spectrum antibacterial activity of 
pioglitazone mostly active against strict anaerobic Gram-negative strains like Bacteroides and 
Fusobacterium.  Other studies demonstrated that E. coli was susceptible, while S. pneumoniae and K. 
pneumoniae were resistant to pioglitazone. However, its antibacterial activity was considered low 
compared to standard antibiotics, but when pioglitazone was used at sub-inhibitory concentrations it 
was able to enhance the antibacterial effect of some antibiotics[30].  
We consider that a lack of inherent antibacterial activity for 5-ASA and GED-0507-34-Levo might avoid 
further disturbance of the intestinal microbiota during inflammation. In the case of pioglitazone, its 
narrow-spectrum of action might cause further imbalance in gut microbiota that could enhance 
intestinal inflammation. In contrast, it has been proved that antibiotics with a broad-spectrum of action 
were effective in animal models of colitis[31,32] and in CD patients[33]. In the context of IBD, broad-
spectrum antibiotics are preferred as treatment adjuvants, since a reduction of the total bacterial loads 
might have a beneficial effect in intestinal inflammation. Surprisingly, besides of the lack of antibacterial 
activity of 5-ASA and GED-0507-34-Levo, none of the antibiotics used in this work had a broad-spectrum 
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of action against the anaerobic isolates tested. This fact could also denote the lack of antibacterials with 
a veritable broad-spectrum of activity. 
 
5. Conclusion 
These results show that the PPARγ agonists 5-ASA and GED-0507-34-Levo do not have inherent 
antibacterial activity against anaerobic clinical isolates in vitro. In the context of IBD, where an imbalance 
of the gut microbiota is involved in the pathogenesis, compounds with narrow-spectrum activity, like 
pioglitazone, could further enhance the dysbiosis. In these pathologies, broad-spectrum antibiotics 
would be preferred; however neither of the antibiotic families tested possess a veritable broad-
spectrum of action. 
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GENERAL CONCLUSION 
GENERAL CONCLUSION 
 
In this work we present CIN-102 as a promising broad-spectrum antibacterial agent acting also against multi-
resistant bacteria, this novel agent might have as well a therapeutic effect through modulation of the 
microbiota in case of intestinal inflammation. 
Firstly, the broad-spectrum of action of CIN-102 has been confirmed. All the 175 bacterial clinical isolates 
tested, comprising aerobic and anaerobic bacteria, were susceptible to CIN-102. This new agent was active 
against multi-resistant bacteria of great interest in hospital and community-acquired infections as: NDM-1 
producing E. coli, OXA-48 producing K. pneumoniae, MDR A. baumannii and P. aeruginosa, VRE and MRSA. 
CIN-102 also presented a fast logarithmic reduction time, especially against Gram-negative bacteria. 
Furthermore, the fact that CIN-102 exerted a PAE and slowed down bacterial growth at sub-MICs are of 
especial importance in future drug dosing. Importantly, it was demonstrated that CIN-102, when combined 
with other antibacterials: did not show antagonistic effects, resulted in synergistic interactions with all 
antibiotics tested (mostly with colistin and aminoglycosides) and was able to overcome resistance and 
restore antibiotic activity against resistant strains. These results suggest that CIN-102 has a promising broad-
spectrum antibacterial activity and that further in vivo and clinical studies are needed to confirm these 
findings. 
Second, sustained release CIN-102 dosage forms effectively delivered CIN-102 in the lower gastrointestinal 
tract in vivo in an experimental model of colitis. We have demonstrated that CIN-102 was released from 
coated pellets and mini-tablets at the appropriate site of action in order to exert is antibacterial activity. In 
this regard, CIN-102 was able to significantly reduce enterobacterial concentrations not only in luminal 
colonic contents (stools) but also in colonic tissue (adhered to mucosa). This targeted antibacterial effect 
seems to be linked to the improvement of the course of colitis in mice (reduction of bloody stools and 
diarrhea). These results suggest that CIN-102, when efficiently delivered into the colon, can modulate 
intestinal microflora which might ameliorate the state of inflammation. Further studies will better explain 
how does CIN-102 act in case of colitis.  
In third place, the need of broad-spectrum antimicrobials in the treatment of IBD has been observed.  PPARγ 
agonist with anti-inflammatory effects in IBD were not provided of inherent antibacterial activity in vitro. 5-
ASA and GED-0507-34-Levo were not active against clinical isolates of common intestinal bacteria. Neither of 
the antibiotics tested showed a veritable broad-spectrum activity against the strains tested. This emphasizes 
the need of broad-spectrum antimicrobials able to modulate intestinal microbiota in case of IBD, recovering 
lost intestinal homeostasis. 
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Overall: given the lack of appropriate broad-spectrum antibiotics in IBD treatment, CIN-102, a novel broad-
spectrum antibacterial agent, seems to positively modulate intestinal microflora aiming further therapeutic 
applications.  
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About CIN-102 
We are searching to elucidate the mechanism of action of CIN-102. The lipophilic character of CIN-102 might 
indicate that bacterial membranes are one important target of action. In this regard, morphological changes 
of bacteria exposed to high CIN-102 concentrations were observed by transmission electron microscopy 
(TEM), in preliminary studies (Fig. 18). A leakage of intracellular material is clearly observed after bacterial 
exposure to CIN-102. Studies at lower CIN-102 concentrations (MIC, subMICs) will give further insights about 
the mechanism of action.  
 
 
 
 
 
Another important point is the evaluation of the development of bacterial resistance to CIN-102. For this, 
the “serial passage” is a simple method that could be proposed[1,2]. Bacteria can be grown at different CIN-
102 concentrations. After incubation, the culture below the MIC is used to prepare the inoculum for a new 
MIC determination. Again, after incubation, the culture below the MIC is used to prepare the inoculum for 
the next MIC determination. These “serial passages” can be repeated as many times as wanted. Variation of 
the values of MIC can be thus observed. Preliminary results for some strains showed little variability on CIN-
102 MIC after several passages.  
The study of subMICs of CIN-102 on virulence factors such as biofilm formation is also contemplated in a 
future approach.  The crystal-violet biofilm formation assay could be proposed[3,4]. Bacteria are grown in 
polystyrene plates with or without CIN-102. Cells cultures are washed with water to remove not-adhered 
cells, biofilms are stained with crystal violet, extracted with ethanol and absorbance is measured at 570 nm. 
About sustained release formulations 
We are interested in the optimization of the sustained release formulations of CIN-102. A particular problem 
encountered during the fabrication of these formulations was the loss of CIN-102 due to volatilization. For 
this purpose, encapsulation of EOs can improve their stability through protection against volatilization, 
oxidation or heat damage; allowing the EOs to remain effective under environmental conditions for longer 
A B 
Fig. 18: TEM photos of S. aureus A) without exposure to CIN-102 B) after exposure to 1% of CIN-102 
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time periods. Furthermore, micro- and nano-particles of encapsulated EOs can improve water solubility and 
enhance drug delivery through increased bioavailability. Finally, the release of encapsulated EOs can also be 
controlled. After this process, if a power is obtained by freeze-drying or directly by spray-drying, the 
sustained release formulation could be fabricated using the encapsulated CIN-102.  
In this regard, microencapsulation with cyclodextrins is an attractive approach. β-cyclodextrins have already 
been used to efficiently encapsulate EOs[5] and even cinnamaldehyde[6,7]. Preliminary studies show that 
hydroxypropyl-β-cyclodextrin (HP-β-CD) can encapsulate cinnamaldehyde present in CIN-102 (Fig. 19). A 
solution of 0.05M of cinnamaldehyde was exposed to 0.5; 2.6; 5.3; and 25 mM of HP-β-CD. As seen in Fig. 19, 
the maximum absorption of cinnamaldehyde at 290 nm remains unchanged, but the absorbance is 
considerably decreased as increasing HP-β-CD concentrations, confirming the presence of an interaction 
between the cyclodextrin and cinnamaldehyde, possibly by the formation of an inclusion complex.  
 
 
 
 
 
 
 
 
 
Nanoparticles for encapsulation of EOs is another methodology that could be applied. In this regard, 
biodegradable polymers like poly(lactic-co-glycolic acid) (PLGA)[8], alginate and cashew gum[9] or chitosan[10] 
have already been used to encapsulate EOs. Another option could be the fabrication of microparticles by 
spray drying using polysaccharides as wall materials. Lipophilic compounds have already been 
microencapsulated using arabic gum, maltodextrin[11] pectin and chitosan[12]. 
About potential treatment against IBD 
In a first approach we are interested in studying the in vivo effect of CIN-102 in optimized protocols of acute 
models of colitis: use of placebo formulations, well-established criteria for colitis evaluation, different CIN-
102 concentrations, use of CIN-102 as preventive or treatment agent. 
Fig. 19: Effect of cyclodextrin on the UV spectrum cinnamaldehyde 0.05 mM at (a) 0; (b) 
0.5; (c) 2.6; (d) 5.2; (e) 26.4 mM of HP-β-CD 
 
a 
 
b c 
d 
e 
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In this regard, CIN-102 (50mg/Kg/day) sustained release formulations as well as placebos (formulations 
without CIN-102) are being tested in a DSS model of colitis. The Disease Activity Index (DAI) is used to assess 
the severity of colitis and is calculated as the sum of the diarrheal score and the bloody stool score. The 
colon weight/colon length ratio is used as a reliable indicator of the severity and extent of the inflammatory 
response in colitis. Preliminary results for CIN-102 coated pellets show significant reduction of DAI and 
colonic weight/length ratio compared to placebo coated pellets (Fig. 20). These studies will be completed by 
a bacteriological analysis of colonic flora, colonic cytokine expression and histological studies.  
 
 
 
 
 
 
 
 
 
 
 A second approach will be the evaluation of a combined therapy of CIN-102 with immunomodulatory agents 
like 5-ASA, GED-0507-34-Levo and corticosteroids in experimental models of colitis 
Future approaches will include evaluation of CIN-102 in chronic and infection induced-models of colitis. For 
example, HLA-27 transgenic rats spontaneously develop chronic inflammation mainly involving the colon, 
providing a powerful animal model for IBD. Furthermore, normal luminal bacteria play an essential role in 
initiating and perpetuating chronic colitis in HLA-B27 rats[13]  Infection by Citrobacter rodentium is another 
robust model for studying IBD pathogenesis. C. rodentium is a murine mucosal pathogen, its increased 
growth in the colon results in a pronounced dysbiosis, causing colonic hyperplasia, inflammation and 
systematic dissemination of the pathogen[14,15].  
 
 
Fig. 20: CIN-102 and placebo treatment in DSS-induced colitis in C57BL6 mice: A) DAI and B) colonic 
weight/length ratio 
A B 
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About PPARγ agonists 
In vivo studies of the impact of GED-0507-34-Levo on the intestinal flora of colitic mice are intended. This 
would explain if the anti-inflammatory activity of this molecule can indirectly impact the composition or 
concentrations of the intestinal microbiota during colitis. 
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RÉSUMÉ EN FRANÇAIS 
 
La résistance des bactéries aux antibiotiques constitue un problème majeur de santé. La 
dissémination des bactéries multi-résistantes, spécialement chez les bactéries à Gram négatif, 
risque de provoquer des infections hospitalières et communautaires pour lesquelles aucun 
antibiotique n’est effectif. Il a été estimé qu'en Europe, au moins 25 000 patients par an décèdent à 
cause d'infections provoquées par des bactéries résistantes aux antibiotiques. Les coûts liés à ces 
infections s’élèvent à plus de 1.5 billion d’euros chaque année. 
 
Ces faits mettent en relief le besoin urgent de développer des nouveaux antibiotiques capables de 
cibler ces bactéries résistantes. Cependant, le domaine de la recherche et développement 
d’antibiotiques est peu entrepris par les compagnies pharmaceutiques. Plusieurs facteurs ont 
contribué à l’abandon de la découverte des antibiotiques, parmi eux, le manque de rendement sur 
les investissements, les défis scientifiques impliqués dans leur approbation et les appels à la 
restriction de l’usage d’antibiotiques pour éviter le développement de résistance.  Il est donc 
nécessaire d’établir de nouveaux modèles encourageant l’investissement dans la recherche 
d’antibiotiques tout en proposant des mesures intelligentes afin d’éviter leur mauvaise utilisation.  
 
 Dans la recherche de nouveaux antibiotiques, un vaste réservoir de composants bioactifs qui 
mérite d’être exploité est retrouvé dans la nature. Les métabolites secondaires des plantes sont 
dotés d’une activité antimicrobienne inhérente résultant d’un long processus d’évolution visant la 
protection des plantes dans leur environnement. Les huiles essentielles sont des mélanges 
complexes dont  les composants majoritaires ainsi que les mineurs, participent dans l’activité 
antibactérienne. En effet, il semble que des interactions synergiques entre les composants des 
huiles essentielles pourraient potentialiser l’effet antibactérien. Par ailleurs, les huiles essentielles, 
en agissant sur plusieurs cibles bactériennes, présentent un risque inférieur de développement de 
résistance par rapport aux antibiotiques qui agissent sur une seule cible. Dans la perspective du 
développement d’antibiotiques basé sur des produits d’origine naturelle, une compagnie 
pharmaceutique a développé CIN-102, un mélange synergique et synthétique à des concentrations 
définies pour chaque composant. Cela évite les inconvenants des concentrations inconnues et de 
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variabilités dans la composition, typiquement retrouvés dans les médicaments d’origine botanique.  
Des études préliminaires ont montré que CIN-102 est un agent antibactérien avec le potentiel de 
traiter les infections provoquées par des bactéries résistantes. Parmi toutes les potentielles 
applications thérapeutiques envisageables pour ce nouvel antibactérien, nous sommes intéressés à 
cibler des Maladies Inflammatoires Chroniques de l’Intestin (MICIs) 
 
Les MICIs comprennent la maladie de Crohn (MC) et la recto-colite hémorragique (RCH), qui sont 
des pathologies dont l’étiologie n’est pas encore complètement connue. Néanmoins, il a été 
largement démontré  que les bactéries entériques jouent un rôle important dans leur origine et 
développement. Bien que le traitement des MICIs soit essentiellement orienté vers une approche 
immuno-modulateur, l’utilisation d’agents capables de réguler le microbiote intestinal a un intérêt 
croissant. Parmi ces agents, les antibiotiques peuvent être utiles afin de réduire l’augmentation de 
la charge bactérienne généralement trouvée dans l’ileum et le colon des patients atteints de MICIS, 
aussi bien que de cibler des bactéries pathogènes spécifiques comme par exemple les 
entérobactéries. De cette façon, la réduction des déséquilibres au niveau de la flore intestinale, 
pourrait diminuer l’agressivité de la réponse immunitaire envers les antigènes bactériens et 
atténuer les signes cliniques d’inflammation intestinale. 
 
Les principes actifs qui visent une action locale dans le bas tractus gastro-intestinale, comme dans 
le cas des MICIc, présentent le défi de la conception d’une formulation galénique appropriée. Étant 
donné qu’une forme galénique à administration orale doit parcourir l’estomac et l’intestin grêle 
avant d’arriver au colon, il pourrait se produire une libération ou absorption du principe actif dans 
le haut tractus gastro-intestinale. Ceci pourrait  limiter la concentration de principe actif disponible 
au site d’action, exigeant donc l’administration de grandes concentrations de molécules actives  
pour assurer un effet thérapeutique, entrainant un risque d’apparition d’effets secondaires. Dans 
ce contexte, les systèmes à libération colique ciblée permettent que les formes galéniques à 
administration orale soient capables de contenir la libération et de résister à la dégradation des 
principes actifs dans le tractus gastro-intestinale, évitant les problèmes mentionnés ci-dessus. Pour 
cela, ces systèmes à libération colique doivent détecter leur arrivé dans le colon afin de déclencher 
la libération des molécules actives. Les caractéristiques physiologiques trouvées spécifiquement au 
niveau  du colon, différentes de celles de l’estomac ou de l’intestin grêle, peuvent ainsi être 
utilisées dans la fabrication des formes orales à libération colique.  
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Les objectifs de ce travail de thèse sont les suivants : 
- Caractériser l’activité antibactérienne in vitro du CIN-102 
o Une longue évaluation de l’activité antibactérienne du CIN-102 sur un large éventail 
d’isolats bactériens cliniques afin de confirmer son large spectre d’action. 
o Détermination du temps de réduction logarithmique du CIN-102 contre un éventail 
d’isolats bactériens. 
o Déterminer si le CIN-102 possède un effet post-antibiotique et si le CIN-102 exerce 
un effet sur la croissance bactérienne à des concentrations sub-inhibitrices. 
o Une étude des interactions entre le CIN-102 et des antibiotiques existant sur le 
marché contre un large éventail d’isolats bactériens cliniques, envisageant une 
future application thérapeutique dans des thérapies combinées.  
 
- Fabriquer des formes galéniques multi-particulaires contenant le CIN-102 dans le but d’une 
future application thérapeutique contre les MICIs. 
o Fabrication et optimisation des systèmes réservoir du CIN-102 : évaluation in vitro de 
la libération du principe actif à partir des mini-granules pellicules.  
o Fabrication et optimisation des formes matricielles du CIN-102 : évaluation in vitro 
de la libération du principe actif à partir des mini-comprimés. 
o Evaluation in vivo de l’efficacité des formes galéniques multi-particulaires à 
libération prolongée du CIN-102 : étude de l’activité antibactérienne du CIN-102 
dans un modèle expérimentale de colite. 
 
- Analyser l’activité antibactérienne in vitro des agonistes du récepteur activé par les 
proliférateurs des peroxysomes gamma (PPARγ) et des antibiotiques communément utilisés 
dans le traitement des MICIs. 
o Détermination de l’activité antibactérienne de l’acide 5-aminosalicylique (5-ASA) et 
du GED-0507-34-Levo contre des isolats bactériens anaérobies. 
o Détermination de l’activité antibactérienne des antibiotiques à spectre étroit et large 
contre des isolats bactériens anaérobies.  
 
RÉSUMÉ EN FRANÇAIS 
133 
 
Ce travail de thèse est composé de quatre chapitres : le premier est une introduction sur la 
problématique de la résistance aux antibiotiques, le  rôle des compagnies pharmaceutiques dans la 
recherche et développement d’antibiotiques, le potentiel des produits d’origine naturelle comme 
source de nouveaux antibactériens, l’importances des bactéries entériques dans l’étiologie et le 
traitement des MICIs ; et les différentes approches utilisées pour cibler la libération des principes 
actifs dans le colon. Le deuxième, troisième et quatrième chapitre correspondent aux travaux de 
recherche effectués pour atteindre les objectifs décrits ci-dessus, respectivement. Chacun de ces 
trois derniers chapitres se compose d’une brève introduction sur le sujet à développer, les 
matériels et méthodes utilisés, les résultats obtenus ainsi que les discussions ; et une conclusion 
concise. Finalement une conclusion générale permettra de regrouper les buts atteints  et les 
perspectives suggèreront de nouvelles idées pour la suite de ce projet de recherche. 
 
Deuxième chapitre : Sur la caractérisation de l’activité antibactérienne du CIN-102 in vitro 
 
La problématique : La résistance aux antibiotiques est une menace de santé et de nouveaux  
antibactériens ont besoin d’être développés. Malgré ce besoin, la plupart des compagnies 
pharmaceutiques ont abandonné la recherche et développement d’antibiotiques.  
Il existe dans l’actualité un groupe de bactéries résistantes qui pose des problèmes au niveau 
hospitalier mais aussi communautaire, parmi elles on retrouve : Enterococcus faecium résistant 
à la vancomycine, Staphylococcus aureus résistant à la méticilline, Escherichia coli et Klebsiella 
pneumoniae productrices de β-lactamases à spectre étendu, Klebsiella pneumoniae productrice 
de carbapénémase, ainsi qu’Acinetobacter baumannii, Pseudomonas aeruginosa et 
Enterobacter spp. multi-résistants. Néanmoins, un phénomène d’importance mondiale est la 
propagation des bactéries multi-résistantes à Gram négatif, pour lesquelles il n’y a 
pratiquement pas d’antibiotiques qui soient effectifs. En effet, plusieurs études ont montré que 
ces bactéries sont souvent retrouvées chez des individus sains, en faisant partie de la flore 
intestinale commensale. 
Il a été suggéré que, dans la lutte contre la résistance aux antibiotiques, les composants 
bioactifs d’origine naturelle méritent d’être exploités dans le développement de nouveaux 
antibiotiques. Les huiles essentielles par exemple, sont des métabolites secondaires des 
plantes qui exercent une activité antibactérienne inhérente. De plus, grâce à la présence de 
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nombreux composants dans leur composition, le risque de développement de résistance 
contre ces mélanges est moins important 
Dans ce contexte, une compagnie pharmaceutique française (Septeos), a élaboré un mélange 
synthétique qui ressemble à la composition des huiles essentielles de cannelle, mais à des 
concentrations définies pour chaque composant chimique. Ce mélange, appelé CIN-102, 
semble avoir une activité antibactérienne à large spectre et constitue donc un agent 
prometteur contre les bactéries résistantes. Les objectifs de ce travail étaient : caractériser 
l’activité antibactérienne in vitro du CIN-102 et étudier les interactions entre le CIN-102 et les 
différentes familles d’antibiotiques existantes sur le marché.   
 
Matériels et méthodes : Un total de 175 isolats bactériens cliniques, comprenant des souches 
aérobies et anaérobies, a été étudié ; parmi eux, plusieurs bactéries multi-résistantes aux 
antibiotiques. La concentration minimale inhibitrice (CMI) a été déterminée en respectant les 
guides du Clinical & Laboratory Standards Insitute (CLSI), cependant le CIN-102 a été solubilisé 
à l’aide des tensioactifs pour lesquels l’absence d’activité antibactérienne a été préalablement 
vérifiée. Le temps de réduction logarithmique du CIN-102 a été étudié à des concentrations 
supra-inhibitrices (4 fois la CMI et 1%). L’effet post-antibiotique a été déterminé par la 
méthode proposée par Craig et Gudmundsson, à la CMI et 4 fois la CMI du CIN-102. L’effet des 
concentrations sub-inhibitrices du CIN-102 sur la croissance bactérienne a été déterminé à la 
CMI/2 et à la CMI/4. Les interactions entre le CIN-102 et les antibiotiques ont été déterminées 
par la méthode du checkerboard et les résultats ont été interprétés à l’aide du Fractional 
inhibitory concentration (FIC) index.  
Résultats et discussions : Toutes les souches testées sont inhibées par le CIN-102. Les bactéries 
anaérobies sont les plus sensibles au CIN-102, et Pseudomonas aeruginosa possède les CMIs les 
plus élevées. Le temps nécessaire pour réduire la concentration bactérienne d’un log est court 
pour le CIN-102, spécialement chez des bactéries à Gram négatif.  
Ensuite, le CIN-102 présente un effet post-antibiotique et il ralentie la croissance bactérienne à 
des concentrations sub-inhibitrices sur plusieurs types de bactéries : aérobies, anaérobies, à 
Gram positif et à Gram négatif.  
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Finalement, quand le CIN-102 est utilisé en combinaison avec des autres antibiotiques : il y a une 
absence d’interactions antagonistes, il existe des interactions synergiques (notamment avec la 
colistine et les aminogycosides), les souches résistantes aux antibiotiques redeviennent 
sensibles.  
Il semble que l’activité antibactérienne du CIN-102 est principalement due à la présence du 
cinnamaldehyde, composant majoritaire (86,7%). Il a été démontré que le cinnamaldehyde est 
capable de se lier à la protéine FtsZ, qui est un homologue de la tubuline chez les procaryotes. Le 
fait que cette protéine soit largement conservée chez les bactéries, pourrait expliquer le large 
spectre d’action du CIN-102. Néanmoins, il est important de prendre en considération la 
présence des composants minoritaires du CIN-102. Ces terpenoides sont capables de 
perméabiliser les membranes bactériennes, entrainant une fuite du contenu intracellulaire. Par 
conséquent, le mécanisme d’action du CIN-102 est un ensemble des différentes cibles 
bactériennes. Il est important de noter que, des études sur des modèles d’infection chez l’animal 
semblent indiquer que des concentrations actives du CIN-102 peuvent être atteintes in vivo.  
De plus, la présence d’un effet post-antibiotique et la réduction de la croissance bactérienne à 
des concentrations sub-inhibitrices du CIN-102 sont importantes pour établir la future posologie 
du CIN-102 visant une application thérapeutique.  
Enfin, la présence d’interactions synergiques avec des antibiotiques est d’importance capitale 
dans le cadre des thérapies combinées, ou des concentrations sub-inhibitrices du CIN-102 
pourraient aider à rétablir l’activité des antibiotiques contre des bactéries multi-résistantes. Il 
est donc important de poursuivre des études in vivo et des essais cliniques afin de confirmer ces 
résultats encourageants in vitro.  
Conclusion intermédiaire: CIN-102 est un antibactérien a large-spectre d’action et un agent 
prometteur dans la lutte contre des bactéries multi-résistantes.  
 
Troisième chapitre : Sur les formulations à libération prolongée du CIN-102, performance in 
vitro/in vivo 
 
La problématique : Les MICIs sont des pathologies chroniques dont l’étiologie n’est pas encore 
complètement connue. Cependant, il a été largement démontré que les bactéries entériques 
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jouent un rôle primordial dans l’étiologie, le développement et le phénotype de ces maladies. 
Par exemple: les lésions sont localisées dans des endroits ou la charge bactérienne est la plus 
forte, il y a une composition et une activité métabolique anormales de la flore intestinale, il y a 
une augmentation de la concentration de bactéries adhérées a la muqueuse intestinale, il y a 
une réponse immunitaire exacerbée aux bactéries intestinales commensales, entre autres. Dans 
ce contexte, des antibiotiques peuvent agir soit en ciblant les bactéries pathogènes soit en 
diminuant les concentrations bactériennes au niveau de la lumière intestinale ou adhérentes à la 
muqueuse. La modulation de la microflore intestinale en cas d’inflammation pourrait donc 
améliorer les symptômes de la colite et réduire la réponse immunitaire aux antigènes bactériens. 
Il semble donc que l’utilisation d’agents antibactériens, seuls ou comme adjuvants des 
immunomodulateurs, pourrait être utile dans les traitements des MICIs.  
Apres avoir confirmé l’activité antibactérienne à large spectre du CIN-102, nous nous sommes 
intéressés à l’utilisation de cet agent dans le cadre des MICIs. L’hypothèse de cette étude se base 
sur la délivrance du CIN-102 dans le colon, qui pourrait améliorer le cours de la colite à travers 
une diminution de la charge bactérienne totale du colon et/ou d’une activité ciblée sur des 
bactéries pathogènes. Des études préliminaires ont montré que des rats atteints d’une colite 
induite au trinitrobenzene sulfonate (TNBS) et traités avec le CIN-102 par gavage orale ont eu 
des effets mineurs sur la flore intestinale. Il a été conclu qu’une forme galénique appropriée 
pourrait être capable d’assurer la délivrance et donc l’activité antibactérienne du CIN-102 dans 
le site d’action souhaité : le colon.  
Plusieurs approches sont décrites dans la littérature afin de cibler la libération des principes 
actifs au niveau du colon. Les principales comprennent des systèmes dépendants du pH, du 
temps de transit gastro-intestinal et de l’activité enzymatique des bactéries coliques. Etant 
donné que les patients atteints des MICIs ont souvent des variations du pH intestinal et des 
temps de transit altérés, l’approche enzymatique semble plus appropriée. En effet, la 
concentration bactérienne au niveau du colon est beaucoup plus grande (1011- 1012 unités 
formant colonies (UFC)/g) par rapport à l’estomac (102 UCF/g) ou l’intestin grêle (103-104 UFC/g). 
Ces bactéries sont capables de dégrader des polysaccharides non-digestibles qui proviennent du 
haut tractus gastro-intestinal, et de les utiliser comme source d’énergie. Des systèmes à 
libération colique à base de ces polysaccharides d’origine naturelle ont été amplement étudiés.  
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Ce travail a comme objectif la fabrication des formulations à libération prolongée du CIN-102 
(des mini-granules pelliculés et des mini-comprimés) en utilisant des polysaccharides 
dégradables par des bactéries coliques. Dans un deuxième temps, l’efficacité de ces systèmes a 
été étudiée dans un modèle de colite aigüe chez la souris, où l’activité antibactérienne du CIN-
102 au niveau du colon a été analysée.  
Matériels et méthodes : Mini-granules : les noyaux des granules contenant le CIN-102 ont été 
fabriqués par extrusion-spheronization. Différents excipients ont été utilisés : cellulose 
microcristalline, lactose, silice et/ou aluminosilicate de magnésium.  Ensuite les mini-granules 
ont été pelliculés à l’aide des mélanges des polysaccharides (inuline ou amidon de pois) et des 
polymères insolubles dans l’eau (Aquacoat® ou Kollicoat®). Eventuellement, un enrobage 
intermédiaire à base d’un polymère hydrophile (Opadry®) a été incorporé. Finalement les mini-
granules enrobés sont curés à 60° C pendant 24h.  
Mini-comprimés : les mini-comprimés ont été fabriqués par compression directe. Des 
triglycérides solides,  l’aluminosilicate de magnésium, l’inuline et l’ethylcellulose ont été utilisés 
comme excipients.  
Tests de libération in vitro : la libération du cinnamaldehyde a partir des formulations à 
libération prolongée a été étudiée dans des milieux simulant le pH de l’estomac et de l’intestin 
grêle. 
 Etudes in vivo : les mini-granules enrobés et les mini-comprimés qui ont montré les meilleurs 
profiles de libération in vitro ont été soumis à des tests in vivo. Des souris de fond génétique 
B57CL6 ont été traitées au dextran sodium sulfate (DSS) afin d’induire une colite. Les formes 
galéniques ont été administrées par voie orale. Le cours de la colite a été évalué en observant la 
présence de sang dans les selles et l’occurrence de diarrhées. A la fin du traitement, les souris 
ont été sacrifiées et des échantillons de selles ainsi que des tissus coliques ont été récupérés 
pour suivre une analyse bactériologique. Une étude de l’expression des cytokines dans des tissus 
colique a été aussi effectuée.  
Résultats et discussions : Mini-granules enrobés : les noyaux à base de cellulose microcristalline, 
lactose et/ou silice et enrobés avec un mélange d’amidon de pois et d’Aquacoat®, ont montré 
une libération prématurée du cinnamaldehyde in vitro. Pour cette raison, certains excipients ont 
été retirés de la formulation (lactose) et d’autres ont été incorporés (aluminosilicate de 
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magnésium) afin d’augmenter la rétention du CIN-102 dans les noyaux des mini-granules. Un 
enrobage intermédiaire a aussi été incorporé, et l’enrobage externe s’est composé d’un mélange 
d’inuline et de Kollicoat®. De cette façon, la libération prématurée du cinnamaldehyde dans des 
milieux mimant l’estomac a été significativement diminuée.  
Mini-comprimés : la libération du cinnamaldehyde a été significativement réduite dans des 
milieux simulant l’estomac et l’intestin grêle. Cependant, l’incorporation de l’inuline déclenche 
une libération prématurée du principe actif. Afin de contourner ce problème, l’ethylcellulose a 
été additionnée dans la composition des mini-granules. Ainsi, la libération du cinnamaldehyde a 
été largement réduite dans les milieux simulant le haut tractus gastro-intestinal.  
Etudes in vivo : Il a été montré que, les souris atteintes de colite et traitées avec les formulations 
à libération prolongée du CIN-102 présentaient une diminution de la présence de sang dans les 
selles ainsi qu’une diminution des diarrhées, par rapport aux souris non-traitées. D’ailleurs, les 
souris traitées avec les formulations à libération prolongée ont eu une diminution significative 
de la concentration d’entérobactéries dans les selles et dans la muqueuse colique, par rapport 
aux souris non-traitées. La diminution des entérobactéries, considérées comme des espèces 
pathogènes en cas de MICIs, semble donc être associée à l’amélioration du cours de la colite.  
Conclusion intermédiaire: Les mini-granules enrobés et les mini-comprimés de CIN-102 ont un 
potentiel pour le traitement de la colite. La libération du CIN-102 au niveau du colon permet une 
réduction de la charge d’entérobactéries dans les selles et dans la muqueuse chez les souris 
atteintes de colite. Cela s’accompagne d’une amélioration clinique du développement de la 
colite. Des études supplémentaires sont nécessaires afin de mieux élucider l’action du CIN-102 
en cas de colite.   
Quatrième chapitre : Sur l’activité antibactérienne in vitro des agonistes des PPARγ et des 
antibiotiques utilisés contre les MICIs 
La problématique : Les MICIs sont des pathologies chroniques dont l’étiologie est 
multifactorielle mais n’a pas encore été complétement élucidée. Ces maladies semblent être 
provoquées par une réponse immunitaire exacerbée aux bactéries commensales intestinales 
chez des individus génétiquement prédisposés. De plus, des facteurs environnementaux peuvent 
précipiter leur déclanchement ou leur réactivation.  
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Le but principal du traitement des MICIs est l’induction d’une rémission clinique ainsi que la 
maintenance de cette rémission au cours du temps. Le 5-ASA est très utilisé dans les thérapies 
des MICIs, notamment chez les patients atteints de RCH. Le 5-ASA inhibe la production de 
prostaglandines, de leucotriènes, et les effets du facteur de nécrose tumorale alpha, entre 
autres. Par ailleurs, il a été récemment démontré que le PPARγ est un récepteur clé qui 
détermine les principaux effets du 5-ASA dans le colon.  
En effet, le PPARγ est capable d’inhiber deux des plus importantes voies de signalisation qui 
régulent l’expression des gènes pro-inflammatoires : les voies du facteur nucléaire-κB et des 
kinases activées par le stress. De cette façon, ce récepteur joue un rôle important dans la 
régulation de l’inflammation intestinale. Par exemple, l’expression de PPARγ est réduite dans 
les tissus coliques des souris atteintes de colite, ainsi que dans les cellules épithéliales du colon 
des patients atteints de RCH. De plus, dans des modèles expérimentaux de colite, des agonistes 
de PPARγ peuvent inhiber la réponse inflammatoire. Dans le contexte clinique, les agonistes 
PPARγ ont été effectifs en cas de RCH. D’ailleurs, il existe un lien étroit entre le microbiote 
intestinal et la régulation de l’expression du PPARγ par les cellules épithéliales du colon.  
Ces faits ont amené au développement des analogues du 5-ASA mais en possédant une affinité 
plus forte pour le PPARγ et moins d’effets secondaires. Dans ce contexte, le GED-0507-Levo a 
été conçu en tant que nouveau candidat possédant des propriétés anti-inflammatoires et 
analgésiques très puissantes.  Cette molécule est actuellement en essai clinique de phase 2 
contre les MICIs.  
Compte tenu de l’intérêt croissant pour le PPARγ comme cible d’action dans le traitement des 
MICIs, et son étroite relation avec la microflore intestinale, une étude de l’activité 
antibactérienne in vitro des agonistes du PPARγ est présentée dans ce travail. Ces résultats 
pourraient donner des informations supplémentaires sur le mécanisme d’action de ces agents 
contre l’inflammation intestinale. Egalement, plusieurs familles d’antibiotiques communément 
utilisées en cas de MICIs ont était soumises à une évaluation de leur activité antimicrobienne 
contre des isolats bactériens anaérobies.  
Matériels et méthodes : Un total de 32 isolats bactériens cliniques comprenant des bactéries 
anaérobies à Gram positive et à Gram négatif a été considéré dans cette étude. Les agonistes 
du PPARγ utilisés étaient : le 5-ASA, le GED-0507-Levo et la pioglitazone. Les antibiotiques 
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testés : amoxicilline, amoxicilline + acide clavulanique, imipenème, érythromycine, 
ciprofloxacine et métronidazole. Pour la détermination des CMIs, les procédures décrites dans 
les guides du CLSI ont été suivies. La gélose columbia supplémentée avec du sang de cheval a 
été utilisée comme milieu pour la détermination des CMIs.  
Résultats et discussions : Concernant les bactéries à Gram positif, les β-lactames y compris 
les carbapenemes ont été capables d’inhiber la plupart des souches testées. L’érythromycine,  
le ciprofloxacine et le métronidazole ont montré une activité moins efficace. Pour les 
agonistes du PPARγ : le 5-ASA et le GED-0507-34-Levo n’ont exercé aucune activité 
antibactérienne, cependant la pioglitazone a inhibé une souche de C. clostridioforme et de F. 
magna.  
Concernant les entérobactéries anaérobies facultatives, aucun antibiotique n’a été capable 
d’inhiber toutes les entérobactéries. Les agonistes du PPARγ se sont montrés dépourvus 
d’activité antibactérienne  contre ces bactéries. 
Concernant les bactéries anaérobies strictes à Gram négatif, l’imipenème et le métronidazole 
ont été les antibiotiques les plus actifs. Le 5-ASA et GED-0507-34-Levo n’ont montré aucune 
activité contre ces bactéries, Bacteroides et Fusobacterium ont été inhibés par la pioglitazone. 
Ces études montrent que le 5-ASA et GED-0507-Levo sont dépourvus d’activité 
antibactérienne in vitro. Malgré que d’autres études ont montré une activité antibactérienne 
in vivo du 5-ASA, il est possible que ceci soit dû à un effet indirect de la régulation de 
l’inflammation intestinale sur la microflore. Néanmoins, il a aussi été montré que le 5-ASA est 
capable d’altérer l’expression des gènes liés aux activités métaboliques et aux facteurs de 
virulences des bactéries. Ce constat pourrait aussi avoir un impact sur le microbiote intestinal 
en cas d’inflammation.  Ceci est la première étude qui porte sur l’activité antibactérienne du 
GED-0507-Levo. L’analyse de la flore intestinale chez l’animal après administration de ces 2 
agonistes du PPARγ pourrait expliquer si la réduction de la réponse inflammatoire a un effet 
indirect sur les bactéries entériques.  
Conclusion intermédiaire : Ces résultats montrent que les agents anti-inflammatoires utilisés 
contre les MICIs (5-ASA et GED-0507-Levo) n’ont pas une activité antibactérienne inhérente in 
vitro. De plus, aucun des antibiotiques testés n’était capable d’inhiber toutes les souches 
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bactériennes étudiées. Cette observation témoigne d'un manque d’agents à large-spectre 
d’action, capables de réduire la charge bactérienne augmentée en cas de colite.  
 
Conclusion générale  
Dans ce travail nous présentons CIN-102 comme un agent antibactérien à large spectre 
d’action prometteur, aussi capable d’agir contre des bactéries multi-résistantes. Ce nouvel 
antibactérien pourrait également avoir un effet thérapeutique grâce à la modulation du 
microbiote intestinal en cas d’inflammation. 
 
 Dans un premier temps, le large spectre d’action du CIN-102 a été confirmé. Les 175 
isolats bactériens testés ont été inhibés par le CIN-102. Ce nouvel agent a ainsi inhibé 
des bactéries multi-résistantes suscitant un grand intérêt dans le cadre des infections 
hospitalières et communautaires. CIN-102 a exercé un temps rapide de réduction 
logarithmique, spécialement chez les bactéries à Gram négatif. De plus, CIN-102 a 
montré un effet post-antibiotique et a été capable de ralentir la croissance 
bactérienne a des concentrations sub-inhibitrices, ces deux derniers aspects sont 
d’importance capitale pour la posologie du médicament. Un aspect remarquable a 
été l’étude des interactions entre CIN-102 et antibiotiques, ces résultats ont montré 
que : il n’y a pas d'interaction antagonique, il y a des interactions synergiques avec 
tous les antibiotiques testés (surtout avec la colistine et les aminoglycosides), CIN-
102 a rétabli l’activité des antibiotiques contre des souches résistantes. Ces résultats 
suggèrent que CIN-102 est un antibactérien à large spectre d’action prometteur mais 
des études in vivo et des essais cliniques permettront de confirmer son activité.  
 
 Deuxièmement, des formes à libération prolongée du CIN-102 peuvent délivrer cet 
agent dans le tractus gastro-intestinal inférieur dans un modèle expérimental de 
colite. Nous avons démontré que le CIN-102 contenu dans des mini-granules enrobés 
et des mini-comprimés a été libéré dans le site d’action cible pour exercer son 
activité antibactérienne. Dans ce cadre, CIN-102 a réduit significativement la 
concentration d’entérobactéries présentes dans les contenus de la lumière colique 
(selles) ainsi que dans les tissus coliques (adhérentes à la muqueuse). Cet effet 
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antibactérien ciblé au colon, semble être lié à l’amélioration du développement de la 
colite chez la souris (réduction de la présence du sang dans les selles et des 
diarrhées). Ces résultats suggèrent que CIN-102, une fois libéré dans le colon, peut 
moduler la microflore intestinale, qui pourrait donc améliorer l’état de 
l’inflammation. Des études futures permettront de mieux comprendre le mécanisme 
d’action du CIN-102 en cas de colite. 
 
 En troisième lieu, nous avons constaté le besoin d’antibiotiques à large-spectre 
d’actions dans le traitement des MICIs. Les agonistes des PPARγ utilisés en tant 
qu’anti-inflammatoires en cas des MICI sont dépourvus d’activité antibactérienne in 
vitro. 5-ASA et GED-0507-34-Levo n’ont pas été actifs contre des souches anaérobies 
testées. De la même façon, aucun des antibiotiques étudiés n'a montré une véritable 
action à large-spectre contre les souches anaérobies testées. Cette observation 
souligne le besoin d’antibiotiques à large spectre d’action capables de moduler la 
microflore colique afin de rétablir l’homéostasie intestinale en cas de MICIs  
 
Perspectives  
 Concernant le CIN-102  
Nous sommes intéressés à l’élucidation du mécanisme d’action du CIN-102. Le 
caractère lipophile du CIN-102 semble indiquer que les membranes bactériennes 
constituent une cible d’action importante. A cet égard,  des changements 
morphologiques chez des bactéries exposées au CIN-102 ont été observés par 
microscopie électronique en transmission. Les photos montrent une fuite du 
contenu intracellulaire après l’exposition des bactéries à une grande concentration 
de CIN-102. Des études à des concentrations inférieures permettront de mieux 
comprendre le mécanisme d’action. 
Ensuite, nous envisageons d’effectuer des études afin de détecter l’apparition de 
résistance bactérienne au CIN-102 et les effets des concentrations sub-inhibitrices 
sur des facteurs de virulence tels que la formation des biofilms.  
 Concernant les formulations à libération prolongée : 
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 Un problème important retrouvé au cours de la fabrication des mini-granules 
pelliculés et des mini-comprimés du CIN-102 a été les pertes de cet agent à cause 
de sa volatilisation. Nous souhaitions, par conséquent, encapsuler le CIN-102 afin 
de renforcer sa stabilité au sein des formulations à libération prolongée. 
L’encapsulation des huiles essentielles, sous forme de micro- ou nanoparticules, 
permet non seulement d’améliorer leur stabilité mais aussi d’augmenter leur 
solubilité dans l’eau et donc leur biodisponibilité. Dans ce but, la micro-
encapsulation des principes actifs à l’aide des cyclodextrines est une approche 
intéressante. Des études préliminaires montrent que le cinnamaldehyde, 
composant majoritaire du CIN-102, est capable d’interagir avec l’hydroxypropyl-β-
cyclodextrines probablement à cause de la formation d’un complexe d’inclusion. 
Cela a été montré par spectroscopie UV, en observant une diminution de 
l’absorbance du cinnamaldehyde à 290 nm en présence des concentrations 
croissantes de cyclodextrine.  
 
D’autres approches comprennent la fabrication des nanoparticules en utilisant des 
polymères biodégradables comme l’acide poly(lactique-co-glycolique) (PLGA) ou les 
microparticules composées des polysaccharides naturels fabriquées par spray 
drying.   
 
 Concernant l’application thérapeutique contre les MICIs 
Dans un premier temps, nous sommes intéressés à mieux analyser l’activité du CIN-
102 dans des modèles expérimentaux de colite aigüe. Pour cela nous avons besoin 
des protocoles mieux structurés, par exemple : à travers l’utilisation des 
formulations placebo, des critères bien définis pour l’évaluation de la colite, l’effet 
à différentes concentrations du CIN-102. Dans ce cadre, des mini-granules placebo 
et contenant le CIN-102 ont été évaluées dans un modèle de colite aigüe chez la 
souris. Deux paramètres bien définis : l’indice d’activité de la maladie et le rapport 
poids/taille du colon ont permis d’évaluer les effets du CIN-102. Actuellement, ces 
résultats sont complétés par une analyse de la microflore colique, l’expression des 
cytokines et des études histologiques.  
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Dans un deuxième temps, nous souhaitions étudier l’activité du CIN-102 en 
combinaison avec des anti-inflammatoires dans des souris atteintes de colite. De la 
même façon, il est envisagé d’analyser dans le futur, l’effet de CIN-102 dans des 
modèles de colite chronique et infectieuse.  
 
 Concernant les agonistes des PPARγ 
L’étude in vivo de l’activité antibactérienne des agonistes des PPARγ confirmera si 
l’effet anti-inflammatoire de ces agents pourrait influencer indirectement la flore 
intestinale des souris.  
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